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1 NANOPARTICLES AS DRUG DELIVERY SYSTEM 
Since the 1970s nanoparticles are increasingly researched as drug delivery systems. 
One reason is that they have several advantages, such as being able to target 
different organs, e.g. the lymphatic system, the brain, the lung, the liver and the 
spleen, as well as tumours. Furthermore, nanoparticles are capable to carry various 
drugs, including hydrophilic and lipophilic molecules, proteins, nucleic acids, 
vaccines and other biological macromolecules. This specific delivery enables that 
therapeutic effects can be improved at the intended target site and systemic toxic 
side effects can be reduced [1]. Besides this, nanoparticles can protect the drug from 
(bio)degradation and consequently increase its bioavailability [2]. Both 
characteristics may allow a dose reduction. Other important advantage of 
nanoparticles is their ability to create a controlled and sustained release of the drug, 
as well as an enhanced cellular uptake [3-5]. All these points show why there is a 
strong research interest in nanoparticulate drug delivery systems.  
2 MATERIALS FOR NANOPARTICLE PREPARATION 
2.1 SYNTHETIC AND NON-PROTEINEOUS BASE MATERIALS 
A variety of different starting materials is available to prepare nanoparticles for 
pharmaceutical purposes. Generally, these materials should be biocompatible and 
at least partly biodegradable. Nanoparticles may be prepared from synthetic 
polymers, such as polyethylenimine (PEI), poly(lactic-co-glycolic) acid (PLGA), or 
natural polymers, such as polysaccharides or lipids [3, 6-8].  
The polymer PEI was demonstrated to be a potential non-viral gene delivery system 
in vitro and in vivo. Here, nucleic acids were attached to the cationic polymer by 
electrostatic interactions [9, 10]. However, due to a rather high toxicity of the 
material combined with a strong complement activation, the dosing is limited [11, 
12]. Certainly, this could successfully be overcome by structural modifications of the 
polymer, such as PEGylation or introduction of negatively charged residues [12-14]. 
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Nonetheless, due to the lack of biodegradability and subsequent accumulation of the 
polymer when multiple administered, further biodegradable derivatives need to be 
developed [15]. 
On the other hand, PLGA is a widely used starting material for drug delivery systems 
as it is biocompatible, biodegradable and approved by the US Food and Drug 
Administration (FDA). It solely consists of acids, which are part of the human 
metabolism, lactic acid and glycolic acid. Furthermore, by changing the ratio of the 
particular components or the molecular weight, its physical properties, such as 
mechanical strength, swelling behaviour or degradation time frame can be 
controlled. Therefore, it is mostly researched for controlled and sustained delivery 
of small molecules, proteins or nucleic acids [16, 17]. Due to tuneable particle sizes, 
PLGA based nanoparticles can be used to target different parts of the immune 
system, such as antigen presenting cells (APCs) or the lymph nodes. In combination 
with a prolonged release, a more effective immune response can be initiated when 
antigens are applied via PLGA nanoparticles [16]. Nevertheless, when PLGA 
derivatives are degraded, acidic components are released resulting in a 
microclimate pH drop [18, 19]. This may affect sensitive active pharmaceutical 
ingredients, such as proteins or nucleic acids. 
Thirdly, lipids are established materials to prepare nanoparticulate carries for drug 
delivery as they are biodegradable and non-toxic. This class includes, inter alia, solid 
lipid nanoparticles (SLNs) and liposomes. SLNs are composed of lipids that are solid 
at room and body temperature and offer several advantages: great physical stability, 
controlled or sustained drug release, protection of the drug from degradation and 
good physiological tolerability [8]. Their main disadvantage is a possible burst drug 
release due to polymorphic transitions of the lipids during storage [8]. However, this 
could be circumvented by optimal storage conditions, lipid composition and 
addition of emulsifiers [20]. Besides small molecules, SLNs are also used to carry 
macromolecules, such as proteins or nucleic acids [21-23]. However, there is still 
few research regarding vaccination or immunotherapy using SLNs. On the other 
hand, liposomes demonstrate a lipidic nanoparticulate drug delivery system 
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intensively utilised to target the immune system [24]. They offer the possibility to 
incorporate various types of antigens and adjuvants, either into their aqueous core 
or into the phospholipid bilayer. In addition, attachment of the payload onto the 
particle’s surface is possible. Furthermore, due to modifiable features, such as 
particle size, size distribution, lipid composition or charge, different types of 
immune reaction can be stimulated [25]. The excellent potential of liposomes to 
acitvate the immune system is proved by two marketed 
vaccines (Epaxal®, hepatitis A vaccine and Inflexal® V, influenza vaccine) and one 
cancer vaccine (Stimuvax®), which is tested in a phase III clinical trial [26]. 
Moreover, liposomes showed good clinical effects in delivering plasmid DNA to treat 
allergic diseases, such as canine atopic dermatitis, and are able to enhance the 
immunotherapeutic efficacy of cytosine phosphate guanine oligonucleotides 
(CpG ODNs) in the treatment of cancer and infectious diseases [27, 28]. However, to 
prepare effective lipoplexes (liposomes carrying nucleic acids) cationic lipids are 
often required, which are known to be cytotoxic in vitro and in vivo [29]. 
Furthermore, they are less stable against biological and physiological stresses 
compared to polymeric nanoparticles [30]. 
2.2 PROTEINS AS BIODEGRADABLE BASE MATERIALS FOR NANOPARTICLES 
Proteins are intensely studied for the preparation of nanoparticles. Proteins consist 
of different amino acids and therefore, many moieties are available for chemical 
modification (covalent or non-covalent) in the matrix or on the particle surface. 
Altering the particle surface allows attaching bioactives and/or targeted 
delivery [31]. Due to their biodegradability, the accumulation of proteins is unlikely 
to occur and degradation products are usually non-toxic [32].  
Considering multiple dose administrations of protein nanoparticles, possible 
immunogenicity associated with the protein particles should be kept in mind. 
However, there are mechanisms to metabolise natural proteins. Rapid enzymatic 
degradation is expected to decrease the chance of triggering an immune 
response [31]. The long parenteral use of gelatine and albumin nanoparticles 
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support this statement. Particles based on human serum albumin (HSA) have been 
thoroughly researched and their characteristics are well-established [3]. The first 
nanoparticulate product licensed for the use in humans is based on 
HSA (Abraxane®) and was marketed in 2005 [3]. Many in vitro and in vivo studies 
showed that albumin nanoparticles have a high drug loading capacity for a variety 
of active agents (hydrophilic, hydrophobic, proteins, oligonucleotides) [30]. 
Furthermore, they are both biodegradable and biocompatible and capable of 
crossing the blood brain barrier [33]. Although, albumin nanoparticles are 
promising drug carriers and successfully tested in delivering interferon γ (IFN-γ) to 
macrophages, there is only few research on targeting the immune system [34, 35]. 
Particles based on recombinant silk protein have been developed as promising drug 
delivery systems due to their biocompatibility, slow biodegradability, mechanical 
properties, controllable morphology and structure [36]. Further advantage is that 
silk nanoparticles can be prepared by desolvation of the protein without the need of 
organic solvents [37-39]. Moreover, they show a constant drug release and 
promising results as vaccine carriers [40, 41]. However, the recombinant 
production causes high prices for the starting material. 
 
Besides these different synthetic and natural starting materials, this work will 
concentrate on nanoparticles prepared of gelatine. 
2.3  WHY GELATINE NANOPARTICLES? 
Gelatine is a natural polymer obtained from collagen mainly by acidic (Type A, from 
porcine skin, isoelectric point (IEP) pH 9.0) or alkaline (Type B, from bovine ossein 
and skin, IEP pH 5.0) denaturation [42]. Abundant natural sources are an advantage 
over some other proteins and lead to low prices. Besides, gelatine is available from 
recombinant origin (recombinant human gelatine, rHG) [43]. The latter overcomes 
the problem of impurities and inhomogeneity of molar mass [43], as well as the risk 
of immunogenicity of proteins from non-human sources [42].  
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Gelatine has a long history of use in medicine due to its biodegradability, 
biocompatibility, low immunogenicity and high physiological tolerance [4]. The FDA 
classifies gelatine as “Generally Recognised as Safe” (GRAS) in the record of safety 
for food supplement [42]. Gelatine derivatives are intravenously applied as e.g. 
plasma expander (Gelafundin®, Gelafusal®) since the 1950s without serious adverse 
effects [44, 45]. Another successful medicinal use of gelatine is the application as 
patches for vascular seal (Gelsoft®, Gelseal®) [46, 47]. 
Further benefit of gelatine as starting material for nanoparticles is its variety of 
functional groups. This allows different possibilities of surface modification [48, 49], 
cross-linking [42, 50, 51] and marker coupling [52, 53]. In addition, targeting-
ligands [54, 55] as well as various types of drugs [56-58] may be coupled. Mainly, 
the amino acid lysine, providing a primary amino group, is very useful for all these 
modifications.  
Altogether, these characteristics make gelatine nanoparticles (GNPs) a promising 
carrier system for drug delivery. This is supported by the emerging interest in 
gelatine nanoparticles as drug delivery system displayed in an increasing number of 
publications over the last 20 years (Figure I-1). 
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Figure I-1 Number of publications per year regarding gelatine nanoparticles. (Source: Pubmed; 
search criteria: “gelatine nanoparticles” or “gelatin nanoparticles”). 
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3 OLIGODEOXYNUCLEOTIDE-LOADED GELATINE NANOPARTICLES AS APPROACH IN 
IMMUNOMODULATORY THERAPY 
3.1 CPG OLIGODEOXYNUCLEOTIDES AS POTENTIAL THERAPEUTIC OPTION IN ALLERGIC 
DISEASES 
The prevalence of allergic diseases, such as atopic dermatitis, is steadily rising, in 
humans as well as in domestic animals [27, 59, 60]. A prominent example in 
veterinary medicine is canine atopic dermatitis (CAD), a chronic relapsing 
inflammatory and pruritic allergic skin disease similar to human neurodermatitis. 
This multifactorial disease results from a complex interaction between genetic and 
environmental factors and involves a disrupted skin barrier, flare factors, allergic 
sensitisation and cutaneous inflammation. Furthermore, CAD is associated with IgE 
antibodies most commonly directed against environmental allergens, such as house 
dust mites and pollen [61, 62]. The acute reaction is characterised by an increase of 
Th2-derived cytokines, such as IL (Interleukine)-4, IL-5, which are involved in 
activation and degranulation of granulocytes as well as immunoglobulin isotype 
switching to pro-allergic IgE. Furthermore, IgE-coated mast cells degranulate and 
release histamine and proteases when IgEs are crosslinked by antigen. Proteins 
released from granula induce acute and delayed dermal inflammation [61, 63]. The 
acute inflammation is characterised by hyperpermeability of vasculature, whereas 
the delayed inflammation is related to tissue damage caused by pro-inflammatory 
cells. This acute allergic reaction is followed by a chronic phase of CAD, which shows 
Th1-dominant cellular inflammation marked by cytokines, such as pro-
inflammatory tumour necrosis factor α (TNF-α) and INF-γ, which activate 
macrophages [63]. Characteristic acute clinical signs are pruritus, erythrema, 
oedema or excoriations (Figure I-2) [64]. In the chronic phase, symptoms such as 
self-induced alopezia, hyperpigmentation and/or lichenification may additionally 
develop [61]. Furthermore, due to pruritus and subsequent scratching skin lesions 
increase. This is often followed by secondary infections with Malassezia yeasts or 
staphylococci, which exacerbate inflammatory reactions [63].  
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Allergen-specific immunotherapy (ASIT) is the only therapeutic approach, which is 
able to prevent the development of symptoms and modify long-term course of 
CAD [61]. However, for successful treatment, ASIT has to be performed up to a year 
and in some cases life-long therapy is necessary. Despite all efforts, the success rate 
of ASIT may only be between 50-70% [27]. 
Other available treatment options aim to control the symptoms rather than the 
origin of the disease. This includes reduction of the allergen burden, anti-
inflammatory glucocorticoids or immunosuppressive drugs, such as ciclosporin or 
tacrolimus [63]. 
 
Figure I-2 Clinical signs of acute flare of canine atopic dermatitis including erythrema, oedema and 
excoriations taken from [61]. 
A causal therapy approach would include unmethylated cytosine phosphate 
guanosine oligodeoxynucleotides (CpG ODNs) that are recognised by the innate 
immune system via Toll-like receptor (TLR) 9 [65]. The activation cascade following 
CpG ODN recognition is displayed in Figure I-3. Pro-inflammatory cytokines, such as 
INF-α and β, TNF-α or IL-6 are secreted and cellular non-specific defence 
mechanisms are induced. This includes the activation of natural killer cells, as well 
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as differentiation of Th1 effector cells. On the other hand, a humoral immune 
reaction is initiated. This leads to the suppression of allergy-associated IgE secretion 
together with an isotype switch from IgE to IgG [65]. Thus, less allergic reactions 
such as mast cell degranulation can be induced by antigen-binding IgE [65]. 
 
Figure I-3 Representation of the cascade initiated by CpG-mediated TLR 9 activation taken from [65]. 
Furthermore, IL-10 releasing regulatory T (Treg) cells are involved in the cascade 
initiated by TLR 9 activation by CpG ODNs [66]. IL-10 is a beneficial agent in the 
pathophysiology of atopic diseases by modulating mechanisms associated with 
allergies. For instance, IL-10 inhibits the pro-allergic IgG to IgE switch as well as the 
activation of mast cells and dendritic cells. In this way, the production of pro-
inflammatory cytokines, such as TNF-α and IL-6 is reduced [66]. Thus, the pro-
inflammatory Th1 shift can be controlled, too. Recent studies proved the activation 
of Treg and further release of IL-10 as promising therapeutic option in allergies [66, 
67]. 
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In summary, CpG ODNs lead to a shift from a Th2-dependent pro-allergic immune 
response to a Th1-mediated immune response. In the treatment of atopic diseases, 
such as canine atopic dermatitis, this redirection of the immune responses from Th2 
to Th1 is a very promising approach.  
3.2 GELATINE NANOPARTICLES AS DELIVERY SYSTEM FOR CPG ODNS 
When immunomodulating nucleic acids should be applied in vivo, the most 
important technical aspect is to protect them from enzymatic degradation through 
DNases. Therefore, DNAse-resistant synthetic CpG ODNs have been developed. This 
resistance could be achieved by the partial or complete substitution of oxygen of the 
phosphodiester backbone by sulphur, which results in a stable 
phosphorothioate (PTO) backbone [68]. A further approach is the application of 
nanoparticulate drug delivery systems, such as GNPs [68]. 
 
So far, only a few groups investigated the capability of nanoparticles to prevent 
DNase-dependent degradation of CpG ODNs [69]. For instance, a study by Zorzi et al. 
investigated the DNase resistance of plasmid DNA when it was incorporated into 
GNPs [70]. The authors showed stability against DNase I of the GNP-DNA system for 
at least one hour, whereas free DNA was degraded immediately. Moreover, there is 
a lack of studies probing the DNase protection of electrostatically bound CpG ODNs 
onto the surface of GNPs. Nevertheless, various successful in vitro and in vivo studies 
support the assumption that GNPs are able to protect DNA when it is attached to 
their surface [71-79]. 
Additionally, through co-delivery of CpG ODNs with GNPs the cellular uptake may 
be enhanced and an interaction of CpG ODNs with the intracellular target TLR 9 is 
more likely. Due to their sizes between 150 nm and 350 nm, which is similar to those 
of microorganisms, ODN-loaded GNPs are predominantly phagocytised by APCs [5, 
80].  
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In a previous murine in vitro and in vivo study, GNPs have proven to enhance the 
uptake and the immunostimulatory effects of CpG ODNs [71]. In the same study, 
CpG-GNPs were successfully evaluated to induce production of proinflammatory 
cytokines in human primary plasmacytoid dendritic cells and B cells [71]. The 
authors concluded that GNPs are biodegradable and well tolerated drug delivery 
systems for CpG ODNs and strongly increase activation of the immune system. A 
follow up in vivo study in a murine melanoma model confirmed these conclusions 
and showed that CpG-GNPs are superior in activating an antitumoral immune 
response compared to free CpG ODNs [72]. Furthermore, GNPs were able to prevent 
a CpG-mediated destruction of lymphoid follicles [72]. 
A further in vitro study dealing with the investigation of CpG-GNPs in the treatment 
of allergy-derived canine atopic dermatitis demonstrated a significant stronger 
increase in IL-10 production compared to free CpG ODNs [75]. Consequently, GNPs 
again showed their potential to protect nucleic acids from degradation and to 
enhance cellular uptake.  
 
Moreover, CpG-GNPs have a long history in the experimental treatment of recurrent 
airway obstruction (RAO) in horses, an allergic disease similar to human asthma. A 
first in vitro study found the optimal CpG ODN sequence to induce the desired 
immune responses, IL-4 downregulation as well as IL-10 and IFN-γ upregulation in 
equine bronchoalveolar lavage (BAL) cells [74]. Furthermore, the advantage of 
delivering CpG ODNs via GNPs was demonstrated by higher cell viabilities [74]. A 
second study showed that CpG-GNPs can be efficiently nebulised and retained their 
immunostimulatory effects in equine BAL cells [81]. 
These in vitro studies paved the way for several in vivo studies in RAO-affected 
horses and a formulation patent [76-78, 82]. Firstly, five successive inhalations of 
CpG-GNPs led to a significant induction of IL-10 release and a partial remission of 
the clinical signs [76]. This was followed by a double-blinded, placebo-controlled, 
prospective, randomized clinical trial, which showed an potent and prolonged 
clinical effect [78]. This included a decrease in respiratory effort, nasal discharge, 
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tracheal secretion and an increase in arterial oxygen pressure. Furthermore, the 
effect of a co-administration of the relevant allergens was investigated [77]. This 
study revealed that a co-application of the specific allergen is not relevant to initiate 
an appropriate immunomodulatory effect and to improve clinical parameters [77]. 
Currently, the results of a fourth clinical trial are evaluated. This investigation 
combined a dose-response study and a comparison to the standard therapy 
inhalative glucocorticoids to inhaled CpG-GNPs [83].  
 
Besides, different in vitro and in vivo studies showed that GNPs are also capable to 
carry, protect and efficiently deliver other types of nucleic acids, such as plasmid 
DNA, RNA oligonucleotides, NF-κB inhibiting decoy oligodeoxynucleotides or 
double stranded DNA and RNA oligonucleotides [49, 73, 84, 85]. 
 
These positive attributes as well as the previously mentioned biodegradability, 
biocompatibility and physiological tolerance of gelatine make GNPs very attractive 
delivery systems for CpG ODNs.  
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4 AIM OF THE THESIS 
This thesis is based on long successful research and development of GNPs in the field 
of treating allergic diseases and aimed to achieve a further step into 
commercialisation of CpG ODN-loaded GNPs.  
 
The work focusses on the preparation of gelatine nanoparticles with the aim to 
optimise the production process and provide methods for scale-up. For this, a 
straightforward one-step desolvation method was introduced to replace the 
common, but delicate two-step desolvation process. A commercially available 
gelatine type should be found that enables to perform the already described one-
step desolvation without the need of customised gelatine and subsequent large-
scale production of GNPs. Additionally, with regards to future application in 
humans, suitable non-toxic cross-linkers are investigated to substitute the 
standardly used glutaraldehyde (Chapter II). 
 
Furthermore, bearing a future commercial implementation and wide medicinal use 
in mind, this project aimed to develop a storage stable ready-to-use formulation. In 
order to achieve this, freeze-dried ODN-loaded GNPs were further developed, and 
new lyophilisation approaches were investigated, such as controlled nucleation 
prior to freeze-drying or novel amino acid containing formulation compositions. 
Furthermore, MALDI MS was examined as a versatile tool to evaluate ODN 
integrity (Chapter III).  
 
A further requirement for commercialisation and clinical use is an approach to 
sterilise the final drug product. Therefore, this project addressed the goal to 
establish suitable sterilisation processes for GNPs. For plain GNPs, this work 
researched steam sterilisation as an easy and suitable method. On the other hand, 
gamma irradiation was studied as promising sterilisation process for lyophilised 
ODN-loaded GNPs (Chapter IV). 
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In addition, this work concentrates for the first time on in vivo effects of ODN-loaded 
GNPs in the treatment of canine atopic dermatitis. A preliminary study was 
examined to provide the basis for further clinical studies. This study was carried out 
in cooperation with the small animal clinic of the Ludwig-Maximillians-Universität 
München (Chapter V). 
 
Further aim of this project, but not explicitly described in this thesis, was to supply 
different clinical studies in recurrent airway obstruction (RAO) affected horses with 
CpG-loaded GNPs. The first study dealt with the question if a co-application of CpG-
GNPs and specific allergens would further increase the efficacy of the 
treatment [77]. The main outcome of this investigation was that additive allergens 
are not necessary to initiate an efficient improvement of RAO by CpG-GNPs. The 
second study supplied during this project focussed on the determination of a dose 
response relationship and the comparison of CpG-GNP treatment with the standard 
inhalative glucocorticoid therapy [83]. The results are currently under evaluation. 
Both studies were carried out at the equine clinic of the Ludwig-Maximillians-
Universität München. Lastly, lyophilised CpG-GNPs were provided for a future 
clinical trial in racehorses suffering from a mild form of asthma, so called 
inflammatory airway disease (IAD). This study will be conducted at the equine clinic 
of the Freie Universität Berlin.  
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ABSTRACT 
Gelatine nanoparticles (GNPs) are biodegradable and biocompatible drug delivery 
systems with excellent clinical performances. A two-step desolvation is commonly 
used for their preparation, although this methodology has several shortcomings: 
lack of reproducibility, small scales and low yields. A straightforward and more 
consistent GNP preparation approach is presented with focus on the development 
of a one-step desolvation with the use of a commercially available gelatine type. 
Controlled stirring conditions and ultrafiltration are used to achieve large-scale 
production of nanoparticles of up to 2.6 g per batch. Particle size distributions are 
conserved and comparable to those determined for two-step desolvation on small 
scale. Moreover, further approaches are investigated to scale GNP production: an 
increasing contact area between gelatine solution and acetone during common 
desolvation process, as well as the alternative preparation method 
nanoprecipitation. Additionally, a range of cross-linking agents is examined for their 
effectiveness in stabilising GNPs as an alternative to glutaraldehyde. Glyceraldehyde 
demonstrated outstanding properties, which led to high colloidal stability. This 
approach optimises the manufacturing process and the scale-up of the production 
capacity, providing a clear potential for future applications. 
 
KEYWORDS 
Gelatine nanoparticles, one-step desolvation, scale-up, cross-linking, AF4 
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1 INTRODUCTION 
Over the past few decades, the frequency of allergic diseases, such as asthma, has 
been steadily increasing in the human population. Today, it is estimated that 300 
million people suffer from asthma worldwide, furthermore by 2025, an 
additional 100 million people will be affected [1]. Evidence also indicates that there 
are an increasing number of domestic animals, which is afflicted with allergic 
pulmonary disorders. For example, recurrent airway obstruction (RAO) is currently 
the most common airway disease in horses [2]. RAO shares many similarities with 
human asthma and is described as a genetically predisposed allergic immune 
response to inhaled environmental allergens [3]. The allergic response leads to the 
development of major clinical signs, such as bronchoconstriction, mucus 
hypersecretion and inflammation of the lower airways [2, 4]. 
Conventional therapies include corticosteroids or β2-sympathomimetics. However, 
these therapeutics only aim to improve symptoms instead of treating the underlying 
disease mechanism. Thus, there is a strong need for novel causal treatment options. 
Cytosine phosphate guanosine oligodeoxynucleotides (CpG ODNs) have been 
identified to redirect the immune response from the pro-allergic Th2 pathway to the 
pro-inflammatory Th1 via the toll-like receptor (TLR) 9 stimulation [5]. The most 
important aspects of applying immunomodulatory ODNs in vivo are their protection 
from enzymatic degradation by DNase and their delivery into cells. Both can be 
achieved by using nanoparticles as delivery systems [6, 7]. Several nanoparticles 
have provided promising results as carrier systems for CpG ODNs, such as 
mesoporous silica nanoparticles (MSN) [8], protamine nanoparticles (“proticles”) 
[9] or gelatine nanoparticles [10-13]. MSN could successfully prevent CpG ODNs 
from degradation and enhance cellular uptake [8]. However, in vitro studies using 
MSN revealed complications, such as formation of reactive oxygen species or 
inhibition of cellular respiration [14]. “Proticles” loaded with CpG ODNs showed the 
ability to prevent an allergen-induced Th2 immune response in mice [9]. 
Nevertheless, protamine may induce severe side effects, such as histamine release 
or anaphylactic reactions [15]. 
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On the other hand, gelatine is one of the most popular biopolymers and widely used 
in pharmaceutical and medical applications due to its biodegradability, 
biocompatibility and its physiological tolerance. Its unfunctionalised amine groups 
allow surface modifications that enable loading of CpG ODNs via electrostatic 
interactions. All of these features make GNPs a very attractive delivery system for 
CpG ODNs.  
An aerosol formulation of cationised GNPs loaded with CpG ODNs (CpG-GNPs) has 
previously been developed to improve the immunotherapy of RAO, and was recently 
applied successfully in several in vivo studies [10-12, 16]. The inhalation of CpG-
GNPs led to a significant improvement of clinical parameters, such as respiratory 
effort, nasal discharge or tracheal secretion in comparison to a placebo [12]. 
However, the co-application of allergens did not further increase the efficacy of this 
treatment [11, 17].  
Besides RAO in horses, CpG-GNPs also showed the first positive results in the 
treatment of allergy-derived canine atopic dermatitis [18, 19]. All these studies 
indicate that CpG-GNPs are very effective for the treatment of allergic diseases and 
provide a promising and innovative strategy beyond the conventional symptomatic 
therapies. 
 
The most common preparation method for GNPs is two-step desolvation [20]. In 
principle, stretched gelatine molecules change their conformation into coiled 
structures due to the controlled addition of acetone to a gelatine solution followed 
by the stabilisation of GNPs with a chemical cross-linker. During the first desolvation 
step, the high molecular weight (HMW) fraction of gelatine is separated from the 
low molecular weight (LMW) fraction by precipitation. In the second desolvation 
step, GNPs are formed. This separation is necessary due to the heterogeneous 
molecular mass distribution of gelatine. Monodisperse GNPs can only be formed 
from the HMW fraction. Without discarding the LMW fraction, the desolvation 
method would lead to the formation of large nanoparticles in a wide size range, 
which are prone to aggregation [20, 21]. The lab-scale preparation of these 
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nanoparticles has become a standard method, although it is susceptible to several 
issues: low particle yields, lack of reproducibility of the first desolvation step, and 
difficult process scale-up.  
Due to the exceptional clinical results of GNPs as carrier systems in the treatment of 
asthmatic horses, GNPs are no longer only a research tool [10, 12]. The present work 
provides an improved and more reproducible process that enables the transfer from 
the conventional bench lab methodology to the large-scale production of GNPs. This 
novel approach is based on preliminary studies by our group led by C. Coester using 
a non-commercial, customised high molecular weight gelatine type A [22-24], which 
allowed to neglect the first irreproducible desolvation step. A previous study by 
Ofokansi and co-workers [25] demonstrated how the commercially available 
gelatine type B 225 bloom could be used in a one-step desolvation. However, this 
procedure involved a complex series of incubation steps and a strong effect of pH on 
particle size was reported. The current study was performed to establish a more 
robust and straightforward one-step desolvation for monodisperse GNPs from a 
commercially available gelatine type A 300 bloom as well as gelatine type B 300 
bloom. 
In addition to the gelatine quality, the process conditions during desolvation are 
crucial parameters for nanoparticle formation [22]. A higher gelatine concentration 
promotes higher inter-molecular interactions and co-aggregation of gelatine during 
desolvation. As a result larger nanoparticles are formed [22]. The pH value strongly 
influences the net charge of gelatine. If the pH of the gelatine solution is similar to 
the isoelectric point (IEP), the overall net charge is insufficient and particle 
aggregation most likely occurs [22, 26]. However, the further away the pH value is 
from the IEP, the more sufficiently charged the particles are and higher 
intermolecular electrostatic repulsion forces prevent aggregation, but the particle 
size and yield decrease. If the pH is too far away from IEP, the net charge is too strong 
to allow desolvation and nanoparticle formation. Moreover, the solvent used for 
desolvation has an influence on particle characteristics. Commonly used solvents 
are acetone and ethanol, where acetone is the preferred desolvation agent due to 
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smaller particle sizes and lower PDI values [26]. Azarmi et al. could show that GNPs 
prepared with ethanol showed particles, which were 100 – 150 nm larger in size 
than GNPs prepared with acetone [26]. 
Two-step desolvation has become the standard preparation process for gelatine 
nanoparticles, but a reliable scale-up method has not yet been established [27]. It is 
known from human serum albumin (HSA) nanoparticles that a higher stirring 
efficiency during desolvation enabled large-scale preparation without a negative 
influence on particle size or size distribution [28]. With a paddle stirrer, a 
homogeneous distribution of the HSA molecules could be ensured, which was not 
achieved sufficiently with a stirring bar due to reduced stirring efficiency in higher 
volumes and irregular hydrodynamics. This principle was transferrable to GNP 
preparation by one-step desolvation. Furthermore, the purification process could be 
enhanced by ultrafiltration. 
Aside from pH value and stirring efficiency, the contact area between gelatine 
solution and desolvation agent was defined as an important process parameter [29]. 
The GNP formation mainly occurs at the surface of the gelatine solution where the 
desolvation agent gets in contact with the gelatine molecules and causes interfacial 
turbulences [30]. By enlarging this area, GNP output should increase, too. The 
present study was conducted to evaluate if expanding this area via spreading the 
tubes, which are used to add acetone, over the whole gelatine solution or using a 
dual syringe pump system could efficiently raise GNP yield.  
A completely different concept to optimise and scale GNP preparation is via 
nanoprecipitation [31]. For this approach two miscible solvents are required. 
Gelatine should be soluble in one of them (typically water) and insoluble in the other 
liquid (“non-solvent”, typically ethanol). The aqueous gelatine solution is slowly 
poured into the “non-solvent” phase containing a stabiliser, such as 
poloxamer 407 [31]. Due to the miscibility of the liquids a violent diffusion is 
observed, which causes the torn of small solvent droplets from the interface. The 
stabilising agent rapidly preserves these droplets until the solvent is completely 
spread and protein coagulation occurs [30]. Khan and Schneider have stated that 
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nanoprecipitation is an advantageous, rapid and easy method that enables the 
preparation of nanoparticles (approximately 200 - 250 nm) with unimodal size 
distribution [31]. The following study was performed to investigate the feasibility of 
nanoprecipitation for GNP scale-up.  
 
Micro- and nanoparticles are commonly prepared through glutaraldehyde cross-
linking of gelatine [32, 33]. Although glutaraldehyde is well established as a cross-
linker, it represents a potential risk to humans and can cause irritations and 
inflammations at low concentrations [34, 35]. It is therefore essential to remove any 
unconsumed glutaraldehyde after particle preparation. As these systems could 
potentially be used for treating human diseases, more suitable and safer cross-
linking agents have to be identified. Alternative cross-linking methods for GNP 
preparation such as genipin [36], transglutaminase [37] or glyceraldehyde [38] have 
previously been investigated. Nonetheless, none of these has successfully 
substituted glutaraldehyde as the standard cross-linking agent. In this study, we 
addressed whether particle stabilisation with genipin or glyceraldehyde could 
generate GNPs with properties comparable to those stabilised with glutaraldehyde.  
 
Due to the increasing biological application of CpG-loaded GNPs, this study aimed to 
simplify the desolvation manufacturing process in order to improve reproducibility, 
as well as the rate of yield. A screening of factors, such as gelatine type, 
concentration, pH value and contact area was performed on small scales. 
Furthermore, nanoprecipitation was examined as a different GNP preparation 
method. To evaluate the effect of alternative cross-linking agents, we studied 
incubation time, cross-linking degree and colloidal stability. 
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2 MATERIALS AND METHODS 
2.1  MATERIALS 
Gelatine type A 300 bloom and gelatine type B 300 bloom were obtained from Gelita 
AG (Eberbach, Germany). Acetone was supplied by Fisher Chemicals 
(Loughborough, UK). Gelatine type A 175 bloom, type A 100 bloom, type B 75 bloom, 
glutaraldehyde (25% solution), glyceraldehyde, 1-Ethyl-3-(3-
dimethylaminopropyl) carbodiimide (EDC), (2-Aminoethyl) trimethylammonium 
chloride hydrochloride (Cholamine), 2,4,6-Trinitrobenzenesulfonic acid (TNBS) and 
poloxamer 407 were purchased from Sigma (Taufkirchen, Germany). Genipin was 
acquired from Wako Chemicals GmbH (Neuss, Germany). Highly purified water 
(HPW), which was produced by a PURELAB Plus device (conductivity < 0.055 
µS/cm, Elga Labwater, Celle, Germany), was used in all experiments. 
2.2  PREPARATION OF GELATINE NANOPARTICLES 
2.2.1 OPTIMISATION OF GELATINE NANOPARTICLE PREPARATION 
Gelatine nanoparticles were prepared either by two-step desolvation [20] or one-
step desolvation [24], as a modification of the common two-step desolvation 
method. In brief, an amount of 750 mg gelatine type A 300 bloom was dissolved in a 
volume of 25 mL of HPW under constant stirring at 50°C. The pH was adjusted to a 
value below the isoelectric point (IEP pH 8 – 9). In case of gelatine type B 300 bloom 
the pH was adjusted to a value above the isoelectric point (IEP pH 4.5 – 5.0). Acetone 
was then added drop-wise to the gelatine solution in order to initiate desolvation 
and nanoparticle formation. With respect to particle stability, a volume of 175 µL 
glutaraldehyde solution was added to cross-link GNPs. The dispersion was stirred 
overnight and purified by two-fold centrifugation (20000*g for 15 min; Sigma 
Laborzentrifugen, Osterode, Germany).  
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Varied gelatine concentrations [2.0%, 3.0%, 4.0% and 5.0% (w/v)] were 
investigated as well as different pH values between 2.5 - 3.0 and 6.0 – 8.0 for gelatine 
type A and B, respectively, at a fixed initial gelatine concentration [3.0% (w/v)]. 
With the aim to scale up the one-step desolvation process, the five-fold 
amount (3.75 g) of gelatine type A 300 bloom was used and GNP preparation was 
performed as mentioned above. 
2.2.2 CATIONISATION OF GELATINE NANOPARTICLES  
Cationisation of GNPs was performed according to the standard protocol [39]. In 
brief, GNP dispersion was diluted with HPW (1-2 mg/mL) and pH was adjusted to a 
value between 4.5 and 5.0. Then, 50 mg of each 1-Ethyl-3-(3-dimethylaminopropyl) 
carbodiimide (EDC) and (2-Aminoethyl) trimethylammonium chloride 
hydrochloride (Cholamine) were added. The reaction mixture was incubated for 
30 min and purified by two-fold centrifugation (16000*g for 15 min; Sigma 
Laborzentrifugen, Osterode, Germany). 
2.2.3 GELATINE NANOPARTICLE PURIFICATION BY ULTRAFILTRATION 
The GNP dispersion was purified via ultrafiltration using a solvent resistant stirred 
cell (Millipore S.A.S., Molsheim, France) with an ultrafiltration disc of regenerated 
cellulose and a molecular weight cut-off of 100’000 kDa (Millipore S.A.S., Molsheim, 
France). To ensure purification from acetone and residual glutaraldehyde, the 
filtration was repeated three times. 
2.2.4 ALTERNATIVE APPROACHES TO INCREASE PARTICLE YIELD 
INCREASING THE CONTACT AREA BETWEEN GELATINE AND ACETONE 
Gelatine nanoparticles were prepared using the standard two-step desolvation 
method [20]. As a modification, the way of adding acetone to induce desolvation, 
was changed. During the second desolvation step the contact area between gelatine 
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and acetone was increased by positioning the two tubes in opposite position. In a 
second experiment, a peristaltic pump using six tubes (MINIPLUS 3, Gilson Inc., 
Middleton, USA) was utilised. During the acetone addition, the tubes were placed 
over the whole area of the gelatine solution. 
DUAL SYRINGE PUMP SYSTEM 
The standard two step desolvation method [20] was modified to adopt the process 
to the dual syringe pump 100 DX system (Teledyne Isco, Lincoln, USA) used for e.g. 
spider silk particle production [40]. The first desolvation step was performed in the 
standard manner, which is necessary to separate the LMW fraction of gelatine. The 
dual syringe pump system was used to perform the second desolvation step. After 
discarding the LMW fraction, the gelatine sediment was redispersed in a volume of 
25 mL of HPW and pH adjusted (pH 2.5 - 3.0). Subsequently, the gelatine solution 
was filled into one of the two syringes (max. filling volume 100 mL). The other 
syringe was filled with 100 mL acetone and both syringes were connected via a T-
shaped mixing element. Both liquids were mixed with a flow rate ratio of 1:3 
(gelatine solution: acetone). Afterwards, GNPs were cross-linked by 
glutaraldehyde (25%). 
NANOPRECIPITATION 
Nanoprecipitation was performed as described by Khan and Schneider [31]. 
Gelatine of different type and bloom number was dissolved in highly purified water 
under stirring and heating (50°C). Afterwards, the gelatine solution was added 
dropwise to an ethanol solution 95% (v/v) that contained poloxamer 407 as a 
stabiliser. Subsequently, formed GNPs were cross-linked by the addition of 
glutaraldehyde (25%). The exact compositions of the solutions are presented in 
Table II-1.  
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Table II-1 Different formulation compositions for preparation of GNPs by nanoprecipitation. 
Formulation 
Composition 
Gelatine type/ 
Bloom number 
Gelatine conc. 
[mg/mL] 
Ratio gelatine 
solution: ethanol 
Conc. Poloxamer 
407 [%] (w/v) 
A A / 175 bloom 25 1:10 7 
B A / 175 bloom 25  1:10 10 
C A / 100 bloom 25  1:10 7 
D A / 100 bloom 25  1:10 10 
E B / 75 bloom 25  1:10 7 
F B / 75 bloom 25  1:10 10 
G B / 75 bloom 20  1:10 10 
 
2.2.5 EVALUATION OF ALTERNATIVE CROSS-LINKING AGENTS 
Plain GNPs were prepared by one-step desolvation according to the aforementioned 
protocol without subsequent cross-linking by glutaraldehyde. To stabilise GNPs, 
either glyceraldehyde or genipin were added. Different pH conditions as well as 
cross-linking agent concentrations were evaluated (Table II-2). After incubation, 
GNPs were purified by two-fold centrifugation and redispersed in HPW. GNPs were 
stored at 4°C and colloidal stability was tested by measuring particle size and PDI 
values over a period of 35 days.  
Table II-2 Concentrations and pH conditions of alternative cross-linking agents. (*referred to volume 
of gelatine solution). 
Gelatine Cross-linking agent pH value 
Conc. cross-linking 
agent [mg/mL] * 
Incubation 
time [h] 
Type A Glyceraldehyde 2.5-3 8-20 20-65 
Type A Genipin 2.5-4.5 10-30 24-48 
Type B Glyceraldehyde 6-7 10-30 19 
Type B Genipin 6 10-30 19 
Scaled batches using glyceraldehyde as cross-linking agent were performed 
following the standard procedure of one-step desolvation with the five-fold amount 
of gelatine (3.75 g) and purification by ultrafiltration. 
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2.3  CHARACTERISATION OF GELATINE BULK MATERIAL BY ASYMMETRIC FLOW FIELD-FLOW 
FRACTIONATION (AF4) 
Characterisation of gelatine bulk material was performed by asymmetric field flow-
field fractionation (AF4). Gelatine type A 300 bloom and gelatine type B 300 bloom 
were analysed. Control samples were standard gelatine type A 175 bloom, the 
sediment, which is obtained by the first desolvation step during two-step 
desolvation, as well as customised gelatine (VP413-2) that possessed less 
than 20% (w/w) peptides < 65 kDa. Measurements were conducted with a Wyatt 
Eclipse 2 system (Wyatt Technology, Dernbach Germany) combined with an 
Agilent 1100 HPLC system (Agilent Technologies, Palo Alto, USA) equipped with UV 
and RI detection and a Wyatt Dawn Eos multi-angle laser light scattering (MALS) 
detector. The refractive index increment dn/dc was set to 0.174 mL/g and the 
second virial coefficient was set to 0. The channel height was 350 μm and a 
regenerated cellulose membrane with 10 kDa molecular weight cut-off was applied. 
Phosphate buffer (2M Na2HPO4 * 2 H2O) pH 6.0 was chosen as running buffer. 
According to Schultes et al. [41] channel flow was set to 1.0 mL/min and a cross flow 
of 0.05 mL/min was applied. The complete measurement period was 20 minutes.  
2.4  CHARACTERISATION OF GELATINE NANOPARTICLES 
2.4.1 PARTICLE SIZE AND ZETA POTENTIAL MEASUREMENTS  
Particle size and polydispersity index (PDI) were determined by dynamic light 
scattering (DLS) using a Zetasizer Nano ZS (Malvern Instruments, Worcestershire, 
UK). Zeta potential measurements were carried out by electrophoretic light 
scattering with the Zetasizer Nano ZS.  
2.4.2 PARTICLE CONCENTRATION 
The particle concentration was obtained via gravimetric determination using a 
UMX2 ultra-microbalance (Mettler Toledo, Greifensee, Switzerland). 
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2.4.3 DETERMINATION OF CROSS-LINKING DEGREE 
Cross-linking degree of GNPs was determined by TNBS assay. Briefly, an aliquot of 
the GNP dispersion was diluted with HPW to a certain concentration (1 mg GNPs in 
total volume of 250 µL). A volume of 0.25 mL of 0.05% TNBS (v/v) (Sigma Aldrich 
Chemie GmbH, Steinheim, Germany) and 0.25 mL of 4% NaHCO3 (w/v) (pH 8.5, 
Sigma Aldrich Chemie GmbH, Steinheim, Germany) were added. The samples were 
incubated in a Thermomixer (Eppendorf, Hamburg, Germany) for 2 hours under 
constant shaking (500 rpm) at 40°C. A volume of 750 µL of HCl 6M was then added 
to each sample, which were further incubated for 90 min at 60°C under constant 
shaking at 500 rpm. Subsequently, specimens were diluted with HPW for 
photometric determination of the reaction product at 349 nm (Agilent 8453 UV-
visible sprectrophotometer, Agilent Technologies, Santa Clara, CA, USA). Blank 
samples of gelatine (≙ 0% cross-linking) and control samples of gelatine (≙ 100% 
cross-linking) were prepared. The control samples were treated as the specimens 
except that HCl was added prior to the TNBS solution to avoid the reaction between 
TNBS and free amino groups of gelatine. Cross-linking degree was determined by 
the following equation: 
𝐶𝐿 [%] = (1 −
𝐴(𝑠𝑎𝑚𝑝𝑙𝑒) − 𝐴(𝑏𝑙𝑎𝑛𝑘)
𝐴(𝑐𝑜𝑛𝑡𝑟𝑜𝑙) − 𝐴(𝑏𝑙𝑎𝑛𝑘)
) ∗ 100% 
2.4.4 SCANNING ELECTRON MICROSCOPY (SEM) 
Gelatine nanoparticles were freeze dried according to the protocol of 
Zillies et al. [42] and immobilised on an aluminium sample grid. Samples were 
carbon sputtered under vacuum and analysed by a Helios NanoLab G3 UC scanning 
electron microscope (FEI, Hillsboro, Oregon, USA) at 2.0 kV and a working distance 
of 4.0 – 4.2 mm.  
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2.5  STATISTICAL EVALUATION 
Data were analysed for difference in particle yields between standard and scaled 
batches using a paired t-test performed by SigmaPlot 12.5 (Systat Software Inc., 
Erkrath, Germany). 
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3 RESULTS 
The objective of the present study was to optimise the manufacturing procedure for 
gelatine-based nanoparticles with the main focus on method robustness and overall 
particle yield. Here we present an enhanced and scalable gelatine nanoparticle 
preparation process using a commercially available gelatine in combination with a 
paddle stirring system (Figure II-1).  
 
Figure II-1 Schematic representation of the optimised gelatine nanoparticle preparation process and 
scale-up. 
3.1  PREPARATION OF GELATINE NANOPARTICLES BY ONE-STEP DESOLVATION 
3.1.1 EFFECT OF GELATINE CONCENTRATION AND PH VALUE 
TYPE A 300 BLOOM 
As reported in a previous study [22], the initial gelatine concentration and the pH 
value during desolvation with acetone are crucial parameters for nanoparticle 
formation. Here, we screened various gelatine concentrations and a range of pH 
values in order to define optimal conditions required for particle formation during 
one-step desolvation using gelatine type A.  
The different gelatine amounts and their effect on particle size and yields are shown 
in Figure II-2. The particles obtained had diameters between 150 – 300 nm, with a 
uniform size distribution (PDI < 0.15). The gelatine concentration affected the 
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particle size, whereby a higher input led to an increase in measured diameter. An 
initial increase in yield was observed with increasing gelatine concentrations; 
however, the percentage decreased with 4% and 5% of gelatine. In comparison to 
the two-step desolvation (yield ca. 1.5%), all batches showed higher particle yields. 
 
Figure II-2 Particle characteristics of GNPs prepared by one-step desolvation. Effect of 
concentrations on size and yield for gelatine type A 300 bloom (particle size: black dots, relative 
particle yield: black triangles) and type B 300 bloom (particle size: white dots, relative particle 
yield: white triangles) compared to two-step desolvation (particle size: dashed line, relative particle 
yield: dotted line). Data is presented as mean ± SD (n=3). 
To ensure that particles were formed with the pH conditions used for two-step 
desolvation, a range of pH 2.5-3.0 was tested during the desolvation process. At any 
value investigated, particles were obtained, which met the required criteria based 
on the results of common two-step desolvation (Figure II-3). This includes particle 
sizes between 150 – 200 nm and PDI values below 0.2. Thus, by using a gelatine type 
with 300 bloom, successful one-step desolvation can be performed without the 
initial drawback of a broad size distribution. 
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Figure II-3 Particle sizes (bars) and PDI values (dots) of GNPs prepared by one-step desolvation of 
gelatine type A 300 bloom at different pH values compared to two-step desolvation (particle 
size: dashed line, upper limit PDI value: dotted line). Data is represented as mean ± SD (n=3): 
TYPE B 300 BLOOM 
In the interest of producing GNPs with alternative particle characteristics, such as a 
negative surface charge, the one-step desolvation process was adapted to gelatine 
type B 300 bloom. Gelatine type B has an IEP of 4.7 – 5.6 [43] and thus leads to the 
formation of negatively charged particles at pH value between 6.0 – 8.0. Again, 
different initial gelatine concentrations [2-5% (w/v)] and pH values beyond the IEP 
were evaluated (pH 4.7 – 5.6). Similar to gelatine type A 300 bloom, the particle 
diameter became larger with increased initial gelatine amount (Figure II-2). No 
effect was observed on the homogeneity of the samples and all GNP batches showed 
uniform size distribution (PDI < 0.15). In contrast to gelatine type A 300 bloom, 
higher initial concentrations of type B resulted in higher particle yields.  
For further experiments, a gelatine concentration of 3% was chosen for both 
gelatine types due to acceptable particle yields combined with adequate particle size 
and PDI value. 
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The evaluation of different pH values during desolvation showed smaller particle 
sizes as well as decreasing particle yields with increasing pH (Figure II-4). The 
further away the pH value was from the IEP, the higher the net charge of the gelatine 
molecules was. This results in stronger intermolecular electrostatic repulsion 
forces, which hinder the inter-molecular co-aggregation and thus particles with 
smaller diameter are formed.  
 
Figure II-4 Particle characteristics of GNPs prepared by one-step desolvation. Particle size (dots) and 
relative particle yield (triangles) of GNPs prepared at different pH values by one-step desolvation 
from gelatine type B 300 bloom compared to two-step desolvation (particle size: dashed line, relative 
particle yield: dotted line). Data is presented as mean ± SD (n=3). 
3.1.2 MEAN MOLECULAR WEIGHT OF GELATINE BASE MATERIAL 
The different types of gelatine starting material were analysed by AF4/MALS to 
determine their molecular weight distributions. The samples suitable for one-step 
desolvation (A 300 bloom and B 300 bloom) were compared to the standard gelatine 
type A 175 bloom, its sediment, as well as customised gelatine VP413-2 with a 
reduced LMW fraction. The aim of this study was to identify a range of molecular 
weights where GNP preparation by one-step desolvation is possible. Compared to 
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the customised gelatine batch VP413-2 (ca. 700 kDa), the standard gelatine A 175 
bloom (ca. 300 kDa) showed a lower mean molecular weight (Figure II-5). The 
molecular weight of the sediment was found to be around 400 – 500 kDa and the 
distribution of the gelatine qualities used for the one-step approach were 
comparable to that of the sediment. This demonstrated that a slight shift to a higher 
mean molecular weight was sufficient to enable one-step desolvation instead of two-
step desolvation.  
 
Figure II-5 Differences in molecular weight distribution of the various gelatine types and the 
sediment: Gelatine type A 175 bloom (A), sediment of gelatine type A 175 bloom after first 
desolvation (B), gelatine type A 300 bloom (C), gelatine type B 300 bloom (D), customised gelatine 
VP413–2 (E). 
3.2  SCALE-UP OF DESOLVATION PROCESS  
In addition to the optimisation of the GNP preparation process, scale-up was a 
central focus of this work. Attempts to maximize the production capacity of the two-
step desolvation have met major obstacles, such as reduced efficiency of the process. 
We were able to successfully enlarge the overall yield of the GNP preparation 
process by combining the one-step desolvation method with a paddle stirrer system 
that provided a tailored mixing intensity and thus more control over the mixing 
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efficiency (Figure II-6). Application of a five-fold initial gelatine amount (type A 300 
bloom) yielded 388.6 ± 53.3 mg per batch as opposed to 50-60 mg achieved with the 
standard batch size for one-step desolvation. Measured particle diameters 
were 185.2 ± 32.6 nm (PDI 0.070 ± 0,050) and therefore met the requirements.  
To increase the particle yield further and also to lower the particle loss during 
purification by centrifugation, ultrafiltration was performed. The purification of 
GNP dispersions using an ultrafiltration cell enabled the preparation of GNPs with a 
particle size of 120.4 nm ± 5.0 nm with a homogeneous size 
distribution (PDI 0.076 ± 0.014). Highly concentrated GNP dispersions were 
achieved with a particle yield of 69 – 83%, referring to 587.5 mg ± 58.4 mg 
GNPs (standard batch size). The combination of the scaled batch size and 
purification with the ultrafiltration cell significantly increased the yield 
to 2627 mg ± 163.8 mg, corresponding to ca. 70% (Figure II-6, p < 0.001). Taken 
together, with a 130-fold overall particle gain compared to two-step desolvation, 
this advanced methodology provides GNPs in high availability with reproducible 
product quality. 
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Figure II-6 Particle yields of GNPs prepared by one-step desolvation from gelatine type A 300 bloom. 
Comparison of standard batch size and purification by centrifugation (black bar), scaled batch size 
and purification by centrifugation (light grey striped bar), standard batch size and purification by 
ultrafiltration (dark grey striped bar) and scaled batch size and purification by ultrafiltration (light 
grey chequered bar). Data is presented as mean + SD (n=3). *** p < 0.001. 
3.3  SURFACE PROPERTIES OF GNPS 
The overall surface charge of gelatine nanoparticles prepared by two- or one-step 
desolvation, different preparation process and types of gelatine (A 300 bloom and 
B 300 bloom) were investigated using electrophoretic light scattering (Figure II-7). 
These measurements enabled comparison of the surface properties of the different 
GNP batches from gelatine type A prepared by two-step or one-step desolvation. 
Through cationisation, the zeta potential of the particles can be increased by at 
least 5 mV. Interestingly, the scaled one-step desolvation batches (gelatine type 
A 300 bloom) showed the highest zeta potential before and after cationisation. In 
contrast, GNPs from gelatine type B 300 bloom showed negative surface charge due 
to the pH value beyond the IEP during particle formation. Nevertheless, the standard 
cationisation process generated a permanent positive surface charge on GNPs from 
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gelatine type B, which is comparable to the zeta potential of cationised GNPs from 
gelatine type A. 
 
Figure II-7 Zeta potential of non-cationised (black bars) and cationised (grey striped bars) GNPs 
prepared by two-step desolvation from gelatine type A 175 bloom (TSD A175), one-step desolvation 
from gelatine type A 300 bloom (OSD A300), large scale one-step desolvation from gelatine type A 
300 bloom (OSD SC A300) and one-step desolvation from gelatine type B 300 bloom (OSD B300). 
Data is presented as mean ± SD (n=3). 
3.4  ALTERNATIVE APPROACHES TO INCREASE PARTICLE YIELD IN TWO-STEP DESOLVATION 
3.4.1 INCREASING THE CONTACT AREA BETWEEN GELATINE AND ACETONE 
Besides the importance of gelatine quality and pH value, it was stated that the area 
where acetone is added to the gelatine solution during the second desolvation step 
is crucial [29]. For that reason, two different approaches were conducted to increase 
the contact area between acetone and gelatine solution: Firstly, the two tubes for 
acetone addition were placed in the opposite position or even six tubes were used 
and evenly distributed above the gelatine solution area. Secondly, the contact area 
between the two solutions was maximized by using a dual syringe pump system for 
the second desolvation step. In this technique, the two liquids are filled into two 
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identical syringes, which are connected via a T-shaped mixing element. The 
precipitation of the nanoparticles occurs in this mixing element. 
Results of these experiments are shown in Figure II-8. Keeping apart the tubes for 
acetone addition had no negative influence on particle characteristics, as particle 
sizes and PDI values did not differ from GNPs prepared by the standard 
method (188.5 ± 25.9 nm vs. 172.2 ± 19.0 nm and 0.077 ± 0.024 vs. 0.079 ± 0.043). 
However, there was no beneficial effect on particle yield (1.3 ± 0.27% 
vs. 1.3 ± 0.35%). By using six tubes and thus further enlarging the contact area, no 
trend to higher particle yields (1.4 ± 0.50%) could be found. Nevertheless, this 
further expansion of contact area correlated with increasing particle 
sizes (207.8 ± 61.2 nm) and PDI values (0.143 ± 0.05), plus broadening of standard 
deviations. Based on these results, it can be assumed that the increase of the acetone 
contact area by a higher number of tubes would be not an option for escalation of 
GNP yields in common two-step desolvation. 
 
The maximisation of the contact area between gelatine solution and acetone by 
using the dual syringe pump system led to 50% higher particle output (2.2 ± 0.52%). 
Furthermore, this method seems to be appropriate for the preparation of GNPs with 
smaller particle sizes (150.1 ± 12.7 nm). Nonetheless, by making use of this benefit 
in production quantity, one needs to accept a reduction in monodispersity of the 
GNPs (PDI 0.143 ± 0.075) compared to the standard method by using a peristaltic 
pump for acetone addition.  
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Figure II-8 Particle characteristics of GNPs prepared by two-step desolvation with either two acetone 
tubes in opposite position, six tubes evenly distributed or using a dual syringe pump (particle 
size: black dots, PDI value: white dots, relative particle yield: white triangles) compared to standard 
two-step desolvation (particle size: dashed line, PDI value dotted line, relative particle 
yield: dashed/dotted line). Data is presented as mean ± SD (n=3). 
3.4.2 NANOPRECIPITATION 
As a completely different approach, nanoprecipitation was investigated as option 
for scaling GNP preparation. Different types of gelatine, gelatine concentrations and 
stabiliser concentrations were screened in order to find appropriate conditions.  
Results are displayed in Figure II-9. Interestingly, original conditions of gelatine type 
B 75 and 7-10% stabiliser as used by Khan and Schneider [31] led to very large and 
inhomogeneous GNPs with particle sizes between 443.4 ± 43.4 nm 
and 649.0 ± 226.8 nm and PDI values between 0.424 ± 0.032 and 0.672 ± 0.155 
(formulation compositions E-G). By using gelatine type A with a similar bloom 
number (100 bloom), hardly any change in particle size could be 
achieved (358 ± 87.4 nm and 443.8 ± 8.76 nm), but PDI values decreased to values 
between 0.298 ± 0.097 and 0.330 ± 0.035 (formulation compositions C-D). The best 
results were achieved with the standard two-step desolvation gelatine type A 175 
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bloom (formulation compositions A-B). Particle sizes ranged 
between 293.0 ± 12.9 nm and 328.7 ± 36.9 nm with corresponding PDI values 
of 0.272 ± 0.049 and 0.355 ± 0.085. Nonetheless, GNP characteristics were still far 
from those prepared by two-step desolvation (see reference lines in Figure II-9). 
However, nanoprecipitation enabled much higher particle yields than two-step 
desolvation. Relative outcomes varied between 13.4 ± 6.5% and 33.9 ± 10.4%.  
 
Figure II-9 Particle characteristics of GNPs prepared by nanoprecipitation (particle size: black dots, 
PDI value: white dots, compared to standard two-step desolvation (particle size: solid line, PDI 
value: dotted line) A: Gelatine A 175, 25 mg/ml, 7% stabiliser;  B: Gelatine A 175, 25 mg/ml, 
10% stabiliser; C: Gelatine A 100, 25 mg/ml, 7% stabiliser; D: Gelatine A 100, 25 mg/ml, 10% 
stabiliser; E: Gelatine B 75, 25 mg/ml, 7% stabiliser; F: Gelatine B 75, 25 mg/ml, 10% stabiliser, G: 
Gelatine B 75, 20 mg/ml, 10% stabiliser. Data is presented as mean ± SD (n=3). 
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3.5  EVALUATION OF ALTERNATIVE CROSS-LINKING AGENTS 
3.5.1 GLYCERALDEHYDE 
Glyceraldehyde is commonly used to increase the mechanical strength of the sclera 
via cross-linking collagen [44]. Here we applied glyceraldehyde for cross-linking of 
gelatine nanoparticles in order to substitute the commonly used glutaraldehyde. 
Glyceraldehyde was evaluated for its ability to cross-link GNPs made from either 
type A 300 bloom or type B 300 bloom. Various conditions, such as concentration of 
cross-linking agent and incubation time, were screened. Table II-3 Results of cross-
linking (CL) GNPs from different types of gelatine (type A 300 bloom and type B 300 
bloom) with glyceraldehyde and genipin (n=3) summarises the parameters that 
were examined for the preparation of stable particles, as well as the resulting 
particle characteristics. An extended cross-linking time of 65 hours was necessary 
to stabilise the nanoparticles from type A 300 bloom, compared to 15 hours 
required for glutaraldehyde. Additionally, particle sizes and PDI values strongly 
increased. Only a glyceraldehyde concentration of 16 mg/mL gave GNPs with 
acceptable characteristics; however, this forfeited the particle yield.  
In comparison to the standard reagent glutaraldehyde, similar particle 
characteristics were achieved when GNPs made from type B 300 bloom were cross-
linked with glyceraldehyde (Table II-3). Stable and monodisperse GNPs in a particle 
size range of 200 – 250 nm with high cross-linking degree and particle yield were 
prepared.  
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Table II-3 Results of cross-linking (CL) GNPs from different types of gelatine (type A 300 bloom and 
type B 300 bloom) with glyceraldehyde and genipin (n=3). 
Gelatin 
Type 
CL agent 
CL agent 
[mg/mL] 
Incuba-
tion [h] 
Particle 
size [nm] 
PDI 
CL 
degree 
[%] 
Yield 
[%] 
Colloidal 
stability 
A300 Glutaraldehyde 1.75 15 ≈ 200 < 0.2 ≈ 85 ≈ 10 yes 
B300 Glutaraldehyde 1.75 15 150 - 200 < 0.15 ≈ 85 ≈ 15 yes 
A300 Glyceraldehyde 16 65 300 - 350 < 0.2 ≈ 40 ≈ 2.5 yes 
B300 Glyceraldehyde 20 19 200 - 250 < 0.1 ≈ 75 ≈ 20  Yes 
A300 Genipin 10 - 30 24 - 48 gelation --- --- --- --- 
B300 Genipin 20 19 280 - 370 < 0.2 ≈ 40 ≈ 15 no 
In scale-up experiments, it could be shown that glyceraldehyde is suitable for large 
scale production of GNPs (Figure II-10). Using a five-fold amount of gelatine to 
produce particles combined with ultrafiltration gave similar particle sizes and PDI 
values to the standard procedure (200-250 nm, PDI < 0.15). A considerable increase 
in particle yield was obtained (2517 mg ± 411.8 mg vs. 112 mg ± 30 mg). 
 
Figure II-10 Preparation of GNPs in large scale using glyceraldehyde. Comparison of particle 
size  (bars), PDI value (white dots) and particle yield (black dots) of a standard batch purified by 
centrifugation or ultrafiltration, and a scaled batch size purified by ultrafiltration. GNPs were 
prepared using gelatine type B 300 bloom. Data is presented as mean ± SD (n=3). 
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3.5.2 GENIPIN 
In addition to glyceraldehyde, the naturally occurring cross-linking agent genipin 
was evaluated for its suitability to stabilise GNPs (Table II-3). In case of gelatine type 
A, no stable GNPs were obtained with the various parameters studied. Incubation of 
GNPs with genipin over a maximum of 48 hours led to gel formation. On the other 
hand, genipin enabled the preparation of monodisperse GNPs based on type B in a 
particle size range between 280 – 370 nm. In comparison to 
glutaraldehyde (ca. 85%) or glyceraldehyde (ca. 75%), these particles showed a 
decrease in the degree of cross-linking (ca. 40%), resulting in reduced colloidal 
stability. Further increase of the genipin concentration or the incubation time led to 
gel formation. Consequently, scale-up experiments with GNPs cross-linked by 
genipin were not performed. 
3.6  EVALUATION OF DIFFERENT TYPES OF GNPS BY SEM 
To visualise the different types of GNPs and analyse their morphology SEM was 
performed. In the micrographs, all GNPs appeared to be smooth particles with a 
spherical shape (Figure II-11). With respect to the size, the particle diameters 
obtained with SEM differed by approximately 100 nm from the sizes recorded with 
DLS. This was expected as the freeze-drying process caused a modest shrinking of 
the particles. Furthermore, in contrast to SEM, which determines the particle 
diameter in a dry state, DLS measures the hydrodynamic radius of a 
nanoparticle [45].  
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Figure II-11 SEM images of GNPs prepared by (A) two-step desolvation using gelatine type A175, (B) 
one-step desolvation using gelatine type A300, (C) one-step desolvation using gelatine type B300. 
These formulations were stabilised with glutaraldehyde. An image of GNPs prepared by (D) one-step 
desolvation using gelatine type B300, in which the particles were stabilised with glyceraldehyde, was 
added for comparison. 
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4 DISCUSSION 
The purpose of this study was to improve the commonly used two-step desolvation 
for GNP preparation and to develop a straightforward and reproducible protocol. 
This, we hoped would allow us to provide a toolbox to establish large-scale 
processes. By eliminating the first unreliable desolvation step, as well as introducing 
new process parameters and purification techniques, we were able to scale the 
procedure from 15-20 mg particle yield with the standard two-step desolvation to a 
maximum output of 2.6 g GNPs with one-step desolvation. Moreover, further 
approaches were investigated for their potential to scale common two-step 
desolvation. This included an enlarged contact area between gelatine and acetone 
as well as nanoprecipitation. Furthermore, two alternative cross-linking agents 
were evaluated to substitute the critical substance glutaraldehyde. 
4.1  PREPARATION OF GELATINE NANOPARTICLES BY ONE-STEP DESOLVATION 
In the interest of circumventing the irreproducible first desolvation step, a one-step 
desolvation method has previously been developed, which uses a customised 
gelatine type A (VP413-2, reduced LMW fraction) [24]. As this gelatine is not 
regularly available, there was a need to establish a one-step desolvation process 
with a standard gelatine. Significant contributions towards achieving this were 
made by Ofokansi et al. [25], who successfully prepared GNPs from gelatine type 
B 225 bloom applying ethanol as the desolvation agent. However, this method was 
accompanied by several incubation steps and a strong effect of pH on particle sizes. 
Despite those efforts, none of the methods has been proven to be feasible. Towards 
this aim, we were able to successfully establish a robust and straightforward one-
step desolvation method with two commercially available gelatine types (type A and 
B 300 bloom).  
To identify optimal conditions, GNP preparations were performed with different 
initial gelatine concentrations. Interestingly, with increasing gelatine 
concentrations, particle sizes of GNPs also increased. This effect has previously been 
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shown by Zwiorek et al. [22], where a higher amount of the gelatine sediment 
resulted in larger nanoparticles during a two-step desolvation. This may be caused 
by a denser packing of gelatine molecules during desolvation, which promotes inter-
molecular interactions and co-aggregation of gelatine, resulting in larger particle 
sizes. However, in our study, all nanoparticles made from both gelatine types 
showed diameters between 143.4–281.7 nm and were therefore acceptable for our 
purposes. The similar sizes and shapes of GNPs prepared by one-step or two-step 
desolvation were additionally verified by SEM. 
Furthermore, particle yields obtained from one-step desolvation were 
significantly (p < 0.001) higher when compared to two-step desolvation. This is 
most likely due to the subjectivity of the first of two desolvation steps, in, which the 
amount of the HMW fraction (sediment) is determined visually and the supernatant 
discarded manually. This led to an uncontrolled loss of starting material and 
extensive between- and within-person variations. By circumventing this step, the 
entire particle preparation can be conducted in a more controlled and reproducible 
manner. A further increase in yield was achieved with gelatine type B. The initial pH 
value of 6 of this solution was found to be optimal for particle preparation and thus 
pH adaption was not required.  
With respect to the optimal pH during particle production, in a solution of type B the 
pH value can be much closer to its IEP compared to type A. Thus, the lower overall 
net charge of the gelatine molecules led to decreased repulsion forces and stronger 
inter-molecular interaction resulting in larger particles with a higher yield. 
Nevertheless, the lower net charge is strong enough to prevent aggregation. This 
hypothesis is supported by the observation of lower particle yields when pH values 
were increased or decreased for gelatine type B and gelatine type A, respectively.  
Due to the highest particle output with the required parameters and morphology, 
an initial gelatine solution of 3.0% (w/v) was chosen to be optimal for one-step 
desolvation with both gelatine qualities.  
The analysis of the fractionation experiment provided insight into the molecular 
weight distribution of several gelatine samples and may help to understand, which 
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properties are required for successful particle formation. Gelatine type A 175 is a 
mixture of HMW and LMW fractions, whereby the relatively high content of the 
latter led to the formation of large particles with a broad size distribution, making it 
unsuitable for one-step desolvation. On the other hand, the customised 
gelatine (VP413-2) with a mean MW of 700 kDa has previously been shown to 
produce particles due to its low LMW fraction (< 20%) [24]. However, the mean MW 
of this gelatine, as measured by Schultes et al. [41], was lower than the mean MW 
determined in our study. This higher mean MW may be explained by self-cross-
linking during storage of VP413-2, a phenomenon known from gelatine 
capsules [46]. Furthermore, Schultes et al. showed a mean MW of the sediment that 
was by one order of magnitude higher than in our measurements. This confirmed 
the issue of batch-to-batch variability of the first desolvation step. Based on their 
findings, they defined a mean molecular weight of ~400 – 500 kDa as the threshold 
for the one-step desolvation [41], which is in the range of the mean MW of gelatine 
type A and B 300 bloom. In conclusion, the HMW fraction included in an overall MW 
of 400 – 500 kDa is sufficient to prepare stable GNPs, whereas the LMW fraction is 
low enough to not affect GNP preparation and colloidal stability. 
Consistent with the results of Ahlers et al. [24], the one-step desolvation with type 
A 300 bloom was successfully performed over the complete pH range used in two-
step desolvation (pH 2.5 – 3.0). On the other hand, type B 300 bloom had an optimal 
pH value of 6.0. Although, GNPs from gelatine type B show an overall negative 
surface charge, we were able to permanently cationise the particles via the standard 
cationisation process. The cationisation reagents react with free carboxyl groups, 
free amine groups as well as glutaraldehyde residues [22]. Zeta potential values 
measured for gelatine type B were comparable to those of type A, indicating that the 
free functional groups on the surface of GNPs from gelatine type B are similar to 
those from type A. GNPs from either gelatine type A or gelatine type B are suitable 
for cationisation and for electrostatic loading of CpG ODNs onto their 
surface (loading efficiency > 95%).  
Optimisation of One-Step Desolvation and Scale-Up of GNP Production 
 
 
 
57 
 
4.2 SCALE-UP OF GNP PREPARATION AND ULTRAFILTRATION 
Here, we demonstrated that the large-scale production of GNPs by one-step 
desolvation can be achieved via an increase in stirring intensity to ensure 
homogenous distribution of the gelatine molecules during desolvation. In a similar 
fashion, Wacker et al. [28] showed that a stirring bar and a small paddle 
stirrer (21 x 16 mm) are inappropriate for the preparation of HSA particles due to 
ineffective homogenisation of large volumes of albumin solutions and greater 
variability. By contrast, the usage of a larger paddle stirrer (30 x 25 mm) ensured 
homogeneous protein distribution and allowed scale-up in a reproducible manner.  
Furthermore, by employing ultrafiltration to remove acetone and unreacted 
glutaraldehyde, the high particle loss and the low product outcome seen with 
centrifugation and redispersion could be overcome [47]. Here, we demonstrated an 
efficient way to apply stirred ultrafiltration cells, which are commonly used for 
protein concentration and purification [48]. Through the combination of a pressure-
driven membrane process and gentle stirring, the proportion of particle loss was 
decreased remarkably and, as a result, the yield improved by 60-70%. This study 
reports, for the first time, the possibility for a large-scale production of GNPs in gram 
ranges by linking a maximised one-step desolvation process with ultrafiltration.  
4.3  ALTERNATIVE APPROACHES TO INCREASE PARTICLE YIELD IN TWO-STEP DESOLVATION 
4.3.1 INCREASING THE CONTACT AREA BETWEEN GELATINE AND ACETONE 
Besides the simplification of GNP preparation, it was also followed the approach to 
optimise the standard two-step desolvation to enlarge GNP yield. It was stated that 
an increasing contact area between gelatine solution and desolvation agent could 
result in a higher particle amount [29]. Based on the assumption that GNPs are only 
formed at the liquid-liquid interface due to interfacial turbulences, when acetone 
gets in contact with the gelatine molecules [30], acetone should be added to the 
gelatine solution in a more distributed way. By spreading the acetone over a larger 
area, more gelatine molecules should be desolvated, resulting in an increasing 
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number of particles. An initial approach in this direction was the separation of the 
acetone addition tubes during the second desolvation step. As this did not improve 
in particle yield, the acetone addition area was further increased by six tubes evenly 
distributed above the gelatine solution. However, no increase in GNP amount could 
be observed, but a trend to larger and more inhomogeneous GNPs. This may be 
explained by the fact that a larger amount of gelatine gets in contact with a reduced 
amount of acetone compared to the standard method. This results in a slowed down 
desolvation process and an apparently higher gelatine density. Consequently, inter-
molecular interactions are enhanced and larger and more polydisperse particles can 
be formed, but overall yield does not increase [22]. This could be probably 
circumvented by an accelerated pump rate of acetone. However, this approach was 
not further pursued.  
Instead, a dual syringe pump system was tested, which is an established method for 
the preparation of spider silk particles [40]. This technique allows a maximization 
of contact area between protein solution and desolvation agent, as well as a more 
controllable pump rate and contact time compared to a peristaltic pump. These 
features enabled the preparation of GNPs in a more reproducible size and extended 
particle yield. However, PDI values were still elevated compared to standard 
procedure. This may be due to higher shearing forces in the T-shaped mixing 
element leading to more irregularities. Further optimisation could solve this issue, 
but this technique has not been further pursued due to limited filling volume of the 
syringes of the used system. By using a tailored system, this method could be 
applicable for continuous manufacturing of GNPs combined with one-step 
desolvation.  
4.3.2 NANOPRECIPITATION 
Another concept to facilitate GNP preparation is nanoprecipitation. According to 
Khan and Schneider nanoprecipitation is rapid, easy and straightforward [31]. In 
this technique an aqueous gelatine solution is added dropwise to a desolvating agent 
that contains a stabiliser. Consequently, nanoparticles are formed and stabilised. 
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The main postulated advantage of this preparation method is that only one step is 
necessary to form stable and uniform GNPs. Furthermore, in contrast to desolvation, 
no adaption of the pH value below the isoelectric point is required. 
In the study performed by Khan and Schneider [31] GNPs with a particle size 
of 200 - 300 nm and unimodal size distribution (PDI < 0.15) were prepared via 
nanoprecipitation. These results could not be confirmed in our study. Particle 
formation via nanoprecipitation was principally possible, however particle 
characteristics were not comparable to GNPs prepared by two-step or one-step 
desolvation. GNPs showed considerably larger particle sizes and appreciably higher 
PDI values. The trend to higher particle sizes was already observed by Khan and 
Schneider and explained by the different principles of GNP formation [49]. 
Furthermore, utilising a stabiliser ensures the arrangement of a stable emulsion 
droplet and consequently attachment of the stabilising agent to the GNP 
surface [50]. Due to this shell of molecules, particle sizes may be larger and less 
uniform compared to plain GNPs prepared by desolvation. This statement is 
confirmed by the fact that in a direct comparison, GNPs prepared with 10% 
stabiliser were larger and more polydisperse than those with 7%. However, this is 
in contrast to the findings by Khan and Schneider where 10% stabiliser resulted in 
smaller particles [31]. 
Another explanation for these larger and polydisperse GNPs could be the 
heterogeneity of the used gelatine types. Nanoprecipitation is performed with 
gelatine qualities with a low bloom number and consequently a higher LMW 
fraction. From two-step desolvation, it is known that monodisperse GNPs can only 
be formed from the HMW fraction of gelatine. The LMW fraction would disturb this 
process [20, 21]. This may also have an impact on GNP formation by 
nanoprecipitation. The presumption can be strengthened by the observation that 
increasing bloom numbers, meaning increasing HMW fractions, resulted in more 
adequate GNPs. However, this would also contrast with the assertion of Khan and 
Schneider. They developed the nanoprecipitation method for GNP preparation as a 
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straightforward one-step preparation option. Further experiments should be 
performed to clarify these issues and distinct findings. 
Even though nanoprecipitation resulted in high particle yields, this method was not 
further pursued due to the worse particle characteristics. However, by putting some 
effort into optimisation (e.g. test of gelatine with 300 bloom), this procedure could 
be an alternative for GNP preparation by desolvation.  
4.4  EVALUATION OF ALTERNATIVE CROSS-LINKING AGENTS 
Glutaraldehyde is well known as cross-linking agent for proteineous nanoparticles, 
but presents safety issues for the patient and during manufacture [34]. Due to its 
consumption during manufacturing, and adequate purification of the GNPs, no 
adverse effects have been reported. Nevertheless, there is a need to find an 
alternative cross-linking agent. So far, several groups have studied alternative cross-
linking agents for GNPs such as transglutaminase [37], genipin [36] and 
glyceraldehyde [38], but no alternatives have been found that are sufficiently 
effective under the tested conditions.  
For instance cross-linking with transglutaminase gave monomodal GNPs with a 
particle size of 150 – 200 nm after an incubation of 48 hours [37]. However, high 
costs of the recombinant enzyme and reports indicating potential immunogenicity 
of transglutaminase residuals due to incomplete removal limit its applications [51]. 
Moreover, previous studies showed successful cross-linking of nanoparticles from 
recombinant human gelatine with genipin [36]. Stable GNPs with a uniform size 
distribution and particle sizes between 200 and 300 nm were obtained after a cross-
linking time of 72 hours. In our study, these results could not be reproduced with 
porcine gelatine type A 300, which showed gel-like structures and no particle 
formation. The problem here lies in the low pH necessary for desolvation: The amine 
groups of gelatine are protonated at pH 2.5-3 and are therefore not available for the 
cross-linking reaction. The pH conditions required for gelatine type B, are optimal 
for the genipin reaction resulting in monodisperse GNPs. However, the reduced 
cross-linking degree in comparison to glutaraldehyde (ca. 40% vs. ca. 85%) led to 
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instability of the nanoparticles. This could be explained by the complex reaction 
between genipin and a protein and of several ring-opening steps that must take 
place [52]. Longer cross-linking times and higher genipin concentrations had no 
positive effect on stability, but induced gelation. Consequently, this study indicated 
that genipin is not suitable in large scale GNP production. 
Recent studies with a focus on cross-linking GNPs with glyceraldehyde showed that 
the preparation of stable GNPs was successful only in the presence of a high content 
of Poloxamer 407 [38]. In this study, we were able to demonstrate that 
glyceraldehyde is suitable for GNP cross-linking without the addition of a stabiliser. 
Due to different pH conditions during desolvation and, therefore the number of free 
amines present, gelatine type A and type B required different cross-linking 
durations. Glyceraldehyde seems to be more reactive compared to genipin. This may 
be explained by the possible water elimination and following keto-enol tautomerism 
of glyceraldehyde resulting in reactive malondialdehyde [53]. Nevertheless, only 
gelatine type B gave GNPs that met the required characteristics due to more optimal 
reaction conditions for glyceraldehyde. In addition, glyceraldehyde is also a suitable 
cross-linking agent in large scale productions of GNPs. Although the cross-linking 
degree of type B particles was lower than for GNPs cross-linked with glutaraldehyde 
(ca. 75% vs. ca. 85%), the particles showed adequate colloidal stability over 35 days. 
Furthermore, the particle morphology of GNPs cross-linked by glyceraldehyde 
appeared to be less smooth compared to the GNPs cross-linked by glutaraldehyde, 
which could also be a consequence of the lower cross-linking degree.  
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5 CONCLUSION 
The research presented successfully shows for the first time that GNP preparation 
by one-step desolvation is scalable and that the cross-linking agent glutaraldehyde 
can be substituted without significant effects on physicochemical characteristics of 
the nanoparticles. Providing large amounts of GNPs in a reproducible quality is the 
first step to become a standard drug delivery system in the treatment of RAO in 
horses and potentially in the treatment of various diseases in humans.  
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ABSTRACT 
Oligodeoxynucleotide (ODN)-loaded gelatine nanoparticles (GNPs) have proven 
their outstanding potential in the treatment of allergic diseases, such as equine 
asthma and canine atopic dermatitis, which are appropriate models for the 
corresponding human diseases. To encourage the development of a marketable 
product, long term stability need to be ensured. In this work, freeze-drying options 
to stabilise these nanoparticles were advanced. Firstly, matrix-assisted laser 
desorption/ionisation mass spectrometry time-of-flight (MALDI-TOF) was 
implemented as versatile tool to assess ODN stability. Then, long term storage 
stability of lyophilised ODN-loaded GNPs formulated in sucrose or trehalose could 
be shown. Controlled nucleation was introduced in order to optimise lyophilisation 
processes. Freeze thaw experiments confirmed stability of ODN-loaded GNPs 
following controlled nucleation. In comparison to standard freeze-drying process, 
shortening of the freeze-drying process was achieved, but no further advantages 
were observed. Particle sizes, PDI values, ODN stability, residual moisture and glass 
transition temperature were maintained upon storage. Excipient portfolio was 
enlarged by novel amino acid containing formulations for lyophilisates. Histidine 
emerged as appropriate excipient in stabilising lyophilised ODN-loaded GNPs, 
whereas addition of arginine and glycine revealed to be inadequate at accelerated 
conditions.  
KEYWORDS 
Gelatine nanoparticles, oligodeoxynucleotides, lyophilisation, freeze-drying, 
controlled nucleation, amino acid, MALDI-TOF 
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1 INTRODUCTION 
Gelatine nanoparticles (GNPs) provide an exceptional potential for the application 
as drug delivery systems. In contrast to other polymers, gelatine is an excellent 
starting material for nanoparticles due to its biodegradability, biocompatibility and 
physiological tolerance [1]. Additionally, it is known for its long and successful 
history of clinical use for medical applications [2]. Moreover, gelatine offers 
unfunctionalised amino groups for electrostatic attachment of different kinds of 
active substances, such as cytosine phosphate guanosine oligodeoxynucleotides 
(CpG ODNs). By induction of intracellular TLR 9, ODNs are able to rebalance the 
disrupted homeostasis between Th1 and Th2 immune response in order to combat 
the principle of allergic diseases [3]. GNPs proved their ability to protect ODNs from 
degradation and implant them into cells [4-6]. Recent in vivo studies showed the 
exceptional potential of GNPs as drug delivery system in the treatment of equine 
recurrent airway obstruction (RAO), an allergic airway disruption similar to human 
asthma [7-10]. In several equine studies an improvement of clinical parameters such 
as bronchoconstriction, mucus hypersecretion and inflammation of the lower 
airways was described by inhalative application of ODN-loaded GNPs [7-10]. ODN-
loaded GNPs have also proven to be superior compared to free ODNs or placebo. 
Additionally, in contrast to conventional treatment, this therapy led to a sustained 
effect and causal treatment of the disease [8, 10]. 
Besides these findings, further in vitro and in vivo studies indicated that ODN-loaded 
GNPs are also active in the treatment of canine atopic dermatitis (CAD), an allergy 
driven skin disorder in dogs comparable to human atopic dermatitis [11, 12]. In a 
preliminary canine in vivo study, the subcutaneous application of ODN-loaded GNPs 
showed significant improvement of clinical parameters, such as pruritus or skin 
lessons. These results were confirmed by a decreased serum concentration of pro-
allergic IL-4 [12].  
 
Due to the outstanding success and effectiveness in several kinds of applications of 
ODN-loaded GNPs, there was a strong need to prepare GNPs in large quantities for 
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further clinical studies and future commercialisation. A big step in this direction was 
to achieve a more efficient particle production process. This could already be 
realised by our group by the optimisation of GNP production and subsequent scale-
up of the process [13]. A commercially available gelatine type was found, which 
enabled the conversion and simplification of GNP preparation from a critical two-
step process into an easy and straightforward one-step desolvation process. This 
allowed a more reproducible and homogeneous production process and enabled 
scaling up. Large particle quantities up to a 130-fold increase of the initial particle 
gain using the previous method were accomplished. Furthermore, no limitations for 
a further increase in batch size could be observed. This is an important fact for future 
industrial large-scale productions of GNPs.  
 
Besides scalability, a requirement for the wide use of GNPs in different clinical 
applications and the possibility to enter the market is to provide a storage stable 
product. However, in liquid formulations ODN-loaded GNPs show high tendency to 
aggregate. This leads to a maximal verified storage stability of 48 to 72 hours 
depending on ODN sequence [12, 14]. A first step into stabilisation has already been 
done by Zillies et al. They could show the possibility to freeze-dry NF-κB decoy ODN-
loaded GNPs without any loss in physicochemical quality or biological function [15]. 
In the present work, we could confirm these findings regarding the stability of ODN-
loaded GNPs. Furthermore, we established an additional analytical method for ODN 
integrity evaluation, matrix-assisted laser desorption/ionisation time-of-flight mass 
spectrometry (MALDI-TOF). Moreover, storage stability could be extended to six 
months.  
 
Standard lyophilisation is a versatile procedure to stabilise sensitive drug 
formulations such as proteins or as described here ODN-loaded GNPs. However, it 
is also related to some drawbacks, such as high time- and energy-consumption. 
Therefore, lot of research is carried out to shorten lyophilisation processes. 
Promising approaches include controlled nucleation [16], aggressive freeze-drying 
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[17] or collapse freeze drying [18, 19]. Among the mentioned techniques, controlled 
nucleation is the most advanced and most investigated approach.  
Conventional shelf-ramped freezing induces a stochastic ice nucleation in the 
formulation, leading to different ice crystal growing and consequently high vial-to-
vial variability within one batch. This causes unpredictable sublimation rates and 
great quality differences within the final product [20]. Furthermore, many small ice 
crystals are formed that slow down drying due to high specific surface area, small 
pore size and high dry layer resistance. Via a controlled nucleation, simultaneous 
freezing of all vials can be achieved resulting in uniform and large ice crystals in all 
vials. Consequently, specific surface area and dry layer resistance are reduced. This 
leads to a shortened drying time. Besides economic factors, controlled nucleation is 
also beneficial for an increased batch homogeneity [20, 21]. Different methods to 
achieve a controlled ice nucleation, their effects on product quality and stability are 
intensively studied in the field of therapeutic proteins [16, 21, 22]. It is known from 
protein research that methods controlling ice nucleation can be beneficial in 
stabilising the protein due to reduced ice-water interfaces and thus lower protein 
damage [20, 23]. Still, there is only few research on nanoparticles regarding 
controlled nucleation in freeze-drying. The work of Kasper et al. revealed that in 
principle controlled nucleation in lyophilisation of nanoparticulate polyplexes is 
possible without the loss of particle quality. However, DNA concentration is crucial, 
and high additive concentrations are necessary to stabilise them [24]. Interestingly, 
initial freeze-thaw experiments showed that ODN-loaded GNPs are not sensitive to 
the aforementioned factors. 
This work investigates for the first time the applicability of controlled nucleation in 
lyophilisation of gelatine nanoparticles in order to accelerate the freeze-drying 
procedure without adverse influences on product quality or stability.  
 
Additionally, we could expand the portfolio of possible formulations from 
conventional lyophilisation excipients, such as sugars, to amino acid formulations. 
Amino acids were investigated due to their beneficial features in stabilising proteins 
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during lyophilisation and irradiation-based sterilisation [25-27]. Histidine showed 
a clear benefit in stabilisation of ODN-loaded GNPs. Arginine and glycine also 
stabilised particles by preserving sizes and PDI values. However, ODN integrity was 
affected at accelerated storage temperature. 
 
Summarising, this work opens the way for this innovative medicinal approach 
towards marketable products in human and veterinary application.  
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2 MATERIAL AND METHODS 
2.1 MATERIALS 
Gelatine type A 300 bloom was obtained from Gelita AG (Eberbach, Germany). 
Acetone was supplied by Fisher Chemicals (Loughborough, UK). Glutaraldehyde 
(25% solution), 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride, 
(2-Aminoethyl) trimethylammonium chloride hydrochloride, L-arginine base, L-
histidine base and L-glycine base were acquired from Sigma (Taufkirchen, 
Germany). D-(+)-Sucrose and D-(+)-Trehalose dihydrate were purchased from VWR 
International (Leuven, Belgium). Highly purified water (HPW), which was produced 
by a PURELAB Plus device (conductivity < 0.055 µS/cm, Elga Labwater, Celle, 
Germany), was used in all experiments. Oligodeoxynucleotides (ODNs) were 
synthesized by biomers.net GmbH (Ulm, Germany). 
2.2 PREPARATION OF CATIONISED GELATINE NANOPARTICLES 
GNPs were prepared according to one-step desolvation [13]. In brief, after an 
amount of 750 mg gelatine type A (300 bloom) was dissolved in HPW (3.0% w/v) 
under constant stirring at 50°C, the pH was adjusted to a value between 2.5 and 3.0. 
In order to initiate desolvation and nanoparticle formation, acetone was added 
dropwise. A volume of 175 µL glutaraldehyde solution was added to cross-link 
GNPs. The dispersion was stirred overnight and purified via three-fold 
ultrafiltration using a solvent resistant stirred cell and an ultrafiltration disc of 
regenerated cellulose and a molecular weight cut-off of 100’000 kDa (Millipore 
S.A.S., Molsheim, France).  
Cationisation of GNPs was performed according to the standard protocol [28] with 
some modifications. Briefly, GNP dispersion was diluted with HPW (~ 10 mg/mL) 
and pH was adjusted (4.5 - 5.0). Following, 1000 mg of each 1-Ethyl-3-(3-
dimethylaminopropyl) carbodiimide hydrochloride (EDC) and (2-Aminoethyl) 
trimethylammonium chloride hydrochloride (Cholamine) were added. After 
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incubation for 30 min, the reaction mixture was purified by two-fold centrifugation 
(16000*g for 15 min; Sigma Laborzentrifugen, Osterode, Germany). Finally, 
nanoparticle concentration was determined gravimetrically using a UMX2 ultra-
microbalance (Mettler Toledo, Greifensee, Switzerland). 
2.3 OLIGODEOXYNUCLEOTIDE LOADING OF GELATINE NANOPARTICLES 
ODN loading was performed in solutions of different kind of excipients to prepare 
formulations for lyophilisation. GNP dispersion was diluted to a final concentration 
of 1.5 mg/mL and incubated with 5% (w/w) ODNs for 60 min at 21°C and under 
continuous shaking at 350 rpm (Thermomixer Comfort, Eppendorf AG, Hamburg, 
Germany). The excipient-to-ODN ratios for sugar containing samples were 100:1, 
500:1 and 1333:1. The latter represents an isotonic formulation. The ratio is used to 
identify the samples, e.g. “S500” is a formulation consisting of a sucrose-to-ODN of 
500:1.  
For the stability study, amino acids (L-arginine, L-histidine and L-glycine) were used 
in excipient-to-ODN ratio of 333:1 (one amino acid, representing 2.5% [w/v]), 667:1 
(two amino acids, equally mixed) and 1000:1 (three amino acids, equally mixed). 
Sugar amino acid combinations were based on a sugar-to-ODN ratio of 500:1, amino 
acids were added at a ratio of 333:1. 
2.4 FREEZE-DRYING OF ODN-LOADED GNPS AND STORAGE CONDITIONS FOR STABILITY 
STUDY 
Freeze-drying was performed using a volume of 500 µL in 2R glass vials according 
to the following freeze-drying cycle (Figure III-1) adapted from Zillies et al. [15] 
using an EPSILON 2-6D pilot scale freeze dryer (Martin Christ 
Gefriertrocknungsanlagen GmbH, Osterrode, Germany) and type T thermocouples 
(Newport Electronics, Deckenpfronn, Germany). Upon finishing the cycle, the 
product chamber was vented with nitrogen and samples were stoppered at a 
chamber pressure of 800 mbar. The sealed vials were stored at 2-8°C and 20-25°C 
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for six months, as well as at 40°C for four weeks. Analytics was performed directly 
after freeze-drying and after one, three and six months of storage. 
 
Figure III-1 Freeze-drying cycle with shelf temperature (black dots) and chamber pressure (white 
dots) for lyophilisation of ODN-loaded GNPs for storage stability. 
2.5 FREEZE THAW EXPERIMENTS USING DIFFERENT FREEZING PROTOCOLS 
Freeze thaw experiments were performed in an EPSILON 2-6D pilot scale freeze 
dryer (Martin Christ Gefriertrocknungsanlagen GmbH, Osterrode, Germany) 
equipped with thermocouples (Newport Electronics, Deckenpfronn, Germany) for 
temperature monitoring. The following formulations were investigated in 
triplicates: S100, S500, S1333, T100, T500, T1333 and the corresponding sugar free 
formulation (HPW). A volume of 500 µL of each formulation was filled into 2R vials. 
Vials were positioned in the middle of the shelf and surrounded by two rows of vials 
filled with 5% sucrose solution. All samples were equilibrated at 20°C 
for 15 minutes prior to freezing until a shelf temperature of -45°C. In all freeze thaw 
experiments, samples were kept frozen for 10 hours and subsequently thawed by a 
ramp of 2.5°C/min until 20°C, followed by a hold step at 20°C for 60 minutes. 
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2.5.1 CONVENTIONAL SHELF RAMPED FREEZING  
Conventional shelf ramped freezing was conducted with a shelf ramp rate 
of  -1°C/min or -1.5°C/min until -45°C.  
2.5.2 CONTROLLED NUCLEATION 
Controlled nucleation was performed as described by Geidobler et al. [29]. Shelves 
were cooled at a ramp rate of -1°C/min until -4°C and samples were equilibrated at 
that temperature. As soon as all sample reached the equilibrium temperature, the 
product chamber was depressurized to a vacuum of 3.69 mbar. In order to initiate 
controlled ice nucleation, the vacuum was immediately released by opening the 
drain valves and ice fog was brought from the condenser into the product chamber. 
After ice nucleation, shelf temperature was either kept at -4°C for 15 minutes and 
then cooled to -45°C at-1°C/min (w/ hold time) or directly cooled to -45°C 
at -1°C/min (w/o hold time).   
2.6 FREEZE-DRYING USING CONTROLLED NUCLEATION 
Controlled ice nucleation was performed as previously described by our group [29]. 
The applied process is displayed in Figure III-2. The shelves of the freeze-dryer 
(EPSILON 2-6D, Martin Christ Gefriertrocknungsanlagen GmbH, Osterrode, 
Germany) were cooled until a constant product temperature of -4°C was reached. 
The freeze-dryer was then depressurized to a vacuum of 3.69 mbar and immediately 
brought to atmospheric pressure by opening the drain valves. This induced 
repressurization via the cold condenser and ice fog was released into the product 
chamber initiating ice nucleation. Complete solidification was achieved by ramping 
down to −45°C with a ramp of 1°C/min followed by three hours primary drying 
at -20°C and a chamber pressure of 0.05 mbar. Secondary drying was performed for 
eight hours at 20°C. The product temperatures were monitored via type T 
thermocouples (Newport Electronics, Deckenpfronn, Germany). Stoppering and 
sealing was operated as mentioned above. Storage was executed at 2-8°C and 20-
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25°C for three months, as well as four weeks at 40°C. Analytics were carried out 
directly after freeze-drying, as well as after one month and three months of storage. 
 
Figure III-2 Freeze-drying cycle using controlled nucleation with shelf temperature (black dots) and 
chamber pressure (white dots) for lyophilisation of ODN-loaded GNPs for storage stability. 
2.7 FREEZE-DRYING OF AMINO ACID FORMULATIONS 
Amino acid containing formulations were lyophilised using a more cautious freeze-
drying protocol (Figure III-3) due to very low glass transition temperatures of the 
maximally freeze concentrated solution (Tg’ values, down to -53°C). After freezing 
the samples at -60°C for three hours, the chamber pressure was reduced to 
0.009 mbar. Primary drying was carried out at -40°C for 52 hours, followed by a 
pressure increase to 0.03 mbar and a two-step temperature ramp of 0.1°C/min to 
0°C and then 0.33°C/min to 20°C. Secondary drying was performed at 20°C for ten 
hours. Stoppering, sealing, storage and analytics were conducted analogous to the 
aforementioned processes.  
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Figure III-3 Freeze-drying with shelf temperature (black dots) and chamber pressure (white dots) 
for lyophilisation of amino acid containing ODN-loaded GNPs for storage stability. 
2.8 GELATINE NANOPARTICLE CHARACTERISATION 
Particle size and polydispersity index (PDI) were determined by dynamic light 
scattering (DLS) using a Zetasizer Nano ZS (Malvern Instruments, Worcestershire, 
UK). Zeta potentials were evaluated by electrophoretic light scattering (ELS) in a 
sodium chloride solution of 10 mM (Zetasizer Nano ZS, Malvern Instruments, 
Worcestershire, UK). 
2.9 DETERMINATION OF LOADING EFFICIENCY 
Loading efficiency was indirectly determined by centrifugation and following 
measuring of UV absorbance at 260 nm (Agilent 8453 UV-visible 
spectrophotometer, Agilent Technologies, Santa Clara, California, USA) in the 
supernatant of the ODN-loaded GNPs, a GNP control and an ODN-control [12].  
Loading efficiency was calculated using the following equation:  
Loading efficiency [%] = 1 − (
A (ODN−loaded GNP)−A (GNP control)
A (ODN control)
) 𝑥 100 %.  
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2.10 MATRIX-ASSISTED LASER DESORPTION/IONISATION TIME-OF-FLIGHT MASS 
SPECTROMETRY (MALDI TOF) 
Prior to measurement, the samples were desalted on a 0.025 μm VSWP membrane 
(Merck Millipore, Darmstadt, Germany) and co-crystallised in a 3-hydroxypicolinic 
acid matrix (HPA). Matrix-assisted laser desorption/ionisation time-of-flight 
(MALDI-TOF) mass spectra were recorded on a Autoflex II (Bruker Daltonics, 
Germany) and a AnchorChip®-Target (Bruker MTP var/384) in negative mode.  
2.11 KARL-FISCHER TITRATION 
Coloumetric Karl-Fischer titration using Aqua 40.00 titrator with a headspace 
module (Analytik Jena AG, Halle, Germany) was used to determine residual 
moisture. The lyophilised ODN-loaded GNPs were heated to 100°C. The evaporated 
water was transferred into the titration solution and the water content was 
determined.  
2.12 DYNAMIC SCANNING CALORIMETRY (DSC) 
Glass transition temperatures (Tg) and glass transition temperatures of the 
maximally freeze-concentrated solution (Tg’) were determined using a Mettler DSC 
821e (Mettler Toledo, Columbus, OH, USA). An amount of 1-15 mg lyophilisate was 
weighed into aluminium crucibles. To ascertain Tg values, samples were analysed at 
a heating and cooling rate of 10 K/min from 0 to 150 °C in a first and from -10 to 
150°C in a second cycle against an empty crucible as reference. For measuring of Tg’ 
values samples were heated from -60°C to 20°C. Tg and Tg’ values were evaluated 
from heating scans.  
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2.13 BIOACTIVITY ASSAY IN EQUINE BRONCHOALVEOLAR (BAL) CELLS  
This part of the study was performed in close collaboration with the veterinarian 
Dr. med. vet. John Klier. Equine BAL cells were harvested by Dr. Klier, following 
experiments were conducted either together or by me, depending on the individual 
case. 
 
Bronchoalveolar lavage fluids (50 mL sterile, warm, isotonic NaCl solution 
per 100 kg bodyweight) were taken from two healthy horses and two horses 
affected from RAO. Fluids were immediately centrifuged to collect BAL cells (10 min 
at 1200*g; Sigma Laborzentrifugen, Osterode, Germany). An amount of 2 x 105 cells 
in RPMI medium (Biochrom AG, Berlin, Germany; 10% FCS, 67.8 mg/mL penicillin, 
113 mg/mL streptomycin) was seeded per well in 96 well plates and incubated in 
triplicates with the different formulations for 24 h at 37°C and 5% (v/v) CO2 
atmosphere. Investigated formulations were lyophilised S100, S500, S1333, T100, 
T500 and T1333 after six months storage at 2-8°C or 20-25°C, as well as 
corresponding freshly prepared formulations and corresponding ODN-free 
placebos. Reference samples contained freshly prepared ODN-loaded GNPs in water 
(standard formulation used in previous in vitro and in vivo studies) as well as 
corresponding placebo. 
Following incubation, well plates were centrifuged (10 min at 1000*g; Sigma 
Laborzentrifugen, Osterode, Germany) and supernatants were collected in order to 
analyse cytokine concentrations. Supernatants were either directly investigated or 
stored at -80°C until measurements. 
The cytokine determination was conducted using equine ELISAs (R&D Systems, 
Minneapolis, USA) and included evaluation of IFN-γ, IL-4 and IL-10. ELISAs were 
performed according to the manufacturer’s instructions. Cell viability was tested 
using alamarBlue™ Cell Viability Reagent (Thermo Fisher Scientific, Waltham, 
Massachusetts, USA) according to the manufacturer’s protocol. 
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3 RESULTS AND DISCUSSION 
3.1 CONVENTIONAL LYOPHILISATION 
Excipient selection was based on common knowledge and the findings of 
Zillies et al. [15]. Sugars and sugar alcohols, such as sucrose, trehalose or mannitol 
are widely used lyo- and cryoprotectants or bulking agents for freeze-dried 
biomaterials [30]. Sucrose is known for its ability to stabilise biopharmaceuticals, 
such as proteins [31]. Trehalose is stated to be even superior due to a higher glass 
transition temperature [32]. However, trehalose is high-priced compared to 
sucrose. This may be an issue in large scale production, especially when it comes to 
veterinary use. Mannitol is particularly known for its properties as bulking agent. 
Due to its crystallisation during freeze-drying, it is not suitable to be used as lyo- or 
cryoprotectant for proteins. Therefore, it is often mixed with sucrose to combine the 
features of good stabilisation and appropriate cake performance [33].  
Zillies et al. could show equivalent stabilising properties for freeze-dried placebo 
GNPs of all their chosen excipients. ODN-loaded GNPs were sufficiently preserved 
by sucrose and trehalose, whereas mannitol and a mannitol-sucrose mixture were 
not beneficial [15]. Furthermore, they evaluated a minimal ODN-to-sugar ratio 
of 1:100 as necessary to stabilise ODN-loaded GNPs. Hence, we decided to choose 
sucrose and trehalose at ODN-to-sugar ratios 1:100, 1:500 and 1:1333 (isotonic) for 
our experiments. 
3.1.1 PARTICLE SIZES AND PDI VALUES 
DLS measurements of the rehydrated formulations revealed particle sizes of 
around 200 nm and monodisperse PDI values of around 0.2 (Figure III-4). No 
change in particle sizes or PDI values was observed over six months storage at 2-8°C 
or 20-25°C. Used sugar types and sugar concentrations were shown to be equivalent. 
Furthermore, storage at accelerated conditions (40°C, four weeks) had no impact on 
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particle characteristics (Figure III-4 C and F). This indicates GNPs as a very stable 
drug delivery system and prolongs already stated storage stability [15]. 
However, it can be noted that PDI values may depend on used oligodeoxynucleotide 
batch as the utilisation of different batches led to varying PDI values already before 
freeze-drying (same ODN batch for 2-8°C and 20-25°C, different batch for 40°C). 
 
Figure III-4 Particle sizes (bars) and PDI values (dots) of freeze-dried ODN-loaded GNPs directly after 
lyophilisation (dark grey), after four weeks of storage (light grey striped) and six months of storage 
(dark grey chequered). Sucrose formulations at A: 2-8°C, B: 20-25°C and C: 40°C. Trehalose 
formulations at D: 2-8°C, E: 20-25°C and F:40°C. Results are represented as mean + or ± SD (n=3). 
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Interestingly, after freeze-drying and reconstitution, particle sizes were smaller 
than before. Similar results has already been observed for lyophilised GNPs [15] and 
PCL (Poly(epsilon-caprolactone)) nanocapsules [34]. This has been explained by a 
shrinking of the particles during freeze-drying followed by an incomplete 
rehydration [15]. 
Furthermore, most samples showed a tendency to smaller sizes during storage. This 
is only partly comparable to literature. For ODN-loaded GNPs in sucrose, a reduction 
of particles sizes was ascertained after storage of four weeks, whereas preservation 
or even a slight increase in particle sizes is reported for ODN-loaded GNPs in 
trehalose and other types of nanoparticles [35-38].  
Moreover, particle sizes and PDI values after reconstitution of all lyophilised GNPs 
were stable for 48 hours similar to freshly prepared formulations. This was found 
for samples directly after freeze-drying as well as after six months of storage 
at 2-8°C or 20-25°C. 
3.1.2 LOADING EFFICIENCIES 
It is important to point out that the electrostatic interaction between 
oligodeoxynucleotides and GNPs results a sensitive system of loaded NPs. 
Therefore, it is crucial to evaluate changes in loading efficiency after any kind of 
processing.  
Loading efficiencies remained stable after freeze-drying in all formulations and all 
storage conditions (see annex). This stability of high loading efficiency was 
persistent for 48 h after reconstitution. Consequently, it can be assumed that 
lyophilisation has no impact on the positive charge of GNPs and the electrostatic 
interactions of GNPs and oligodeoxynucleotides are not disturbed by lyophilisation. 
3.1.3 OLIGODEOXYNUCLEOTIDE INTEGRITY 
It should be recognized that the integrity of the oligodeoxynucleotides is one of the 
most important points regarding bioactivity of freeze-dried ODN-loaded GNPs. To 
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evaluate ODN stability after freeze-drying and storage, we used matrix-assisted 
laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF).  
MALDI-TOF is a common method to asses oligodeoxynucleotide identity and quality 
in synthesis, which offers rapid and direct analysis of oligodeoxynucleotides [39]. 
Furthermore, MALDI-TOF can be used to analyse degradation of ODNs [40, 41]. 
Intact ODNs can be identified by a sharp peak at the m/z value of the 
oligodeoxynucleotide’s molecular weight. Following degradation the peak of the 
intact ODN would disappear, whereas peaks of degradation products would 
appear [41]. 
We could show that MALDI-TOF is a suitable method to asses ODN integrity even if 
the ODNs are loaded onto GNPs. GNPs are not ionized by the laser and do not desorb 
from the matrix, whereas laser power is high enough to release electrostatically 
bound ODNs from GNPs. However, high laser power may induce depurination of the 
oligodeoxynucleotide, meaning cleavage of the last base, which can be seen by a 
second small peak on the left side of the main peak [39]. This typical phenomenon 
should not be misinterpreted as a degradation product. A representative spectrum 
is displayed in Figure III-5. 
 
Figure III-5 Representative MALDI-TOF spectrum of investigated oligodeoxynucleotide.  
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Results demonstrate that ODNs are stable during lyophilisation, more precisely 
stress during freezing and drying does not degrade ODNs (Table III-1). Furthermore, 
ODNs were stable for six months during storage at 2-8°C and 20-25°C. In higher 
sugar concentrations (S500, S1333, T500, T1333) they were even resistant for four 
weeks at accelerated conditions (40°C). However, at low sugar concentrations 
(S100 and T100) first signs of a starting degradation of ODNs, such as an increase of 
a small additional peak or low signal intensity, were observed (see annex). Hence, 
for long time storage of ODN-loaded GNPs formulations with higher sugar contents 
are recommended. 
Table III-1 Oligodeoxynucleotide integrity after conventional lyophilisation and subsequent storage. 
ODN integrity is represented with symbols:  stable ODN,  degraded ODN, ± indications for starting 
degradation. 
Formulation 
Conventional lyophilisation 
2-8°C 20-25°C 40°C 
6 months 6 months 4 weeks 
..    S100   ± 
S500    
S1333    
T100   ± 
T500    
T1333    
3.1.4 RESIDUAL MOISTURE AND GLASS TRANSITION TEMPERATURE 
In addition to particle and ODN characteristics, residual moisture as well as glass 
transition temperature of the lyophilised samples are important parameters to 
asses storage stability. High residual moisture values are expected to negatively 
influence nanoparticle stability in freeze-dried samples due to higher mobility 
resulting in particle aggregation [42]. Furthermore, ODN degradation may be more 
likely with increasing water content [42]. The relation between water content and 
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glass transition temperature (Tg) of solids in their amorphous states is well 
known [43]. More water absorption leads to lower Tg values. Evaluation of Tg values 
is crucial for stability predictions, as storage far below the Tg is important to 
preserve the glassy state of the lyophilisates and to reduce molecular mobility [44]. 
Consequently, low residual moisture is essential to ensure Tg values above the 
storage temperature [30]. 
 
Evaluation of residual moisture contents in our lyophilisates revealed low starting 
values (< 1%) that increased upon storage depending on excipient content and 
storage temperature. The higher the sugar content, the less pronounced the relative 
water uptake was, whereas the higher the storage temperature was, the stronger 
the increase of residual moisture. However, values did not reach a critical treshold 
inducing particle aggregation. On the other hand, the increased water content may 
be related to slight ODN degradation starting in S100 and T100 after storage at 40°C.  
Tg values agreed with values from literature and remained stable in the higher sugar 
concentrations (S500, S1333, T500 and T1333). The formulations with the lowest 
amount of sugar (S100 and T100) showed a drop in Tg according to their increasing 
water absorption (for further details see annex). 
 
Taken together, residual moisture values and glass transition temperatures 
developed as expected [15]. Regarding stability, no critical values were exceeded. 
3.1.5 BIOACTIVITY ASSAY OF LYOPHILISED ODN-LOADED GNPS 
Although immunological processes of recurrent airway obstruction (RAO) are still 
controversially discussed, a Th2 derived pathogenesis is mainly presumed as its 
origin [45]. By stimulation of pro-inflammatory Th1 pathways and consequent 
suppression of Th2 activation, CpG ODNs are able to redirect the balance between 
Th1 and Th2 derived immune processes [3]. Furthermore, regulatory T-cells (Treg) 
producing IL-10, which acts as beneficial modulator in allergic diseases, are 
assumed to be activated [3]. These effects have been demonstrated in multiple 
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equine in vitro and in vivo studies addressing RAO therapy by the application of 
ODN-loaded GNPs [7-10, 14]. Thus, IL-4 is used as main marker for Th2 dependent 
processes, whereas IFN-γ reflects Th1 derived immune mechanisms. Lastly, IL-10 is 
considered as indicator for Treg activation.  
 
Formulations were assessed for the bioactivity in equine bronchoalveolar (BAL) 
cells to give further information regarding stability. This particular cell type was 
chosen as the main usage of these formulations would be the inhalative treatment 
of RAO in horses. Based on previous studies, the ability of formulations to stimulate 
the release of key cytokines IFN-γ and IL-10 as well to inhibit the production of IL-4 
were evaluated in BAL cells harvested from healthy and RAO-affected horses [14]. 
 
Results of IFN-γ and IL-10 expression are demonstrated in Figure III-6. Lyophilised 
and subsequently stored ODN-loaded GNPs are able to induce INF-γ release in 
healthy (Figure III-6 A) and RAO-affected horses (Figure III-6 B) similar to freshly 
prepared formulations and the standard formulation in highly purified water 
(HPW). This indicates Th1 stimulation by all formulations. Interestingly, in healthy 
horses freeze-dried formulations stored for six months at 20-25°C even induced 
highest levels of IFN-γ. However, this could be a bias caused by the low number of 
available horses as cell donors and overall high variations in the results of ELISA 
measurements. Nonetheless, the ascertained IFN-γ concentrations are in the same 
range as reported in a previous study [14].  
Additionally, IL-10 concentrations induced by lyophilised or freshly prepared ODN-
loaded GNPs were comparable (Figure III-6 C and D). This reinforces that 
lyophilisation and subsequent storage does not affect bioactivity of the 
formulations. Nevertheless, one should admit that IL-10 levels were 10-fold lower 
than in the previously performed study by Klier et al. [14].  
Values for IL-4 were below the detection limit of the ELISA, whereas values for 
placebo formulations were in a quantifiable range. Hence, one can say that freshly 
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prepared as well as lyophilised formulations decreased IL-4 levels indicating a Th2 
suppression.  
Cell viability after incubation with freshly prepared or lyophilised and stored 
formulations did hardly vary (81.8% ± 9.3% vs. 85.2% ± 9.2%).  
 
Figure III-6 IFN-γ expression in equine BAL cells from healthy (A) and RAO-affected horses (B) or IL-
10 expression in equine BAL cells from healthy (C) and RAO-affected horses (D) after incubation with 
lyophilised ODN-loaded GNPs stored for six months at 2-8°C (black), 20-25°C (light grey) and freshly 
prepared formulations (dark grey). Data is represented as mean + SD, n=3 evaluated in two cell 
cultures each. 
The main assertion of this experiment is that lyophilised and stored ODN-loaded 
GNPs are still able to induce their immunomodulatory effects comparable to freshly 
prepared formulations. This finding is independent of the used excipient, their 
concentration or storage condition. However, due to the very limited number of cell 
donors, measured values should be rated as hints and not as absolute values. 
Nonetheless, the findings of intact ODNs after lyophilisation and storage using 
MALDI-TOF confirm bioactivity of the processed formulations. 
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3.2 CONTROLLED NUCLEATION 
Controlled nucleation was investigated as a possibility to shorten lyophilisation 
process time of ODN-loaded GNPs. Furthermore, in a stability study, controlled 
nucleation was evaluated as a potential tool to increase ODN stability compared to 
conventional lyophilisation. For a direct comparison, same formulation 
compositions were chosen.  
3.2.1 FREEZE THAW EXPERIMENTS 
As already mentioned, controlled nucleation has been reported to show positive 
effects on stability of proteins compared to standard ramp freezing [46, 47]. 
However, Kasper et al. found different results for polyplex formulations [24]. To 
stabilise these PEI/plasmid formulations during controlled nucleation, higher 
cryoprotectant concentrations were necessary compared to standard shelf-ramp 
freezing. In order to investigate the effect of controlled nucleation on ODN-loaded 
GNPs, samples with increasing sucrose or trehalose/ODN ratios were frozen via 
controlled nucleation or via conventional shelf-ramp freezing (-1°C/min 
or -1.5°C/min).  
 
The most divergent product temperature profiles and nucleation temperatures are 
displayed in Figure III-7 and Figure III-8. Using conventional freezing, ice nucleation 
occurred stochastically at random product temperatures (-8.1°C ± 2.0°C 
or -8.7°C ± 3.0°C) as well as at random time points (standard deviation nucleation 
times: ± 4.2 min or ± 5.1 min). In contrast, when the controlled nucleation method 
was applied, ice nucleation occurred simultaneously at a temperature 
of -2.7°C ± 0.2°C and a distinct time point (standard deviation nucleation 
time ± 0 min). This confirms that controlled ice nucleation occurred reliably. 
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Figure III-7 Temperature profiles of shelves (dashed) and formulations (solid) during conventional 
freezing at -1°C/min (dark grey) or at -1.5°C/min (light grey) and during controlled nucleation 
(middle grey). 
 
Figure III-8 Nucleation temperatures of samples frozen by conventional freezing at -1°C/min (left 
bar) or -1.5°C/min (middle bar) and controlled nucleation at a shelf temperature of -4°C (right bar). 
Data is represented as mean - SD (n=3). 
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Particle size and PDI values of ODN-loaded GNPs before and after freeze-thawing 
using different freezing methods is displayed in Figure III-9A. In general, particle 
sizes and PDI values were preserved by the addition of sugars as cryoprotectant, 
whereas an excipient free formulation led to aggregation of the ODN-loaded GNPs. 
This reinforces that the vitrification and particle isolation hypothesis as explanation 
for stabilisation of non-viral gene vectors by cryoprotectants can also be applied to 
ODN-loaded GNPs. Briefly, the vitrification hypothesis states that non-viral gene 
vectors, such as lipoplexes or polyplexes, are stabilised by sugars due to their 
immobilisation in the glassy state. This is combined with the isolation of the 
particles in the freeze concentrated solution by the sugar molecules and consequent 
reduced aggregation [48, 49]. Hence, a certain sugar concentration is necessary to 
achieve sufficient stabilisation.  
 
Hardly any difference between sucrose and trehalose formulations could be 
observed. A higher cryoprotectant concentration had slightly beneficial effect on 
particle sizes after freeze-thawing. A tendency to narrower particle size 
distributions could be observed with increasing sugar concentrations indicating 
better stabilisation, which further supports the particle isolation hypothesis [48, 
49].  
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Figure III-9 Particle sizes (top) and PDI values (bottom) of ODN-loaded GNPs in different 
formulations before freezing (black bar), frozen by conventional freezing at -1°C/min (light grey bar 
upwards striped) or -1.5°C/min (dark grey bar chequered) and frozen by controlled nucleation with 
hold time (light grey bar downwards striped) or w/o hold time (dark grey bar stiped across). Data is 
represented as mean + SD (n=3). 
In contrast to polyplexes, different freezing methods have no impact on particle 
sizes and PDI values of ODN-loaded GNPs. During ice formation, strong electric fields 
are generated due to favoured inclusion of one ionic species into the ice [50, 51]. 
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Among others, this phenomenon is dependent on freezing rate, type of ions as well 
as concentrations [50, 51]. For polyplexes, it was stated that destabilisation during 
freezing is related to this charged ice formation and the fact that polyplexes are 
formed due to electrostatic interactions [24]. Thus, their integrity can be disturbed 
leading to aggregation. This is supported by the observation of lipoplexes being 
more stable during freezing due to hydrophobic interactions in addition to 
electrostatic interactions [24, 49]. Upon these nanoparticle types GNPs are most 
stable, because they are covalently cross-linked. Hence, their stability may be less 
disrupted by electric fields and aggregation is less likely. Furthermore, the used GNP 
formulations did not compose any buffer salts. Accordingly, the formation of electric 
fields at the ice interface is less pronounced. In summary, this enables that even low 
sugar/ODN rations are sufficient to prevent ODN-loaded GNPs from aggregation 
during freezing.  
On the basis of the observations during freeze thawing studies no isothermal 
equilibration step (hold time) after controlled nucleation was applied for the 
following lyophilisation experiments.  
3.2.2 LYOPHILISATION USING CONTROLLED NUCLEATION 
By applying controlled nucleation, the drying time could be shortened by only 7%. 
This could save some time, energy and costs. However, it is questionable if these 
fractional savings are worth implementing a more complex freezing method. 
Regarding particle sizes, PDI values, loading efficiencies, residual moisture values, 
and glass transition temperatures no relevant differences of storage time compared 
to a conventional freeze-drying cycle could be found. Only ODN stability (Table A 3, 
annex) seemed to be slightly enhanced in low concentration sugar formulations at 
elevated temperatures (for further details see annex). In contrast to reports in 
literature, controlled nucleation neither has a positive effect as assumed from 
protein research [23], nor has negative impact on the product as reported for 
polyplexes [24]. 
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3.3 AMINO ACIDS 
The intention of this part of the work was to identify excipients for lyophilisation of 
ODN-loaded GNPs apart from classical sugars. Furthermore, keeping a later 
sterilisation via gamma irradiation in mind, the portfolio of potential stabilising 
excipients should be enlarged. It is known form literature that amino acids can have 
stabilising effects on protein formulations and lyophilisates [25, 26, 52, 53], as wells 
as protective properties to shield against sterilising irradiation [27]. The aim of the 
study was to evaluate if this can be transferred to lyophilisation of ODN-loaded 
GNPs. 
Excipient choice was based either on charge of the amino acid and/or known ability 
to stabilise biomolecules. Positively charged amino acids were chosen in order to 
preserve high loading efficiencies. We know from previous experiments, that ODN-
loaded GNPs are very sensitive to the addition of negatively charged molecules 
leading to tremendous loss in loading efficiency. This is based on interaction of the 
negatively charged molecule and the positively charged GNPs and resulting 
competition of ODNs and excipient. Positively charged excipients do not have this 
strong impact on loading efficiency. From the group of basic amino acids, arginine 
and histidine were selected, as they are known to prevent proteins from aggregation 
and form amorphous cakes after freeze-drying [26, 53, 54].  
Furthermore, a neutral amino acid was chosen. Neutral amino acids result in a 
crystalline state after freeze-drying [26]. Therefore, they are not suitable to stabilise 
biomolecules such as proteins, but can be used as bulking agents [33]. For this study, 
we selected glycine.  
Additionally, we evaluated mixtures of these amino acids, as well as combinations 
of a sugar and an amino acid in order to enhance their potential stabilising effect.  
Pre-experiments revealed the following formulations as promising regarding 
particle sizes and PDI values of ODN-loaded GNPs in the liquid state: His, His + Arg, 
His + Gly, Arg + Gly, Arg + His + Gly, Suc + Gly, Tre + Gly.  
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3.3.1 DRYING TIME 
In order to prevent collapse of the formulations due to very low glass transition 
temperatures of the maximally freeze concentrated solution (Tg’ values as low 
as -53°C), process changes in the lyophilisation cycle were necessary. However, this 
led to a strongly prolonged drying time. Further process development is 
recommended to optimise lyophilisation cycles for the amino acids. 
3.3.2 PARTICLE SIZES AND PDI 
In contrast to sugar formulations, no change in GNP particle sizes before and after 
freeze-drying in pure amino acid formulations was observed. Sugar amino acid 
(glycine) combinations showed smaller particle sizes after lyophilisation and 
rehydration similar to plain sugar formulations. This leads to the suggestion that 
either GNPs formulated in amino acids do not shrink to the same extent as in sugar 
formulations, or sugars are involved in incomplete swelling after rehydration. 
Furthermore, sugar glycine combinations showed clearly higher particle sizes 
(~300 nm before and 280 nm after freeze-drying) than amino acid or sugar 
formulations (~200 nm). PDI values of all formulations were acceptable directly 
after freeze-drying, the chosen amino acids had no impact on particle size 
distribution (Figure III-10). During storage at 2-8°C and 20-25°C particle sizes and 
PDI values remained unchanged for three months in all formulations. At accelerated 
conditions, the particle characteristics of the formulations do neither change, except 
for Arg + Gly. This formulation shows a clear particle aggregation after four weeks 
storage at 40°C.  
Regarding particle characteristics, it can be concluded that amino acids are 
equivalent to sugars in stabilising freeze-dried ODN-loaded GNPs, except for the 
combination of arginine and glycine. The aggregation could be caused by the 
crystallisation of glycine after lyophilisation and subsequent destabilisation of the 
nanoparticles. Amorphous arginine was not able to compensate the negative effects 
of crystalline glycine.  
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Figure III-10 Particle sizes (bars) and PDI values (dots) of freeze-dried ODN-loaded GNPs in amino 
acid containing formulations directly after lyophilisation (dark grey), after four weeks of storage 
(light grey striped) and three months of storage (dark grey chequered). Stored at A: 2-8°C, B: 20-25°C 
and C: 40°C. Results are represented as mean + or ± SD (n=3). 
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3.3.3 LOADING EFFICIENCIES 
Investigation of the loading efficiencies is important and interesting, as charged 
amino acids may have a stronger impact than uncharged sugars. Compared to sugar 
formulations and sugar containing amino acid formulations, pure amino acid 
formulations showed slightly reduced loading efficiencies (annex). This may be 
because of an interaction between positively charged amino acids and negatively 
charged ODNs. Nonetheless, loading efficiencies persisted above 80% and remained 
stable during storage at all conditions. However, His as well as Arg + Gly showed a 
trend to stronger loss in loading efficiency with increasing storage temperature.  
Summarising, amino acids seem to interact with the charged surface of GNPs leading 
to a competitive reduction in ODNs loading efficiency.  
3.3.4 ODN INTEGRITY 
The resistance of ODNs loaded onto GNPs has already been shown for sugar 
formulations in previous sections. The focus of this part was to study if the stability 
is transferrable to amino acid formulations. Results are listed in Table III-2. 
ODN integrity was not affected in amino acid formulation after storage for three 
months at 2-8°C or 20-25°C. However, the MALDI-TOF signal in the Tre + Gly 
combination was low, which may indicate starting ODN degradation even if no 
additional peak was detected.  
At accelerated temperature, only His was adequate to stabilise ODNs. In the other 
formulations, ODNs showed degradation by reduced signal intensity or complete 
degradation by a not detectable signal.  
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Table III-2 Oligodeoxynucleotide integrity after lyophilisation of amino acid containing formulations. 
ODN integrity is represented with symbols:  stable ODN,  degraded ODN, ± indications for starting 
degradation. 
Formulation  2-8°C 20-25°C 40°C 
 3 months 3 months 4 weeks 
.. 
    His     
His + Arg     
His + Gly    ± 
Arg + Gly     
Arg + His + Gly    ± 
Suc + Gly    ± 
Tre + Gly  ± ±  
Several reasons are conceivable for ODN degradation in these formulations and shall 
be discussed: I.) Lower ODN protection because of reduced loading efficiency, II.) 
ODN degradation induced by particle aggregation, III.) pH dependent ODN 
degradation during holding time between rehydration and MALDI-TOF 
measurement and IV.) ODN degradation at elevated temperature by increasing 
residual moisture content.  
I.) No correlation between ODN degradation and loading efficiency was 
found. The only formulation that protected ODNs at 40°C showed the 
lowest loading efficiency, whereas no intact ODN was detectable in the 
formulation with the highest loading efficiency.  
II.) The formulation Arg + Gly showed strong particle aggregation after 
storage at 40°C and was not suitable to stabilise ODNs. However, other 
formulations with degraded ODNs did not tend to aggregate. This implies 
that particle aggregation may be involved in ODN degradation, but not the 
only reason for it.  
III.) ODN stability tests at different pH values between 4.5 and 10.5 revealed 
that ODN degradation after 24 hours was only detectable at pH 10.5, 
whereas the highest pH of the examined formulations was 9.09 (annex). 
Furthermore, there is no correlation between pH and ODN degradation. 
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Regarding pH value, ODN degradation seems to be randomly distributed. 
This leads to the conclusion that a pH driven reaction is not the reason 
for ODN degradation in these formulations.  
IV.) A correlation between ODN degradation at accelerated temperature and 
the residual moisture content was already discussed in the sections 
dealing with sugar formulations. Amino acid formulations indicated 
lower hygroscopicity compared to sugar formulations and more stable Tg 
values (for more information see annex). However, no relation between 
the increase in residual moisture and the extend of ODN degradation was 
observed for the amino acid formulations. This leads to the conclusion 
that in contrast to sugar formulations, residual moisture content is not 
the driving factor of ODN degradation after freeze-drying in the amino 
acid containing formulations. 
 
In summary, it can be stated that amino acids can generally be used as excipients for 
lyophilisation of ODN-loaded GNPs. However, due to low Tg’ values, process time, 
costs and energy consumption are affected. Additionally, except for histidine, the 
investigated amino acids seem to be inferior for long term stability compared to 
standard sugars, such as sucrose and trehalose.  
For glycine, this can be related to its crystalline state after lyophilisation [26]. It is 
well known that crystallising excipients are not able to protect proteins during 
lyophilisation [30]. However, in the field of nanoparticles there is disagreement in 
literature about the effects of crystalline agents, such as glycine or mannitol. On the 
one hand, the particle isolation hypothesis conveys that a spatially separation of the 
particles is sufficient to prevent them from aggregation [49]. This can also be 
achieved by crystalline excipients. On the other hand, e.g. a study on albumin 
nanoparticles showed a reduced stabilisation capacity of mannitol compared to 
amorphous sugars that was attributed to crystallisation [36]. For GNPs, Zillies et al. 
demonstrated that mannitol is sufficient to stabilise unloaded nanoparticles [15]. 
However, for oligonucleotide-loaded GNPs mannitol failed to prevent 
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aggregation [15]. Our study confirms for amino acids that crystallisation of the 
excipients is disadvantageous, at least for ODN-loaded GNPs.  
Negative effects of arginine are further discussed in Chapter IV.  
4 CONCLUSION 
Stability of lyophilised ODN-loaded GNPs was proved for at least six months at 2-8° 
and 20-25°C. MALDI-TOF was found to be a versatile tool to investigate ODN 
integrity. 
Freeze thaw studies using conventional shelf ramped freezing versus controlled 
nucleation showed overall stability of ODN-loaded GNPs to stresses induced during 
freezing.  
Controlled ice nucleation leads to slightly reduced drying time in lyophilisation of 
ODN-loaded GNPs. Nevertheless, no further clear advantages compared to standard 
lyophilisation were noticed. 
Amino acids can be used as excipients in freeze-drying of ODN-loaded GNPs. 
However, ODNs stability during storage is reduced at accelerated temperatures 
compared to sugar based formulations. Amongst the investigated formulations, only 
pure histidine is adequate to completely stabilise ODN-loaded GNPs upon storage.  
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6 ANNEX 
6.1 CONVENTIONAL LYOPHILISATION 
6.1.1 LOADING EFFICIENCIES 
Loading efficiencies related to section 3.1.2 of the main text are listed in Table A 1 
Table A 1 Loading efficiencies of ODN-loaded GNPs before freeze-drying, directly after freeze-drying, 
after six months storage at 2-8°C, after six months storage at 20-25°C and after four weeks storage 
at 40°C. Results are represented as mean ± SD (n=3). 
Formulation 
Loading efficiency [%] 
Before 
lyophilisation 
After 
lyophilisation 
6 months 
2-8°C 
6 months 
20-25°C 
4weeks 
40°C 
      
S100 98.4 ± 0.8 99.4 ± 0.4 100.1 ± 0.1 101.1 ± 0.2 99.8 ± 0.6 
S500 97.9 ± 0.3 99.8 ± 0.3 100.5 ± 0.1 100.8 ± 0.3 101.7 ± 0.4 
S1333 95.1 ± 0.7 94.7± 0.3 97.6 ± 0.3 99.4 ± 0.2 101.8 ± 0.8 
T100 95.6 ± 3.7 97.6 ± 0.8 100.2 ± 0.2 100.9 ± 0.4 101.8 ± 0.6 
T500 96.7 ± 2.2 97.3 ± 0.2 100.6 ± 0.5 100.5 ± 0.5 93.5 ± 0.7 
T1333 92.0 ± 2.6 91.5 ± 3.6 97.5 ± 0.3 92.1 ± 4.9 98.6 ± 0.4 
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6.1.2 ODN INTEGRITY 
A representative MALDI-TOF spectrum of ODNs that show indications for starting degradation is 
displayed in Figure A 1. Related discussion can be found in section 3.1.3 of the main text.  
 
Figure A 1 MALDI-TOF spectrum of ODNs in formulation S100 after storage of four weeks at 40°C. 
Additional peak represents starting degradation of ODNs. 
6.1.3 RESIDUAL MOISTURE AND GLASS TRANSITION 
The following section is a detailed description of the results discussed in section 3.1.4 of the main 
text.  
Initially measured water contents of all lyophilised ODN-loaded GNPs were below or close 
to 1% (Figure A 2). However, upon storage, an increase in residual moisture content of the sucrose 
containing formulations could be observed. This was most pronounced in the low concentration 
samples and hardly detectable in the highest sugar concentration. This finding is in accordance with 
observations of Zillies et al. [1]. They also noticed increasing residual moisture contents upon storage 
of ten weeks. However, they saw no further increase after four weeks. An equilibrium moisture 
content was reached after four weeks of storage. For the S100 formulation we saw a similar steady 
state residual moisture after four weeks of storage. Furthermore, a correlation between storage 
temperature and moisture increase is observed. The lower the storage temperature, the less distinct 
is the increase of residual moisture content.  
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The same trend can be seen in the trehalose formulations (Figure A 2), whereas water sorption was 
not that marked, especially the samples stored at 2-8°C showed hardly increase in residual moisture. 
This is in contrast to previous results that demonstrated slightly higher hygroscopicity of trehalose 
containing freeze-dried GNPs [1]. However, our results are in accordance with other research that 
stated trehalose to be less hygroscopic compared to other sugars [2]. 
It is known from the work of Zillies et al. that aggregation of lyophilised GNPs is initiated at residual 
moisture values of 5% [1]. Below this threshold, no particle aggregation was observed. These 
findings are confirmed by our study, as we did not detect increasing PDI values even in samples with 
high residual moisture of around 3%. However, the starting ODN degradation noticed in the lowest 
concentration sugar formulations at 40°C storage may be related to the increasing water content and 
elevated temperature [3].  
Measured initial Tg values (Figure A 2) of all sucrose (~ 60°C) and trehalose (~ 100°C) formulations 
agree with values from literature [4]. 
Sucrose formulations S500 and S1333 showed stable Tg values upon six months storage independent 
of storage conditions. Only the lowest sucrose concentration demonstrated a decrease of Tg, which 
is stronger the more pronounced is the increase in residual moisture and the higher is the storage 
temperature. The Tg values of samples stored at 2-8°C stayed above 40°C during the complete 
storage duration, whereas Tg values of samples stored at room temperature dropped just below 
40°C. Measured Tg values of S100 samples at 40°C were even below 35°C after four weeks. As this 
value is below the storage temperature, particle aggregation and ODN degradation are more likely. 
This assumption is supported by the observation of starting ODNs depletion in MALDI-TOF spectra. 
However, particle aggregation is not yet induced.  
Similar trends can be noticed for the trehalose formulations (Figure A 2). The higher concentrated 
formulations (T500 and T1333) showed hardly changes in Tg values in all storage conditions, 
whereas T100 samples behaved comparable to S100 samples. Admittedly, Tg remained overall at 
higher values than the sucrose samples and did not fall below storage temperatures. However, the 
formulation with the highest residual moisture and the lowest Tg (T100) also showed first evidence 
of ODN degradation expressed in a very low MALDI-TOF signal. Equally to S100, no GNP aggregation 
was observed.  
These findings regarding residual moistures and Tg values are in accordance with results reported 
by Zillies et al. [1, 5]. 
Taking residual moistures and Tg values into account, it can be stated that for long term stability 
trehalose is superior to sucrose and storage at 2-8°C is recommended for lyophilised ODN-loaded 
GNPs.  
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Figure A 2 Glass transition temperatures (bars) and residual moisture contents (dots) of freeze-dried 
ODN-loaded GNPs directly after lyophilisation, after four weeks of storage and six months of storage. 
Sucrose formulations at A: 2-8°C, B: 20-25°C and C: 40°C. Trehalose formulations at D: 2-8°C, E: 20-
25°C and F: 40°C. Results are represented as mean + or ± SD (n=2). 
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6.2 CONTROLLED NUCLEATION 
The following sections represent a detailed report about the results regarding controlled nucleation 
given in section3.2.2 of the main text.  
6.2.1 PARTICLE SIZES AND PDI VALUES 
Particle sizes of ODN-loaded GNPs freeze-dried after controlled nucleation (Figure A 3) were 
comparable to conventional lyophilisation. This supports our initial results of GNPs being more 
stable during controlled nucleation than polyplexes. Similar to conventionally freeze-dried ODN-
loaded GNPs, particle sizes were smaller after lyophilisation than before. The hypothesis of no full 
rehydration of GNPs after freeze-drying [5] is again confirmed.  
 
Furthermore, particle sizes remained stable upon storage. This again indicates no damage of the 
nanoparticles during controlled ice nucleation, which would lead to aggregation during storage. 
Beyond this, PDI values did not change during storage, which also indicates that no aggregation 
occurs (Figure A 3).  
 
However, formulation S100 showed increasing particle size and PDI value at accelerated 
temperature indicating starting aggregation. Consequently, similar to conventional lyophilisation, it 
can be stated that trehalose is superior in stabilising ODN-loaded GNPs compared to sucrose. Besides 
this, results of different sugar types and storage conditions were equivalent. 
Hence, the main finding of that part of the study is that controlled nucleation allows only minor 
process shortage and has no negative impact on particle sizes and monodispersity of ODN-loaded 
GNPs.  
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Figure A 3 Particle sizes (bars) and PDI values (dots) of ODN-loaded GNPs freeze-dried via controlled 
nucleation directly after lyophilisation (left bar), after four weeks of storage (middle bar) and three 
months of storage (right bar). Sucrose formulations at A: 2-8°C, B: 20-25°C and C: 40°C. Trehalose 
formulations at D: 2-8°C, E: 20-25°C and F: 40°C. Results are represented as mean + or ± SD (n=3). 
6.2.2 LOADING EFFICIENCIES 
As a further parameter for stability, loading efficiencies were evaluated after freeze-drying and 
storage. As one can see from Table A 2, loading efficiencies remained stable during freeze-drying with 
controlled nucleation and following storage at different conditions. Loading efficiencies behaved 
comparable to those of the conventionally lyophilised samples. The positive net charge of GNPs and 
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their interaction with ODNs was not affected by controlled nucleation, which is independent of sugar 
type or storage temperature. This further shows the superior stability of ODN-loaded GNPs 
compared to ODN-loaded polyplexes [6]. 
Table A 2 Loading efficiencies of ODN-loaded GNPs before freeze-drying, directly after freeze-drying 
using controlled nucleation, after three months storage at 2-8°C, after three months storage at 20-
25°C and after four weeks storage at 40°C. Results are represented as mean + SD (n=3). 
Formulation 
Loading efficiency [%] 
Before 
lyophilisation 
After 
lyophilisation 
3 months 
2-8°C 
3 months 
20-25°C 
4 weeks 
40°C 
S100 98.8 ± 1.9 95.4 ± 0.6 93.0 ± 0.6 92.9 ± 0.5 96.5 ± 6.0 
S500 98.9 ± 3.5 96.5 ± 1.6 93.7 ± 0.6 97.6 ± 0.5 96.2 ± 0.2 
S1333 102.1 ± 2.2 95.5± 0.6 97.1 ± 0.2 98.5 ± 0.6 89.0 ± 0.3 
T100 96.9 ± 3.4 95.5 ± 0.6 92.0 ± 1.2 92.5 ± 0.6 94.8 ± 0.6 
T500 100.7 ± 0.4 97.0 ± 1.0 94.5 ± 0.6 97.9 ± 0.3 93.2 ± 0.6 
T1333 100.3 ± 1.5 101.9 ± 0.7 96.6 ± 0.3 97.0 ± 0.3 98.9 ± 0.3 
6.2.3 ODN INTEGRITY 
The important factor regarding activity of ODN-loaded GNPs is the integrity of the 
oligodeoxynucleotides. Table A 3 depicts that the ODNs were not affected by controlled nucleation 
followed by lyophilisation in all formulations and were stable upon storage at all conditions. In 
contrast to conventional lyophilisation, no ODN degradation in the low excipient containing 
formulations S100 and T100 was apparent at 40°C. Hence, at least for low sugar content 
formulations, freezing via controlled nucleation prior to lyophilisation seems to be advantageous 
regarding ODN integrity. 
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Table A 3 Oligodeoxynucleotide integrity after lyophilisation combined with controlled nucleation. 
ODN integrity is represented with symbols:  stable ODN,  degraded ODN, ± indications for starting 
degradation. 
Formulation 
 Controlled nucleation 
 2-8°C 20-25°C 40°C 
 3 months 3 months 4 weeks 
..     S100     
S500     
S1333     
T100     
T500     
T1333     
6.2.4 RESIDUAL MOISTURE AND GLASS TRANSITION 
In the conventional lyophilisation experiment, ODN degradation was associated with a higher 
residual moisture. To assess this correlation, residual moisture contents of the controlled nucleated 
samples were analysed and discussed in this section. 
Residual moisture values of controlled nucleated (Figure A 4) and conventional frozen samples 
(Figure A 2) hardly differed directly after freeze-drying and at the end of the storage period. 
Intriguingly, residual moistures of the lowest sugar concentrations reached their maximum value 
after three months, whereas in the conventional samples the maximum was already attained after 
four weeks. This suggests a slower water uptake rate of the controlled nucleated samples, which may 
be explained by a lower specific surface area. However, final residual moistures after three months 
were even higher than of the conventionally freeze-dried products after six months. Nonetheless, 
increased water absorption seems not to be critical regarding three months stability at 2-8°C and 20-
25°C, as it did not lead to particle aggregation or ODN degradation. However, for an industrial 
production and long-term storage, methods to control residual moisture contents are highly 
recommended.  
It is important to be careful when comparing ODN stability in S100 and T100 formulations at 
accelerated conditions. In the controlled nucleated samples ODNs is stable for four weeks, but 
residual moisture is obviously lower than in the conventional samples. This supports the 
presumption that ODN degradation at elevated temperature is directly related to the water content 
of the lyophilisates.  
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Figure A 4 Glass transition temperatures (bars) and residual moisture contents (dots) of ODN-loaded 
GNPs freeze-dried via controlled nucleation directly after lyophilisation, after four weeks of storage 
and three months of storage. Sucrose formulations at A: 2-8°C, B: 20-25°C and C: 40°C. Trehalose 
formulations at D: 2-8°C, E: 20-25°C and F: 40°C. Results are represented as mean + or ± SD (n=2). 
Evaluated Tg values (Figure A 4) are in accordance to literature [4] and comparable to Tg values of 
conventionally lyophilised samples (Figure A 2), whereas there can be seen a trend to slightly higher 
initial values. 
Apart from that, Tg values of S500, S1333, T500 and T1333 were stable over the whole storage period 
at storage temperatures of 2-8°C and 20-25°C. Results were comparable to conventional freeze-
drying. Interestingly, at 40°C S500 and T500 showed stronger Tg decrease than the corresponding 
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conventional samples. Tg values of the lowest sugar formulations behaved also comparable to 
conventionally dried samples resulting in a strong decrease associated with a strong increase in 
residual moisture.  
6.3 AMINO ACIDS 
6.3.1 LOADING EFFICIENCIES AND PH VALUES 
Loading efficiencies related to section 3.3.3 of the main text are displayed in Table A 4. 
In section 3.3.4 of the main text pH values of the formulations are discussed. These values are listed 
in Table A 5 
Table A 4 Loading efficiencies of ODN-loaded GNPs in amino acid containing formulations before 
freeze-drying, directly after freeze-drying using controlled nucleation, after three months storage at 
2-8°C, after three months storage at 20-25°C and after four weeks storage at 40°C. Results are 
represented as mean ± SD (n=3). 
Formulation 
Loading efficiency [%] 
Before 
lyophilisation 
After 
lyophilisation 
3 months 
2-8°C 
3 months 
20-25°C 
4 weeks 
40°C 
His 94.6 ± 0.7 81.0 ± 1.0 92.5 ± 0.6 89.7 ± 0.5 83.6 ± 0.6 
His + Arg 94.3 ± 0.6 84.8 ± 0.6 96.1 ± 0.6 90.0 ± 0.6 95.1 ± 0.3 
His + Gly 96.0 ± 1.7 93.9 ± 0.6 94.9 ± 0.7 90.1 ± 0.7 92.9 ± 0.7 
Arg + Gly 93.0 ± 0.5 96.3 ± 0.6 92.1 ± 0.7 87.8 ± 0.3 85.4 ± 0.7 
Arg + His + Gly 93.8 ± 0.6 87.7 ± 0.6 92.3 ± 0.5 88.8 ± 0.9 90.0 ± 0.7 
Suc + Gly 97.2 ± 0.8 99.6 ± 0.6 100.4 ± 0.5 100.7 ± 0.5 97.8 ± 0.7 
Tre+Gly 98.2 ± 0.3 100.2 ± 0.6 101.4 ± 1.6 101.2 ± 1.1 99.1 ± 0.4 
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Table A 5 pH values of all investigated formulations. Results are represented as mean ± SD (n=3). 
Formulation pH value Formulation pH value Formulation pH value 
..      S100 4.33 ± 0.04 Suc + Gly 5.96 ± 0.09 Gly 2.5 6.00 ± 0.04 
S500 4.56 ± 0.08 Suc + His 7.82 ± 0.06 Gly 5.0 5.74 ± 0.05 
S1333 4.51 ± 0.07 Tre + Arg 10.60 ± 0.06 His 7.59 ± 0.04 
T100 4.46 ± 0.11 Tre + Gly 5.98 ± 0.05 Arg + His 9.09 ± 0.03 
T500 4.69 ± 0.17 Tre + His 7.57 ± 0.07 Arg + Gly 9.08 ± 0.06 
T1333 4.52 ± 0.11 Arg 2.5 10.59 ± 0.07 His + Gly 7.38 ± 0.05 
Suc + Arg 10.53 ± 0.06 Arg 5.0 10.77 ± 0.06 Arg + His + Gly 9.02 ± 0.07 
6.3.2 RESIDUAL MOISTURE AND GLASS TRANSITION 
The following section gives further information on residual moisture contents and glass transition 
values mentioned in section 3.3.4 of the main text. 
Freeze-drying of amino acid containing formulation led to residual moisture contents below 1%, 
except for formulation Arg + Gly with a higher residual moisture content of ~1.4% (Figure A 5). This 
high initial water content may have triggered particle aggregation in this formulation during storage 
at 40°C due to higher product mobility.  
Upon storage none of the formulations, independent of storage temperature, exceeds a residual 
moisture content above 2% (Figure A 5). This indicates lower hygroscopicity or a slowed down water 
sorption rate compared to sugar formulations.  
A stable residual moisture content is normally related to a higher product stability. There is evidence 
to suggest that this pertains for the sugar formulations of ODN-loaded GNPs at higher temperature. 
However, it could not be confirmed by our study regarding the amino acids. A starting ODN 
degradation in the amino acid formulations at 40°C was detected, whereas ODN were stable in more 
hygroscopic sugar formulations. Furthermore, there was no relation between the increase in residual 
moisture and the extend of ODN degradation observed. The formulations with the highest water 
content after 4 weeks at 40°C were Arg + His, His + Gly, Arg + His + Gly, but in only one of them no 
ODN signal could be detected. On the other hand, Tre + Gly was overall one of the driest formulations, 
but ODN degradation started already at 2-8°C. 
So far, there is little information on glass transition temperatures of sugar free lyophilised amino 
acids available. For lyophilised arginine a Tg of 42°C was reported by Mattern et al., whereas a Tg 
of 37°C was declared for histidine [7]. This is not consistent with our findings. The measured Tg of 
the ODN-loaded GNP formulation with pure histidine was found to be much higher, 
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at 105°C (Figure A 5). However, Mattern et al. did not comment if they used histidine base or a salt. 
This would be important information, as the counterion may have an influence on glass transition 
temperatures [8, 9].  
Initial Tg values of Suc + Gly were lower than for pure sucrose. This could be expected due to the Tg 
lowering effects of glycine [10]. The same phenomenon was observed for the Tre + Gly and His + Gly 
formulations. A Tg lowering effect can also be supposed for arginine, as the Arg + His formulation 
revealed a clearly lower Tg of 67°C compared to pure histidine. However, the combination of all three 
amino acids did not further lower the Tg value. Nonetheless, the combination of Arg + Gly strongly 
increased the standard deviation (Figure A 5).  
During storage at 2-8°C and 20-25°C, no decrease in Tg could be detected in the amino acid containing 
formulations, except for pure histidine. This is in correlation with the low increase in residual water 
content. Only at accelerated conditions a reduction in Tg was annotated in most of the formulations 
(Figure A 5). 
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Figure A 5 Glass transition temperatures (bars) and residual moisture contents (dots) of freeze-dried 
ODN-loaded GNPs in amino acid containing formulations directly after lyophilisation (left bar), after 
four weeks of storage (middle bar) and three months of storage (right bar). Storage at A: 2-8°C, 
B: 20-25°C and C: 40°C. Results are represented as mean + or ± SD (n=2). 
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ABSTRACT 
Sterilisation is an important prerequisite for drug products applied via the 
parenteral route. Steam sterilisation is the most common method and 
recommended by pharmaceutical authorities for aqueous formulations. This work 
investigated steam sterilisation for its applicability to sterilise gelatine 
nanoparticles (GNPs). GNP dispersions were subjected to different autoclave 
treatments and subsequently analysed for particle sizes, size distributions, particle 
concentrations, cross-linking degrees and protein secondary structures. GNPs 
mostly remained stable during standard steam sterilisation 
conditions (121°C,15 min), whereas harsher conditions led at least partly  to 
degradation. The second part of the study included the investigation of gamma 
irradiation for sterilisation of lyophilised ODN-loaded GNPs. Different excipients, 
such as sugars and amino acids, were analysed for their suitability to stabilise GNPs 
and ODNs during irradiation. Analytics included particle characteristics, size 
distributions, loading efficiencies, and ODN integrity. Gamma irradiation has proven 
to be a versatile sterilisation method for ODN-loaded GNPs. Additionally, sugars 
have shown be superior in stabilising and protecting during gamma irradiation 
compared to amino acids. 
KEYWORDS 
Steam sterilisation, sterilisation, gamma irradiation, MALDI-TOF, gelatine 
nanoparticles 
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1 INTRODUCTION 
Nanoparticles are widely researched as drug delivery systems for different kinds of 
drugs. Amongst a variety of starting materials, such as poly (lactic-co-glycolic) acid 
(PLGA), albumin, chitosan or lipids, gelatine has proven to be very promising. 
Gelatine nanoparticles (GNPs) have been successfully used as carriers for 
immunomodulatory oligodeoxynucleotides (ODNs) in several veterinary clinical 
studies treating allergic diseases, such as equine recurrent airway obstruction or 
canine atopic dermatitis [1-5].  
 
An important critical quality attribute and prerequisite for medicinal application via 
the inhalative and parenteral route is sterility. So far, an aseptic particle production 
and loading process is necessary to ensure appropriate product quality. However, 
working aseptically is always critical due to a lot of potential contamination risks 
caused by inadequate handling, which cannot completely eliminated by validation 
or monitoring [6, 7]. Consequently, aseptic preparation should be circumvented if 
possible in order to ensure reliable patient safety [7]. The most common and safest 
way to achieve a sterile product is steam sterilisation, preferably performed in the 
final product container. The reason for using this approach is a controllable, 
validatable and calculatable sterility assurance level [6]. However, steam 
sterilisation of nanoparticles is challenging due to different stability issues. For 
instance, it is known from literature that the harsh conditions during autoclaving 
induce degradation and hydrolysis of PLGA [8]. This results in the loss of structural 
integrity of the particles. Furthermore, an acidic microclimate emerges due to the 
immediate release of lactic and glycolic acid, which may cause degradation of the 
loaded drug [9]. Information on effects of steam sterilisation on lipidic composites, 
such as solid lipid nanoparticles (SLNs) or liposomes is contradictory. Depending on 
the lipid composition or buffer system, steam sterilisation may be applicable to 
these systems or cause particle aggregation and lipid degradation [10-12]. On the 
other hand, nano- and microparticles prepared from recombinant spider silk 
protein showed excellent resistance during steam sterilisation [13]. Even extended 
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sterilisation conditions, such as prolonged or repeated autoclaving did not 
negatively impact on the spider silk particles.  
First aim of this study was to evaluate the effects of steam sterilisation on gelatine 
nanoparticles. We could show that standard autoclaving conditions (121°C, 15 min) 
can be applied to sterilise GNPs without negative impact on particle properties.  
However, due to thermal sensitivity of oligodeoxynucleotides, steam sterilisation 
after particle production and ODN loading is not advisable [14]. Aside from this, 
particle sizes of GNPs do not allow sterile filtration of the final formulation. Hence, 
even if pre-sterilised GNPs can be provided, an aseptic loading process would be still 
essential to guarantee adequate product quality for parenteral application. 
Accordingly, there is a need to establish a possibility of sterilisation of ODN-loaded 
GNPs. An alternative procedure to sterilise pharmaceutical products accepted by the 
European Pharmacopeia and United States Pharmacopeia is gamma irradiation [15]. 
Gamma irradiation is an advantageous method due to high penetration depth, low 
temperature rise and no accumulation of toxic residues [15]. It has been reported to 
be a versatile method to sterilise polymeric nano- and microparticles. Several 
studies using synthetic (e.g. PLGA) or natural occurring polymers (e.g. casein or 
chitosan) showed the appropriate use of gamma rays without impact on these drug 
delivery systems. However, most of these particles were loaded with small 
molecules instead of biopharmaceuticals. It is known that gamma irradiation can 
cause degradation and functional loss of biomolecules, such as proteins [16, 17]. 
Nonetheless, the addition of protection agents, such as amino acids [18, 19] or 
antioxidants [17], allows successful sterilisation of proteineous products. 
Furthermore, sterilisation of the protein in a dry state, such as lyophilised or spray 
dried, is beneficial to maintain its function [17, 19].  
In the present work, we could show that lyophilised ODN-loaded GNPs can be 
sterilised in their final container by gamma irradiation without any adverse effects 
on particle characteristics or ODN integrity.  
Summarising, this work provides different approaches to sterilise unloaded and 
ODN-loaded GNPs, which is an important step into commercialisation of GNPs.  
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2 MATERIALS AND METHODS 
2.1 MATERIALS 
Gelatine type A 300 bloom was provided from Gelita AG (Eberbach, Germany). 
Acetone was obtained from Fisher Chemicals (Loughborough, UK). Glutaraldehyde 
(25% solution), 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride, 
(2-Aminoethyl) trimethylammonium chloride hydrochloride, L-arginine base, L-
histidine base, L-glycine base, TNBS (2,4,6-trinitrobenzene sulfonic acid) and 
sodium bicarbonate were supplied by Sigma (Taufkirchen, Germany). D-(+)-Sucrose 
and D-(+)-Trehalose dihydrate were acquired from VWR International (Leuven, 
Belgium). In all experiments highly purified water (HPW) was used, which was 
produced by a PURELAB Plus device (conductivity < 0.055 µS/cm, Elga Labwater, 
Celle, Germany). Oligodeoxynucleotides (ODNs) were synthesized by biomers.net 
GmbH (Ulm, Germany). 
2.2 PREPARATION OF CATIONISED GELATINE NANOPARTICLES 
GNPs were prepared according to one-step desolvation [20]. Briefly, 750 mg 
gelatine type A (300 bloom) was dissolved in 25 mL HPW (3.0% w/v) under 
constant stirring at 50°C. Afterwards, pH was adjusted to a value between 2.5 
and 3.0. Following, acetone was added dropwise to initiate GNP formation. A volume 
of 175 µL glutaraldehyde solution was added to cross-link GNPs. After overnight 
stirring, the dispersion was purified via three-fold ultrafiltration using a solvent 
resistant stirred cell and an ultrafiltration disc of regenerated cellulose and a 
molecular weight cut-off of 100’000 kDa (Millipore S.A.S., Molsheim, France).  
For cationisation, GNP dispersion was diluted with HPW (~ 10 mg/mL) and pH was 
adjusted (4.5 - 5.0). Subsequently, EDC and Cholamine were added. After incubation 
for 30 min, the reaction mixture was purified by two-fold centrifugation (15000*g 
for 60 min; Sigma Laborzentrifugen, Osterode, Germany). Finally, nanoparticle 
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concentration was determined gravimetrically using a UMX2 ultra-microbalance 
(Mettler Toledo, Greifensee, Switzerland). 
2.3 OLIGODEOXYNUCLEOTIDE LOADING OF GELATINE NANOPARTICLES 
For ODN loading, GNP dispersion was diluted with the respective excipient stock 
solution to a final concentration of 1.5 mg/mL and incubated with 5% (w/w) ODNs 
for 60 min at 21°C and under continuous shaking at 350 rpm (Thermomixer 
Comfort, Eppendorf AG, Hamburg, Germany). Sugar containing samples were 
prepared in excipient-to-ODN ratios of 100:1, 500:1 and 1333:1. This ratio is used 
to identify the samples in the following text. Amino acid formulations (L-arginine, L-
histidine and L-glycine) were prepared at an excipient-to-ODN ratio of 333:1 (one 
amino acid, representing 2.5% [w/v]), 667:1 (two amino acids, equally mixed) and 
1000:1 (three amino acids, equally mixed). Sugar amino acid combinations were 
based on a sugar-to-ODN ratio of 500:1, amino acids were added in the ratio 333:1. 
2.4 LYOPHILISATION OF ODN-LOADED GELATINE NANOPARTICLES  
Freeze-drying of ODN-loaded GNPs was performed with a volume of 500 µL in 2R 
glass vials according to the conventional freeze-drying cycle described in chapter III, 
section 2.4 adapted from Zillies et al. [21]. An EPSILON 2-6D pilot scale freeze dryer 
(Martin Christ Gefriertrocknungsanlagen GmbH, Osterrode, Germany) equipped 
with type T thermocouples (Newport Electronics, Deckenpfronn, Germany) for 
temperature monitoring was used. Upon finishing the cycle, the product chamber 
was vented with nitrogen and samples were stoppered at a chamber pressure 
of 800 mbar. 
2.5 STEAM STERILISATION  
GNP dispersions (5 mg/mL) were steam sterilised in glass vials (DIN 2R, closed with 
stoppers and crimped with aluminium caps) using a GTA 50 autoclave (Fritz 
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Gössner, Hamburg, Germany). Samples were autoclaved for 15, 30 and 45 min 
at 121°C or 3 min at 134°C. Repeated sterilisation cycles were performed 
for 2 x 15 min and 3 x 15 at 121°C. Control samples were stored at 2-8°C.  
2.6 STERILISATION BY GAMMA IRRADIATION 
Lyophilised ODN-loaded GNP formulations were sterilised via gamma irradiation by 
a cobalt-60 source and an absorbed dose of 25 kGy (STERIS AST Allershausen GmbH, 
Germany).  
2.7 GELATINE NANOPARTICLE CHARACTERISATION 
Particle yield was determined gravimetrically using a UMX2 ultra-microbalance 
(Mettler Toledo, Greifensee, Switzerland). Particle size and polydispersity 
index (PDI) were ascertained by DLS using a Zetasizer Nano ZS (Malvern 
Instruments, Worcestershire, UK). Derived countrates were calculated from DLS 
measurements using DTS Nano software (Malvern Instruments, Worcestershire, 
UK). 
2.8 DETERMINATION OF LOADING EFFICIENCY 
Loading efficiency was indirectly determined by measuring UV absorbance 
at 260 nm (Agilent 8453 UV-visible spectrophotometer, Agilent Technologies, Santa 
Clara, California, USA) in the supernatant of centrifuged ODN-loaded GNPs, a GNP 
control and an ODN control [5].  Loading efficiency was calculated using the 
following equation:  
Loading efficiency [%] = 1 − (
A (ODN−loaded GNP)−A (GNP control)
A (ODN control)
) 𝑥 100 %.  
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2.9 DETERMINATION OF CROSS-LINKING DEGREE 
TNBS assay was performed to determine cross-linking degrees of GNPs before and 
after steam sterilisation procedures. In brief, the GNP dispersion was diluted with 
water to a concentration of 4 mg/mL. A volume of 0.25 mL GNP dispersion was 
mixed with a volume of 0.25 mL 0.05% TNBS (v/v) and 0.25 mL 
of 4% NaHCO3 (w/v) (pH 8.5). Subsequently, the samples were incubated at 40°C in 
a Thermomixer (Eppendorf, Hamburg, Germany) for 2 hours under constant 
shaking (500 rpm). Afterwards, a volume of 750 µL of HCl 6M was added to each 
sample. Further incubation for 90 min at 60°C under constant shaking at 500 rpm 
followed. After that, samples were diluted with water for photometric 
determination of the reaction product at 349 nm (Agilent 8453 UV-visible 
sprectrophotometer, Agilent Technologies, Santa Clara, CA, USA). Blank samples of 
gelatine (≙ 0% cross-linking) and control samples of gelatine (≙ 100% cross-linking) 
were prepared. Control sample preparation included HCl addition prior to TNBS 
solution to avoid the reaction between TNBS and free amino groups of gelatine. 
Cross-linking degree was calculated by the following equation: 
𝐶𝐿 [%] = (1 −
𝐴(𝑠𝑎𝑚𝑝𝑙𝑒) − 𝐴(𝑏𝑙𝑎𝑛𝑘)
𝐴(𝑐𝑜𝑛𝑡𝑟𝑜𝑙) − 𝐴(𝑏𝑙𝑎𝑛𝑘)
) ∗ 100% 
2.10 SCANNING ELECTRON MICROSCOPY (SEM) 
Gelatine nanoparticles were lyophilised according to the protocol described in 
chapter III, section 2.4 and immobilised on an aluminium sample grid. Following 
carbon sputtering, samples were analysed by a Helios NanoLab G3 UC scanning 
electron microscope (FEI, Hillsboro, Oregon, USA) at 3.0 kV and a working distance 
of 3.2 – 4.2 mm.  
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2.11 DYNAMIC SCANNING CALORIMETRY (DSC) 
Glass transition temperatures (Tg) were analysed using a Mettler DSC 821e (Mettler 
Toledo, Columbus, OH, USA). GNP dispersions were dried overnight in a vacuum 
drying cabinet at 10 mbar and 25°C and weighed into aluminium crucibles. To 
determine Tg values, samples were measured at a heating and cooling rate 
of 10 K/min from 0 to 150°C against an empty crucible as reference.  
2.12 FOURIER TRANSFORM INFRARED SPECTROSCOPY (FT-IR) 
Fourier transform infrared spectroscopy (FT-IR) using the Bruker Tensor 27 FT-IR 
spectrometer (Billerica, USA) was performed to analyse protein secondary 
structure. Particle dispersions were examined by adding 20 µl into a BioATRCell II 
(Harrick Scientific, Pleasantville, USA) at a temperature of 25°C. Each spectrum 
comprises the average of 120 scans at a resolution of 4 cm-1 and was performed in 
triplicate. Data was analysed with the Bruker OPUS software (version 6.5).  
2.13 MATRIX-ASSISTED LASER DESORPTION/IONISATION TIME-OF-FLIGHT MASS 
SPECTROMETRY (MALDI TOF) 
After desalting on a 0.025 μm VSWP membrane (Merck Millipore, Darmstadt, 
Germany), samples were co-crystallised in a 3-hydroxypicolinic acid matrix (HPA). 
Matrix-assisted laser desorption/ionisation time-of-flight (MALDI-TOF) mass 
spectrometry was performed in negative mode using a Autoflex II (Bruker Daltonics, 
Germany) and a AnchorChip®-Target (Bruker MTP var/384).  
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3 RESULTS AND DISCUSSION 
3.1 STEAM STERILISATION 
Providing a sterile product is essential for the inhalative or parenteral application 
of a drug product. According to the European Medicines Agency, steam sterilisation 
is the method of choice for aqueous formulations [6]. Based on these authority 
requirements, the aim of this study was to evaluate the effects of steam sterilisation 
on gelatine nanoparticles.  
3.1.1 VISUAL INSPECTION 
Visual inspection of the autoclaved samples revealed no change in colour or 
turbidity of GNPs treated at 121°C, but a tremendous change in optical appearance 
of GNPs autoclaved at 134°C (Figure IV-1). These samples became almost clear after 
autoclave treatment. Consequently, it can be assumed that particle integrity was 
damaged during steam sterilisation and GNPs subsequently dissolved.  
 
Figure IV-1 Optical appearance of GNPs after different steam sterilisation procedures. A: Not 
autoclaved reference sample, B: 15 min at 121°C, C: 2x 15 min at 121°C, D: 3x 15 min at 121°C, E: 30 
min at 121°C, F: 45 min at 121°C, G: 3 min at 134°C.  
3.1.2 PARTICLE SIZES AND PDI VALUES 
Particle sizes and PDI values of GNPs after different procedures of steam 
sterilisation were analysed (Figure IV-2). A slight increase in particle sizes was 
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noticed after the standard autoclaving process for 15 minutes at 121°C, whereas 
monomodal size distribution remained stable (PDI < 0.1). This indicates a certain 
swelling of the particles caused by moist heat. Repeated (2-fold or 3-fold) or 
prolonged (30 min or 45 min) sterilisation cycles at 121°C did not further influence 
particle characteristics. However, autoclaving at 134°C and consequent elevated 
pressure of 3 bar resulted in an escalation in particle sizes and PDI values. 
Nonetheless, PDI values were still around 0.2. Based on these results, particle 
aggregation is not likely, but a stronger and more irregular swelling of the GNPs 
compared to standard autoclave treatment.  
 
Figure IV-2 Particle sizes (dots) and PDI values (triangles) of plain GNPs after different steam 
sterilisation procedures (black) and subsequent two weeks storage at 2-8°C (white). Data is 
represented as mean ± SD (n=3). 
All particle sizes and PDI values of GNPs after autoclaving remained stable during 
subsequent storage at 2-8°C for two weeks (Figure IV-2). Furthermore, optical 
appearance did not further change. This implies that no damage occurred, which 
would impact storage stability of steam sterilised GNPs.  
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Findings from DLS measurements can be supported by SEM micrographs (Figure IV-
3). All particles retained their round shape and smooth surface after autoclave 
treatment. However, steam sterilisation at 134°C caused intense swelling of the 
GNPs.  
 
Figure IV-3 SEM micrographs of GNPs after different procedures of steam sterilisation. A: Not 
autoclaved reference sample, B: 15 min at 121°C, C: 2x 15 min at 121°C, D: 3x 15 min at 121°C, E: 30 
min at 121°C, F: 45 min at 121°C, G: 3 min at 134°C. Size bar represents 500 nm in each individual 
image. 
3.1.3 DERIVED COUNT RATES AND CROSS-LINKING DEGREES 
These results demonstrate that steam sterilisation at 134°C had a negative impact 
on GNPs compared to steam sterilisation at 121°C. However, so far, one cannot 
explain the discolouration of the samples. To clarify this phenomenon, the derived 
countrates of the particular DLS measurements were analysed. The derived 
countrate is a theoretic value that describes the respective light scattering without 
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laser attenuation calculated from values obtained by attenuated laser intensity [22]. 
This allows to directly compare the countrates of different samples and 
consequently infer on particle concentrations. Figure IV-4 displays the derived 
countrates of GNPs treated by steam sterilisation. From these data it can be 
concluded that autoclave treatment causes particle damage paired with particle loss 
and particle dissolution. This effect is more pronounced the stronger is the stress 
during steam sterilisation. Interestingly, a repeated autoclaving procedure, 
including multiple heating and cooling steps, is more harmful to GNPs than the 
corresponding prolonged process (e.g. 2x15 min vs. 30 min). Furthermore, steam 
sterilisation at 134°C results in a tremendous loss in derived countrate of ~ 95%. 
Consequently, one can expect an immense decrease in particle concentration, which 
provoked that the particle dispersions became almost clear.  
 
Figure IV-4 Derived countrates in DLS measurements of GNPs before and after different steam 
sterilisation procedures. Data is represented as mean ± SD (n=3). 
The described particle dissolution induced by steam sterilisation was further 
confirmed by evaluation of cross-linking degrees (Figure IV-5). One can deduce a 
reduction in cross-linking degree, which was more pronounced the harsher the 
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sterilisation conditions were. A reduced cross-linking degree signifies an increased 
number of free amino groups in the sample. Consequently, this implies degradation 
of GNPs. Considering these data, it can be presumed that steam sterilisation at 134°C 
led to an almost complete disintegration of GNPs, whereas a large population of 
GNPs withstood autoclave treatment at 121°C.  
 
Figure IV-5 Cross-linking degree of GNPs before and after different steam sterilisation procedures. 
Data is represented as mean + SD (n=3). 
3.1.4 SECONDARY STRUCTURE OF GELATINE NANOPARTICLES 
FT-IR measurements of the samples were performed to analyse effects of steam 
sterilisation on secondary structure of GNPs. Figure IV-6 shows the spectra of the 
amide I band between 1600 cm-1 and 1700-1 and the amide II band 
between 1510 cm-1 and 1580 cm-1 in the second derivative. The large number of 
minima in the region of amide I indicate a combination of different structures in 
GNPs. This includes β-sheet (band at 1695 cm-1, two bands between 1620 
and 1630 cm-1), random coil (band at 1646 cm-1), β-turn (band at 1680 cm-1) 
and 310-helix [23]. On the other hand, amide II region illustrates mainly peaks 
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demonstrating a β-sheet structure (bands at 1515 cm-1, 1534 cm-1, 1552 cm-1, 
1569 cm-1) [24]. After autoclave treatment, intensity changes of the respective 
bands were noticed. However, no shift of the local minima was observed. To 
conclude, although GNPs at least partially degraded during steam sterilisation, no 
drastic changes in secondary structure were detectable by FT-IR.  
 
Figure IV-6 Second derivative of the averaged FT-IR spectra in the amide I and amide II region of 
GNPs after different sterilisation conditions (n=3). 
GNPs are subjected to higher stress during autoclaving at 134°C and a pressure 
of 3 bar than at 121°C and 2 bar, even though the exposure time is shorter. 
Furthermore, data from dynamic scanning calorimetry show a glass transition of 
GNPs at 134.57°C ± 0.96°C. This may also contribute to the degradation of GNPs 
during the hasher steam sterilisation process.  
 
On the other hand, literature showed that steam sterilisation is generally not 
applicable for collagen and collagen derived proteins, such as gelatine, due to 
degradation [25-27]. Gelatine microparticles did not withstand steam sterilisation 
and led to degradation of the particles [26]. However, these microcarriers seemed 
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to have strongly reduced initial cross-linking degrees compared the gelatine 
nanoparticles used in our study. No absolute values were stated, but a ten-fold lower 
amount of glutaraldehyde was used to cross-link the gelatine microparticles 
compared to GNPs. Consequently, besides the applied temperatures, one can 
assume that a high degree of cross-linking is an important prerequisite to enable 
resistance of GNPs against stress during steam sterilisation.  
 
Summarising, steam sterilisation of GNPs under standard conditions of 15 minutes 
at 121°C can be performed. However, one has to keep in mind that this treatment 
already causes slight particle degradation. Consequently, alternative concentration 
determination methods need to be evaluated for steam sterilised GNPs, as common 
gravimetric analysis would lead to false high results due to residual gelatine 
fragments. This could include concentration determination using absorption of UV 
light, turbidity or derived countrates from DLS measurements. However, all these 
methods require calibration curves. On the other hand, a purification method to 
remove gelatine residues from autoclaved GNP dispersions should be developed. 
Furthermore, steam sterilisation can only be applied to plain GNPs or GNPs loaded 
with heat resistant drugs, whereas alterations of drug release characteristic might 
be considered and evaluated.  
3.2 GAMMA IRRADIATION 
From the aforementioned section, it can be ascertained that steam sterilisation of 
GNPs is in principle possible. However, ODN loading would still be necessary to be 
performed under aseptic conditions, due to the heat sensitivity of ODNs [14]. 
Moreover, sterile filtration is not applicable due to particle sizes larger than the pore 
size of a 0.2 µm sterile filter. Therefore, the aim of this part of the study was to 
establish a method to sterilise ODN-loaded GNPs without impact on particle 
attributes and ODN integrity.  
In this section, gamma irradiation is evaluated to be a suitable sterilisation method 
for lyophilised ODN-loaded GNPs. Four different formulation principles were 
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investigated: sugar-based and amino acid-based formulations, as well as 
combinations of a sugar and an amino acid or combinations of different amino acids.  
3.2.1 VISUAL INSPECTION 
The energy introduced into the samples by gamma rays did not change the optical 
appearance of the lyophilisates and did not induce collapse of the cakes. However, a 
colouration of the glass vials was observed. This is a common phenomenon, as glass 
is sensitive to radiation induced coloration due to its amorphous structure [28, 29]. 
This is a reversible metastable change in the glass and has no impact on its physical 
properties or the product [29]. 
3.2.2 PARTICLE SIZES AND PDI VALUES 
Data of DLS measurements reveal that gamma irradiation had hardly any impact on 
particle sizes and PDI values in most of the formulations (Figure IV-7). All sucrose 
concentrations (S100, S500, S1333), the higher trehalose concentrations (T500, 
T1333), pure histidine, most sugar amino acid combinations (Suc + Gly or His, Tre + 
Arg or Gly or His) and the amino acid mixtures (Arg + His, Arg + Gly, His +Gly, Arg + 
His + Gly) stabilised ODN-loaded GNPs.  
On the other hand, pure glycine at low concentration (2.5%) was not adequate to 
prevent ODN-loaded GNPs from aggregation indicated by a strongly increasing 
particle size and PDI value. Furthermore, highly concentrated glycine (5.0%), both 
arginine concentrations (2.5% and 5.0%) as well as the combination of sucrose and 
arginine (Suc + Arg) and low concentrated trehalose (T100) showed higher PDI 
values after sterilisation suggesting aggregation. This leads to the conclusion, that 
glycine and arginine and low amounts of trehalose are not suitable to retain particle 
stability during gamma irradiation.  
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Figure IV-7 Particle sizes (bars) and PDI values (dots) of ODN-loaded GNPs in different lyophilised 
formulations before and after gamma irradiation. A: Pure sugar formulations, B: Sugar amino acid 
combinations, C: pure amino acid formulations, D: amino acid combinations. Data is represented as 
mean + or ± SD (n=3). 
3.2.3 LOADING EFFICIENCIES AND ODN INTEGRITY 
Loading efficiencies remained stable in most formulations indicating no breakage of 
the permanently positive charged side chains of GNPs by radiation (Table IV-1). 
However, a tremendous drop in loading efficiency was recognized in formulation 
Gly 2.5% (from 96.6% to 68.5%). This loss in loading efficiency may be related to 
the strong particle aggregation.  
Investigation of ODN integrity revealed that ODNs endured gamma irradiation in all 
sugar formulations (Table IV-1). Additionally, ODNs are stable in all amino acid 
containing formulations free from arginine. Of all the formulations containing 
arginine only high arginine (5.0%) and its combination with trehalose stabilised the 
ODNs.  
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Table IV-1 ODN integrity after gamma sterilisation and loading efficiencies before and after gamma 
irradiation. ODN integrity is represented with symbols:  stable ODN,  degraded ODN. Loading 
efficiency is represented as mean ± SD (n=3). 
Formulation 
ODN integrity 
after γ-irradiation 
Loading efficiency [%] 
Before γ-
irradiation 
After γ-
irradiation 
.. 
   S100  98.2 ± 0.8 99.8 0.2  
S500  98.6 ± 0.9 102.2 2.2 
S1333  97.4 ± 0.5 93.6 ± 0.1 
T100  98.4 ± 0.6 100.7 ± 0.3 
T500  98.9 ± 0.2 96.6 ± 0.6 
T1333  96.3 ± 0.9 95.2 ± 0.6 
Suc + Arg  100.3 ± 0.4 97.4 ± 2.9 
Suc + Gly  98.1 ± 0.5 90.1 ± 1.0 
Suc + His  96.3 ± 0.4 96.8 ± 0.6 
Tre + Arg  95.4 ± 0.4 92.5 ± 0.4 
Tre + Gly  98.5 ± 0.9 96.0 ± 0.6 
Tre + His  94.5 ± 0.6 89.3 ± 0.6 
Arg 2.5  99.1 ± 0.7 97.9 ± 0.3 
Arg 5.0  91.9 ± 0.9 98.6 ± 0.2 
Gly 2.5  96.6 ± 0.4 68.5 ± 1.2 
Gly 5.0  96.5 ± 0.6 96.2 ± 0.6 
His  95.6 ± 0.9 97.4 ± 0.6  
Arg + His  95.1 ± 0.5 91.3 ± 0.3 
Arg + Gly  93.3 ± 0.8 87.5 ± 6.1 
His + Gly  98.3 ± 0.6 97.3 ± 0.5 
Arg + His + Gly  94.8 ± 0.4 102.0 ± 0.5 
 
This leads to the conclusion that arginine is disadvantageous as excipient for ODN-
loaded GNPs during gamma irradiation. This was not expected as arginine is well 
known to stabilise proteins [30]. On the other hand, destabilising effects of arginine 
have already been noticed in the lyophilisation and storage stability study (see 
Chapter III). We hypothesize that this negative impact of arginine is related to its 
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guanidinium group. This group shows a high affinity to the negatively charged 
backbone of nucleic acids and highest binding capacity to DNA motifs consisting of 
guanine rich residues, which are represented in our ODN [31, 32]. Consequently, the 
arginine binding induces conformational changes in the secondary structure of the 
DNA sequences [31]. Lastly, the change in conformation makes the ODNs more 
susceptible for degradation.  
 
In summary, we could show that gamma irradiation is a suitable method to sterilise 
GNPs. Previously, gamma irradiation has shown to induce disintegration of non-
crosslinked gelatine nanoparticles (~ 300 nm) and subsequent reformation of 
smaller ones (~ 10 nm) in aqueous formulations [33]. In our study, covalent cross-
linking and sterilisation in solid state prevented degeneration of GNPs into smaller 
particles.  
However, gamma irradiation aims to eliminate microorganisms by damaging their 
DNA. Therefore, evaluation of ODN integrity was a critical part of this study. 
Interestingly, we could show for the first time that rather simple lyophilised 
formulations were adequate to stabilise ODNs loaded onto GNPs during gamma 
irradiation. A mixture of two amino acids was sufficient for stabilisation, whereas 
arginine had a negative impact on the stability of ODN-loaded GNPs. On the other 
hand, if histidine was used, one amino acid was sufficient to protect ODNs from 
degradation. This beneficial effect of histidine was already noticed during the 
storage stability study of lyophilised ODN-loaded GNPs (see chapter III, section 3.3). 
Furthermore, the addition of a sugar to a pure amino acid formulation was 
advantageous. Similar observations have already been reported for a spray dried 
influenza vaccine, where the addition of trehalose to an amino acid composition was 
found to be favourable [19]. Surprisingly, pure sugar formulations were also 
appropriate and even superior to amino acids for stabilisation of ODN-loaded GNPs 
during gamma irradiation. This was not expected as it was published that complex 
formulation compositions of five to eight excipients, mostly based on amino acids, 
are necessary provide irradiation stability of a dry biomolecular product [18, 19]. In 
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another study, RNA oligonucleotides encapsulated into spray dried albumin 
nanoparticles were found to be stable upon radiation without any excipients [34]. 
Here the RNA was really entrapped inside the particle matrix, and therefore albumin 
may have acted as protecting agent. Based on this, it can be hypothesised that GNPs 
in general may also have protective features, but in our case ODNs are attached to 
the GNP surface and therefore additional excipients are be necessary to stabilise the 
oligodeoxynucleotides.  
Summarising, it can be assumed that sugars are at least equivalent in protecting 
ODN-loaded nanoparticles from gamma rays compared to amino acids. However, 
long term stability of gamma irradiated ODN-loaded GNPs should be studied to 
provide a final recommendation on excipients.  
4 CONCLUSION 
Steam sterilisation is an acceptable method to sterilise plain GNPs. However, due to 
thermal stress a certain particle degradation was even be detected under standard 
conditions. 
Gamma irradiation is a suitable method to sterilise lyophilised ODN-loaded GNPs, 
whereas sugar formulations were superior to amino acid mixtures and arginine was 
even detrimental in terms of ODN stability.  
Amongst the two investigated sterilisation approaches, gamma irradiation of 
lyophilised GNPs is preferable.  
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ABSTRACT 
Cytosine-phosphate-guanine oligodeoxynucleotides (CpG ODNs) are a promising 
new immunotherapeutic treatment option for canine atopic dermatitis (AD). The 
aim of this uncontrolled pilot study was to evaluate clinical and immunological 
effects of gelatine nanoparticle (GNP)-bound CpG ODNs (CpG-GNP) on atopic dogs. 
Eighteen dogs with AD were treated for eight (group 1, n=8) or 18 weeks (group 2, 
n=10). Before inclusion and after two, four, six (group 1+2), eight, 12 and 16 weeks 
(group 2) 75 µg CpG ODNs/dog (bound to 1.5 mg GNP) were injected 
subcutaneously. Pruritus was evaluated daily by the owner. Lesions were evaluated 
and serum concentrations and mRNA expressions of interferon-γ, tumour necrosis 
factor-α, transforming growth factor-β, interleukin-10 and interleukin-4 (only 
mRNA expression) were determined at inclusion and after eight (group 1+2) and 18 
weeks (group 2). 
Lesions and pruritus improved significantly from baseline to week eight. Mean 
improvements from baseline to week 18 were 23% and 44% for lesions and pruritus 
respectively, an improvement of ≥50% was seen in 6/9 and 3/6 dogs, respectively. 
Interleukin-4 mRNA expression decreased significantly. The results of this study 
show a clinical improvement of canine AD with CpG GNP comparable to allergen 
immunotherapy. Controlled studies are needed to confirm these findings. 
 
KEYWORDS:  
Allergy, atopy, dogs, immunomodulation, TLR9    
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1 INTRODUCTION 
Canine atopic dermatitis (AD) is an inflammatory allergic skin disease in genetically 
predisposed dogs associated with distinctive clinical signs [1]. The allergy is mostly 
directed against environmental allergens though food allergens might contribute to 
the disease [2, 3]. In most, but not all dogs, IgE antibodies against those allergens 
can be found [4]. 
The pathogenesis of AD is complex and not fully understood [5]. Besides skin barrier 
impairments, alterations of the immune system seem to play a central role in the 
development of the disease [6]. Atopic dogs as well as humans show a tendency to 
T helper type 2 (Th2)-polarized immune reactions [7-10]. However, although a Th2 
phenotype predominates in early stages of inflammation, chronic lesions show a 
more mixed pattern of lymphocytes and cytokines with a slight trend towards Th1-
polarization [8, 9, 11]. Regulatory T cells (Tregs) and the regulatory cytokines 
transforming growth factor (TGF)-β and interleukin (IL)-10 can modulate the 
immune response to allergens by directly and indirectly suppressing T cells. 
Although still not fully understood, there might be a Treg cell deficiency or an 
impairment of Treg function in AD [4, 12, 13]. 
To date, allergen immunotherapy (AIT) is the only causative therapy [14]. However, 
there are certain disadvantages of AIT. For each dog allergens contributing to the 
disease must be identified, and then an individual allergen extract has to be 
formulated. Allergen testing and extracts are costly [15]. Furthermore, there is a 
subset of dogs not showing positive test reactions excluding them from this 
treatment option [4]. In addition, it may take several months before clinical 
improvement is seen and up to half of the patients may fail to respond to AIT [16, 
17]. Thus, an efficacious immunomodulation of AD that does not require allergen 
identification would be desirable.  
Cytosine phosphate guanine oligodeoxynucleotides (CpG ODNs) offer such a new 
immunotherapeutic approach. CpG ODNs are synthetic DNA oligodeoxynucleotides 
containing at least one unmethylated cytosine guanine (CG) dinucleotide with 
certain flanking bases. Unmethylated CG dinucleotides are relatively common in 
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microbial DNA and represent a pathogen-associated molecular pattern (PAMP), 
which is bound by Toll-like receptor (TLR) 9. They initiate various immune 
responses [18-20].  
In humans, stimulation of TLR 9 by CpG ODNs leads to a polarization of the immune 
response to a Th1 phenotype, which suppresses Th2 responses, increases the 
secretion of regulatory cytokines such as IL-10 and suppresses IgE antibody 
production. Furthermore, differentiation of B-cells to plasma cells and isotype 
switching to IgG is promoted [20-22]. In atopic dogs, CpG ODNs also induce a Th1-
biased immune response and increase the expression of IL-10 mRNA in vitro [23-
25]. These effects resemble those observed in the course of AIT [26-28]. 
Adsorption of CpG ODNs onto cationised gelatine nanoparticles (GNPs) protects the 
CpG ODNs from early enzymatic degradation and enhances uptake into target cells, 
thereby increasing and prolonging the immunostimulatory effects of the CpG 
ODNs [23, 29, 30]. Gelatine as a carrier matrix is biocompatible, biodegradable and 
safe [31]. Unloaded GNPs do not show immunostimulatory activity [30]. Repeated 
inhalation of an aerosol formulation of GNP-bound CpG ODNs (CpG-GNPs) increased 
IL-10 and IFN-γ expression, but also reduced clinical parameters of allergic 
inflammation in horses with recurrent airway obstruction [32, 33]. The CpG-GNP 
used in this study increased secretion of IL-10 in vitro in peripheral blood 
mononuclear cells (PBMCs) obtained from atopic dogs [23]. 
The aims of this study were (1) to evaluate the effects of CpG-GNPs on the clinical 
lesions and pruritus of dogs with nonseasonal atopic dermatitis and (2) to examine 
the influence of the treatment on gene expression and serum concentrations of 
selected Th1, Th2 and regulatory cytokines in these dogs. 
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2 MATERIALS AND METHODS 
2.1 STUDY DESIGN  
The study was conducted as an uncontrolled, prospective pilot study in the setting 
of the Clinic of Small Animal Medicine, LMU, Munich, Germany. 
2.2  STUDY DRUG PREPARATION  
ODNs with the sequence 5’-GGTGCATCGATGCAGGGGGG-3’ were provided with a full 
phosphorothioate backbone (Biomers.net, Ulm, Germany). 
The GNPs were prepared using a two-step desolvation method as previously 
described [34]. Nanoparticles were stabilised by cross-linking with glutaraldehyde. 
Cationisation was performed by attaching permanent positive charges from 
quaternary amines to the surface of GNP according to an established protocol [30]. 
Aseptically prepared GNP were then incubated with CpG ODNs in isotonic sorbitol 
solution to a final concentration of 5 mg/mL GNP and 0.25 mg/mL CpG ODNs for 1 h 
at 22°C under gentle shaking using a thermomixer (Eppendorf, Hamburg, Germany). 
The loading efficiency was calculated by photometric determination at a wavelength 
of 260 nm (Agilent 8453 UV-visible spectrophotometer, Agilent Technologies, Santa 
Clara, California, USA) as follows. Samples (CpG-GNPs) and controls of plain GNPs 
and pure CpG ODNs were centrifuged at 14000*g for 30 min (Sigma 4K15 centrifuge, 
Osterode, Germany). The absorbance (A) of the supernatants was then measured 
and the loading efficiency was calculated using the following equation: 
 
Loading efficiency [%] = 1 − (
A (CpG GNP)−A (GNP control)
A (CpG−ODNs control)
) 𝑥 100 %. 
 
A loading efficiency of at least 95% (w/w) was acceptable. Particle size, 
polydispersity index (PDI) and zeta potential were analysed using a Zetasizer ZS 
Nano (Malvern Instruments, Malvern, UK) before and after loading with CpG ODNs. 
The study drug was then stored at 3 to 7 °C for not longer than 72 hours until 
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injection to ensure that particle size, PDI, zeta potential and loading efficiency meet 
the required quality criteria.  
2.3  PATIENT SELECTION 
Eighteen client-owned dogs with non-seasonal AD were included. Atopic dermatitis 
was diagnosed by history, clinical examination and ruling out differential diagnoses 
with appropriate tests and treatments. Within the last month prior to and during the 
study every dog was treated with appropriate flea control products and its diet was 
unchanged for at least two months prior to inclusion and during the trial. Injectable 
depot formulation of glucocorticoids had to be discontinued at least six weeks prior 
to participation, any oral glucocorticoid or other immunosuppressive agent four 
weeks prior. Patients receiving other medication, such as antihistamines or 
shampoo therapy continued this medication unchanged in the last two weeks prior 
to and during the trial. 
Dogs were withdrawn from the study when requiring any form of additional anti-
inflammatory therapy or when showing unacceptable discomfort or adverse effects 
of immunotherapy. Poor owner compliance also led to exclusion. 
2.4  TREATMENT PROTOCOL 
The procedure was approved by the local animal welfare authorities (District 
Government of Upper Bavaria, Field of interest 54, 80534 Munich, Germany; 
reference number 55.2-1-54-2532-122-13, date of approval: 9/18/2013). Prior to 
treatment of each dog, written informed consent was obtained from the owner.  
Recruitment and treatment of patients started in 04/2014 and ended (for reasons 
of time) in 09/2015. The first group of eight dogs (group 1) was treated over a 
period of eight weeks, whereas the following ten dogs (group 2) received 
immunotherapy over a prolonged period of 18 weeks. The study drug (300 µL of the 
final formulation, which corresponds to 75 µg CpG ODNs bound to 1.5 mg GNPs per 
dog) was injected subcutaneously in the area of the popliteal lymph nodes at 
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inclusion and after two, four and six weeks. Patients of group 2 received additional 
injections after eight, 12 and 16 weeks. 
2.5  CLINICAL EVALUATION  
At inclusion and after eight (group 1+2) as well as 18 weeks (group 2) skin lesions 
were evaluated using the validated Canine Atopic Dermatitis Extent and Severity 
Index (CADESI)-03 which evaluates 62 body sites for erythema, lichenification, 
excoriation and alopecia [35]. 
Pruritus was assessed by the dog´s owner on a daily basis using a validated visual 
analogue scale of zero (no pruritus) to ten (extremely severe and continuous 
pruritus) [36, 37]. For each dog individual weekly values of pruritus were calculated 
by forming the arithmetic mean of the scores of week one, eight and 18 (if available), 
respectively.  
Any given medication or treatment as well as any adverse effects had to be recorded 
by the owner. 
2.6  QUANTIFICATION OF SERUM CYTOKINE CONCENTRATIONS 
Blood samples were collected at the beginning of the study and after 
eight (group 1+2) and 18 weeks (group 2). The latter blood samplings were both 
performed two weeks after the last CpG-GNP injection. Serum was obtained by 
centrifuging the clotted blood samples for 5 minutes at 2540*g (centrifuge Universal 
320R, Andreas Hettich, Tuttlingen, Germany) and stored at -80 °C until further 
usage.  
Serum concentrations of IFN-γ, TNF-α, TGF-β and IL-10 were measured using 
Milliplex MAP Canine Cytokine Magnetic Bead Kits (Merck Millipore, Darmstadt, 
Germany) according to manufacturer’s instructions. Quantification was performed 
by the Bio-Plex 200 Reader, Results were calculated using the Bio-Plex Manager 
Software 4.1 (both BioRad, Hercules, California, USA). The sensitivity limits of the 
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assays were 18 ng/L for IFN-γ, 6.1 ng/L for TNF-α, 8.5 ng/L for IL-10 and 11.4 ng/L 
for TGF-β. 
2.7  RELATIVE QUANTIFICATION OF CYTOKINE MRNA 
Blood samples of group 2 were collected in RNAprotect Animal Blood 
Tubes (500 µL) (Qiagen, Hilden, Germany) at the beginning of the study, after eight 
and 18 weeks (two weeks after the last CpG-GNP injection, each) and stored at -20°C 
until further usage.  
Quantitative RT-PCR was performed to assess mRNA expression of IFN- γ, TNF-α, 
IL-4, TGF-β and IL-10. Genes for ribosomal protein L13a (RPL13A) and succinate 
dehydrogenase complex subunit A, flavoprotein (SDHA) were used as reference 
genes [38, 39]. Briefly, mRNA was extracted from the samples using the RNeasy 
Protect Animal Blood Kit (Qiagen, Hilden, Germany) according to the manufacturer’s 
instructions. Samples were evaluated for quality and quantity of mRNA via 
NanoDrop 1000 Spectrophotometer (PEQLAB Biotechnology, Erlangen, Germany). 
Using the QuantiTect Reverse Transcription Kit (Qiagen, Hilden, Germany), mRNA 
was transcribed to cDNA. Real-time PCR was performed on an Applied Biosystems 
7500 Real-Time PCR System (Thermo Fisher Scientific, Waltham, Massachusetts, 
USA) using the QuantiTect SYBR Green PCR Kit and QuantiTect Primer Assays for all 
target and reference genes (both Qiagen, Hilden, Germany). The PCR conditions 
were 95 °C for 15 min and 40 cycles of 94 °C for 15 s, 55 °C for 30 s and 72 °C for 35 s. 
Data were analysed via Applied Biosystems DataAssist Software v3.01 (Thermo 
Fisher Scientific, Waltham, Massachusetts, USA). Results were normalized using 
RPL13A and SDHA as references [40]. 
2.8  STATISTICAL ANALYSIS 
Data for pruritus, CADESI, serum cytokine concentrations and mRNA expressions 
were tested for normality using the D’Agostino-Pearson omnibus normality test.  
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Individual data pairs of CADESI, pruritus and serum cytokine concentrations at the 
beginning and end of the study were compared by Wilcoxon matched-pairs signed-
rank tests. Results of gene expression analysis (2-(∆CT) values) were compared by 
Friedman-tests followed by Dunn’s multiple comparisons tests. Statistical analyses 
were performed using GraphPad Prism 6 software (GraphPad Software, San Diego, 
California, USA). For all comparisons, a P-value < 0.05 was considered significant. 
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3 RESULTS 
3.1  STUDY POPULATION 
Of the 18 dogs, a total of 15 dogs completed the study (group 1: n=6, group 2: n=9). 
One dog (group 1) was excluded from the study because of severe vomitus after the 
second appointment. The two other dogs (one of group 1 and 2 each) were excluded, 
because clinical signs of AD were severe enough to warrant immunosuppressive 
drugs. The mean age of the patients was 4.7 years (median: 4.8 years). Body weight 
ranged from 8 kg to 49 kg. Ten participating dogs were male (eight of them 
neutered) and eight female (seven of them spayed). Ten breeds were represented in 
this study (two boxers, and one of the following breeds each: Beagle, Doberman 
Pinscher, German Shepherd, French Bulldog, Irish Setter, Jack Russel Terrier, 
Rhodesian Ridgeback, Golden and Labrador Retriever). Seven mixed-breed dogs 
also participated. 
3.2  CONCURRENT MEDICATIONS 
All concurrent medications and treatments were performed according to study 
guidelines, i.e. dosage and frequency of administration remained unchanged. They 
mostly consisted of shampoo therapy, local disinfection and topical and oral 
supplementation of polyunsaturated fatty acids. Only one dog in group 1 received 
an antihistamine (cetirizine) during and before study. 
3.3  CLINICAL PARAMETERS 
Lesions showed a statistically significant improvement in week 8 (P = 0.037). Mean 
CADESI decreased from 21.93 in week 0 to 14.00 in week 8. Although CADESI 
showed further improvement until week 18 (mean CADESI: 11.11), this decrease 
failed to reach statistical significance (Figure V-1 A).  
Mean pruritus in the first study week was 5.58. Pruritus was significantly reduced 
to 4.46 in week 8 (P = 0.008) and 3.19 in week 18 (P = 0.031) (Figure V-1 B). Mean 
Preliminary Evaluation of CpG-ODNs bound to GNPs as Immunotherapy for CAD 
 
 
 
161 
 
values, standard deviations, confidence intervals and medians of CADESI and 
pruritus at the different time points of the treatment can be found in Table V-1. Mean 
percentage reductions of lesions and pruritus as well as the proportion of dogs 
showing at least 25% and 50% improvement in week 8 and 18 are summarised in 
Table V-2. 
 
Figure V-1 Development of mean CADESI (Canine Atopic Dermatitis Extent and Severity Index) (A) 
and pruritus (B) in dogs with atopic dermatitis treated with gelatine nanoparticle-bound CpG 
oligodeoxynucleotides. *P < 0.05. 
Table V-1 Means, standard deviations (SD), confidence intervals (CI) and medians of CADESI (Canine 
Atopic Dermatitis Extent and Severity Index) and pruritus at different time points of the 
immunotherapy of dogs with atopic dermatitis with gelatine nanoparticle-bound CpG 
oligodeoxynucleotides.   
 
Week Mean Value ± SD 95% CI Median 
CADESI 
0 21.93 ± 21.78 9.87 – 33.99 13 
8 14.00 ± 10.49 8.19 – 19.81 11 
18 11.11 ± 11.12 2.57 – 19.66 4 
Pruritus 
1 5.58 ± 1.43 4.79 – 6.38 5.79 
8 4.46 ± 1.97 3.37 – 5.55 4.43 
18 3.19 ± 1.42 1.7 – 4.68 3 
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Table V-2 Improvement of clinical signs in comparison to baseline values in dogs with atopic 
dermatitis at different time points of immunotherapy with gelatine nanoparticle-bound CpG 
oligodeoxynucleotides. 
 
Clinical 
parameter 
Mean ≥ 25% ≥ 50% 
Improvement in week 8 
CADESI a 23.07% 8/15 dogs 5/15 dogs 
Pruritus 24.11% 7/15 dogs 3/15 dogs 
Improvement in week 18 
CADESI a 22.98% 6/9 dogs 6/9 dogs 
Pruritus 44.01% 4/6 dogs 3/6 dogs 
a CADESI, Canine Atopic Dermatitis Extent and Severity Index 
3.4  SERUM CYTOKINE CONCENTRATIONS 
Concentrations of IFN-γ, TNF-α and IL-10 in most of the blood samples were under 
the detection limits of the assay. TGF-β did not significantly change during the study. 
3.5  EXPRESSION OF CYTOKINE MRNA 
There were no significant changes in mRNA expression of IFN-γ, TNF-α, TGF-β and 
IL-10. In contrast, mRNA expression of IL-4 was decreased 3.08-fold in week 18 
compared to baseline (P = 0.048). The observed changes in expression of all 
measured cytokines are displayed in Figure V-2.  
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Figure V-2 mRNA expression of interferon (IFN)-γ, tumour necrosis factor (TNF)-α, interleukin (IL)-
4, transforming growth factor (TGF)-β and IL-10 in dogs suffering from atopic dermatitis during 
immunotherapy with gelatine nanoparticle-bound CpG oligodeoxynucleotides. Depicted are the 
changes in expression in samples of week 8 and 18 in comparison to the expression in samples 
collected at the beginning of the study (fold changes). 
3.6  ADVERSE EFFECTS 
Nine of 18 dogs experienced at least one adverse event. The observed reactions 
included vomitus (6/18 dogs), diarrhoea (4/18 dogs), swelling of the popliteal 
lymph node (1/18 dogs), and swelling at the injection site (3/18). In two cases 
vomitus was heavy, frequent and associated with diarrhoea. One of those two dogs 
was excluded from the study. The other dog initially showed only mild 
gastrointestinal adverse effects and completed the study, but deteriorated further 
after the end of the study. Both dogs recovered completely after symptomatic 
treatment. In the other affected dogs, gastrointestinal symptoms were mild and 
occurred only occasionally and independent of the injections. The swellings of the 
popliteal lymph nodes and at the injection sites were mild, painless and subsided 
within a few days in all cases. 
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4 DISCUSSION 
In this pilot study, immunotherapy with CpG-GNPs reduced pruritus and lesions of 
canine AD. Studies evaluating the efficiency of AIT found that 52 to 65% of the 
treated dogs show a clinical improvement of at least 50% [16, 17, 41]. In a 
prospective blinded study evaluating allergen immunotherapy, improvement of 
CADESI scores and pruritus of at least 50% was reported in 7/11 dogs (64%) and in 
5/11 dogs (45%), respectively [42]. In our study, immunotherapy with CpG-GNPs, 
performed for 18 weeks, led to a clinical improvement of at least 50% in a similar 
proportion of patients (Table V-2).  
In this study, immunotherapy with CpG-GNPs was only conducted for four months 
while cited studies evaluated the efficacy of AIT after at least 12 months of 
treatment. It may take quite long for clinical signs to improve with AIT [14, 16]. In a 
retrospective study about AIT, 21% of the dogs showed first signs of clinical 
improvement in the first two months of AIT, 45% in the period between two and 
five months and 17% of patients later than five months [41]. Unfortunately, only an 
overall assessment of the owner was given and pruritus and CADESI scores were 
not obtained in that study. If prolonged application of CpG-GNPs results in further 
improvement of symptoms, has to be evaluated in further studies, but the fast 
clinical improvement is rather encouraging. 
The adverse effects observed in the course of the study can be divided into 
gastrointestinal symptoms and local reactions, both of which are reported in 
humans treated with CpG ODNs [43-45]. In humans, systemic adverse events such 
as gastrointestinal reactions generally occurred 12 to 24 hours after application of 
CpG ODNs and subsided after a few days [43, 45]. In the two dogs in our study 
suffering from severe and frequent vomitus and diarrhoea, these signs persisted for 
as late as two weeks after the last injection. It is unclear if they were associated with 
the study medication or not. Occasional vomiting or diarrhoea is extremely common 
in otherwise healthy dogs and often spontaneously resolving [46]. In some human 
patients allergic to red meat, hypersensitivity reactions to small amounts of 
intravenously administered gelatine were observed, even when the regularly 
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consumed red meat only caused overt reactions occasionally [47]. It seems possible, 
that gastrointestinal adverse effects could occur in response to porcine gelatine in 
dogs as well. One of the two dogs expressed similar gastrointestinal reactions after 
administration of Fenistil dragées (Novartis, Basel, Switzerland), which also contain 
gelatine. In all other cases, vomitus and diarrhoea were mild and occurred in time 
intervals, which the owners considered ‘normal‘ for their dogs. The painless and 
temporary local reactions observed in the course of the study are compatible with 
the mechanism of action of CpG ODNs and can be considered as mild adverse 
effects [43].  
Overall, during the immunotherapy with CpG-GNPs adverse reactions were 
observed in 50% of the patients. In AIT, the incidence of adverse events is reported 
to range between 5% and 50% [16, 48, 49]. Increased pruritus after injection of the 
immunotherapy is the most commonly observed adverse effect [14, 48]. Systemic 
reactions have been reported in approximately 1% of the treated dogs [49]. They 
include not only gastrointestinal symptoms, but also weakness, anxiety, 
urticaria/angioedema and severe reactions such as collapse and anaphylaxis [16, 
48, 50]. None of the latter ones could be observed in our study. It is assumed that by 
omitting the allergens in immunotherapy of AD, the risk of potentially life 
threatening anaphylactic reactions can be reduced or even eliminated [51]. 
However, it remains to be seen if the adverse effects seen here (exclusive local 
swellings and gastrointestinal signs) using CpG-GNPs will be confirmed in larger 
placebo-controlled studies. 
The mRNA expression of IL-4 significantly decreased in the course of the study. IL-4 
is known as a key cytokine in allergic inflammation, increasing the differentiation of 
naïve T-cells to Th2-cells, inducing antibody class switching to IgE and stimulating 
the activation of mast cells [52]. Hence a reduction in IL-4 mRNA expression, as 
observed in this study, can be regarded as beneficial in the treatment of atopic dogs. 
This observation is in accordance with a study using liposome-DNA complexes as an 
adjuvant in AIT [53]. In another study, conventional AIT augmented the Th1 to Th2 
cytokine ratio, although by an increase in IFN-γ [28]. 
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In contrast to in vitro studies evaluating the effects of CpG ODNs on the PBMCs of 
atopic dogs [23, 24], neither an increase in Th1 nor in regulatory cytokine serum 
concentration and mRNA expression could be detected. However, apart from TGF-β, 
cytokine concentrations in the serum samples were below the detection threshold, 
thus a thorough evaluation of the immunological effects of CpG-GNP 
immunotherapy on serum cytokines was not possible. As blood samples were 
obtained two weeks after the last injection of CpG-GNPs, effects of CpG ODNs on 
cytokine serum concentrations and mRNA expression may already have diminished 
due to this period of time. 
Limitations of this study include the absence of a control group, the small number of 
treated dogs and the short duration of treatment. As to the authors’ knowledge this 
was the first time CpG-GNPs were administered exclusively to atopic dogs, the 
optimal dosage was unknown. In human medicine, safety of CpG ODNs application 
was assessed over a dose range from 0.0025 mg/kg to 0.81 mg/kg [43]. Since little 
empirical data is available for dogs [54-56], the dosage was chosen at the low end of 
the doses assessed in humans. Immunotherapy with CpG-GNPs administered at a 
higher dosage may have resulted in more pronounced clinical improvement but also 
has the risk of more frequent and severe adverse effects. 
In AIT the same dose of allergen extract is typically used for each dog regardless of 
body weight [14]. The same concept was applied in this study. It cannot be ruled out 
that administration of individually adapted doses may have yielded greater clinical 
improvement as well, although the results of our study do not suggest any 
correlation between body weight and grade of improvement in this limited number 
of dogs. 
The injection site (near the popliteal lymph nodes) was selected to deposit the CpG-
GNPs in close proximity to their target, i.e. immune cells. Injection directly into the 
lymph nodes may also have enhanced clinical improvement. However, at this point 
(long term) safety of intralymphatic CpG-GNP administration in dogs is unknown. 
Performance of intradermal testing or allergen-specific serum IgE testing was not 
mandatory for study participation. However, 5/6 dogs in group 1 and 6/9 dogs in 
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group 2 did receive either one independently of the study. All dogs tested showed 
positive reactions to house dust mite (Dermatophagoides farinae), most of them also 
to other environmental allergens. Since, by definition, IgE antibodies directed 
against environmental allergens must be documented to classify the disease as 
canine atopic dermatitis [1], it cannot be excluded that one or more of the remaining 
five dogs were suffering from atopic-like dermatitis rather than from atopic 
dermatitis. This must be considered another limitation of the study. 
A major downside of the immunotherapy of atopic dogs with CpG-GNPs is that 
gelatine nanoparticle-bound CpG ODNs are not commercially available yet. In 
addition, at the time of the execution of the study, the CpG-GNPs were only stable 
for 72 hours. Recent studies indicate, however, that the stability can be extended to 
six months by lyophilisation, enabling upscaling of the process and therefore better 
availability. 
5 CONCLUSIONS 
Results of the present study suggest that immunotherapy with CpG-GNPs can lead 
to significant clinical improvement of canine atopic dermatitis. Administration over 
a period of 18 weeks reached an efficacy similar to that reported for allergen 
immunotherapy. Additionally, treatment with CpG-GNPs reduced expression of the 
Th2-cytokine IL-4 in atopic dogs. However, these results need to be confirmed in 
controlled, randomised, double-blinded studies. 
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1 SUMMARY OF THE THESIS 
Nanoparticles are intensively researched as drug delivery systems since the 1970s. 
Amongst a variety of starting materials for nanoparticles, gelatine has proven to be 
versatile due to its biodegradability, biocompatibility and low immunogenicity. 
Furthermore, gelatine provides several functional groups, which allow cross-linking 
and surface modifications of gelatine nanoparticles (GNPs) [1].  
 
Besides different small molecules, GNPs were sucessfully investigated for their 
potential as drug delivery system for macromolecules, such as therapeutic proteins 
or nucleic acids [2, 3]. Several studies showed the effective treatment of allergic 
diseases, such as equine recurrent airway obstruction, by cytosine phosphote 
guanosine oligodeoxynucleotides (CpG ODNs) bound to gelatine nanoparticles [4-
7]. Following recognition of the innate immune system via toll-like receptor 9 
(TLR9), CpG ODNs are able to restore the disrupted balance between Th1 and Th2 
immune response in allergy driven diseases [8]. Furthermore, regulatory T cells 
(Treg), which control T helper cell reactions in general, can be activated [8]. GNPs 
are able to protect these sensitive oligodeoxynucleotides from degradation and 
enhance their cellular uptake by antigen presenting cells due to their particle sizes 
similar to microorganisms [9, 10].  
 
The work presented in this thesis focused on the optimisation of the preparation 
process of gelatine nanoparticles, their stabilisation and sterilisation. Moreover, a 
preliminary clinical evaluation of CpG ODN-loaded GNPs in canine atopic dermatitis 
is described.  
 
Chapter I contains the general introduction of the thesis. Different starting 
materials for nanoparticles including gelatine are discussed. GNPs are presented as 
promising drug delivery system for CpG ODNs. Furthermore, the mechanism of 
action of CpG ODNs and their potential as immunomodulatory therapeutic option in 
the allergic diseases are described. Lastly, the aims of the thesis are stated.  
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Chapter II focuses on the optimisation of the GNP preparation process and its scale 
up. The establishment of a more straightforward one-step desolvation process 
compared to the common delicate two-step desolvation process is demonstrated. A 
commercially available high molecular weight gelatine for one-step desolvation was 
found that omitted the need of customised gelatine qualities. Beyond that, the scale 
up of this improved preparation method is shown. Using the improved one-step 
desolvation process, a 130-fold increase of particle gain was available. This opens 
the possibility for further industrial large-scale production of GNPs.  
 
Moreover, alternative methods to scale GNP production are discussed in this 
chapter. This includes enlarging the contact area between gelatine solution and 
desolvation agent during the desolvation process, the use of a dual-syringe pump 
system or the alternative preparation method nanoprecipitation. However, no 
satisfying results could be obtained using these alternative approaches.  
 
Besides the optimisation and scale up of GNP preparation, this chapter also 
describes the investigation of alternative non-toxic cross-linking agents to common 
glutaraldehyde. This includes the sugar derivative glyceraldehyde as well as the 
naturally occurring genipin. Glyceraldehyde could successfully be used as 
alternative to cross-link GNPs, whereas genipin did not result in high cross-linking 
degrees, which would be able to stabilise GNPs.  
 
Matrix-assisted laser desorption/ionisation mass spectrometry (MALDI MS) was 
successfully established as analytical tool to evaluate the integrity of ODNs loaded 
onto GNPs as described in Chapter III. Furthermore, this chapter deals with the 
stabilisation of ODN-loaded GNPs via lyophilisation, which is an important topic due 
to the limited stability of 2-3 days in the liquid state. Long-term stability of 
lyophilised ODN-loaded GNPs for six months at 2-8°C and 20-25°C in sugar-based 
formulations is shown. Particle characteristics, such as particle sizes and PDI values, 
Chapter VI 
 
 
 
178 
 
remained stable upon storage and ODN integrity is not affected. Additionally, 
stability at accelerated storage conditions was shown. 
 
Moreover, controlled nucleation was investigated as potential freezing method 
prior to lyophilisation in order to shorten lyophilisation process and increase batch 
homogeneity. ODN-loaded GNPs resisted the stress induced by freezing via 
controlled nucleation equally to standard ramp freezing, which was shown in 
freeze-thaw studies. However, using controlled nucleation prior to freeze-drying 
has hardly benefits on the drying time and the stability of the product. Contrary to 
expectations from literature, controlled nucleation has neither negative impact on 
ODN-loaded GNPs as reported from polyplexes, nor beneficial effects as known from 
proteins [11, 12].  
 
Additionally, amino acids are discussed as alternative excipients in lyophilisation of 
ODN-loaded GNPs. Histidine offers excellent potential in stabilising ODN-loaded 
GNPs, whereas crystallisation of glycine is unfavourable and initiates particle 
aggregation. Furthermore, in glycine formulations starting ODN degradation was 
detected at accelerated storage temperature. Besides, arginine is even detrimental 
and favours ODN degradation during storage. This may be due to the strong binding 
affinity of its guanidinium group to the negatively charged backbone of the ODNs 
and consequent disruption of the secondary structure of the nucleic acid. This 
change in secondary structure makes the ODNs more vulnerable to degradation.   
 
Sterility is a main prerequisite of parenterally applied drug products. So far, GNP 
preparation and ODN loading were performed under aseptic conditions to avoid 
microbial contamination. However, aseptic working is prone to failure and difficult 
to validate. Therefore, Chapter IV approaches the sterilisation of GNPs. Firstly, 
steam sterilisation is shown to be possible for unloaded GNPs under standard 
conditions (121°C for 15 minutes). However, due to high stresses induced by 
temperature and pressure, a certain degradation of GNPs was noticed indicated by 
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loss in derived countrate during dynamic light scattering (DLS) measurements and 
reduced cross-linking degrees. This was more pronounced when repeated 
sterilisation cycles at 121°C (2fold or 3fold) or extended sterilisation periods (30 
and 45 minutes) were applied. Steam sterilisation for three minutes at 134°C caused 
even almost complete particle dissolution. 
 
Due to heat sensitivity of oligonucleotides, autoclaving of ODN-loaded GNPs is not 
applicable. This still entails an aseptic loading process of GNPs. Consequently, 
gamma irradiation is represented as option to sterilise lyophilised ODN-loaded 
GNPs. A variety of excipients was tested for protecting ODN-loaded GNPs during 
gamma irradiation. Interestingly, simple sugar formulations were most appropriate. 
Particle characteristics and ODN integrity could completely be preserved. Amongst 
the investigated amino acids histidine was comparable to sugars, whereas glycine 
and arginine based formulations did not or less protect ODNs from degradation. 
These observations are in common with our findings from lyophilisation studies.  
 
Canine atopic dermatitis (CAD) is a genetically predisposed allergic skin disease, 
mostly directed against environmental allergens. The immunological process is still 
not fully understood, but early stage Th2 activation followed by a chronic Th1 
mediated immune reaction with Treg dysfunction are discussed [13]. Consequently, 
CpG ODNs are stated to be a promising therapy approach. Chapter V describes the 
successful preliminary clinical evaluation of ODN-loaded GNPs in the treatment of 
canine atopic dermatitis (CAD). After 18 weeks of subcutaneous application of ODN-
loaded GNPs a clinical improvement of pruritus and Canine Atopic Dermatitis Extent 
and Severity Index (CADESI) of up to ≥ 50% were noticed. Furthermore, a significant 
reduction in allergy mediated IL-4 mRNA expression was observed. This study 
opens the way for further promising placebo controlled clinical trials using ODN-
loaded GNPs to cure canine atopic dermatitis.  
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Taking together the conclusions of all chapters, GNP production process was 
successfully optimised and scaled. Different lyophilisation options were evaluated 
to find optimal process conditions and formulation excipients for long term stability 
of ODN-loaded GNPs. MALDI MS was evaluated as a versatile analytical approach to 
study integrity of ODNs loaded onto GNPs. Steam sterilisation and gamma 
irradiation were auspiciously investigated to sterilise unloaded and loaded GNPs. A 
preliminary clinical evaluation proved ODN-loaded GNPs to be a promising 
treatment in canine atopic dermatitis. 
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1 LIST OF ABBREVIATIONS 
AD  ............................................................................................................................. Atopic dermatitis 
AF4  .............................................................................. Asymmetric field flow-field fractionation 
APCs   ........................................................................................................... Antigen presenting cells 
Arg   ......................................................................................................................................... L-Arginine 
ASIT   .......................................................................................... Allergen-specific immunotherapy 
BAL   .............................................................................................................. Bronchoalveolar lavage 
CAD   ............................................................................................................ Canine atopic dermatitis 
CADESI   ................................................. Canine Atopic Dermatitis Extent and Severity Index 
CG   .............................................................................................................................. Cytosine guanine 
Cholamine ....................... (2-Aminoethyl) trimethylammonium chloride hydrochloride  
CL   .......................................................................................................... Cross-linking, Cross-linking 
CpG ODNs   ........................................................ Cytosine phosphate guanine oligonucleotides 
CpG-GNPs  Cytosine phosphate guanine oligodeoxynucleotide loaded gelatine 
nanoparticles 
DLS   ............................................................................................................. Dynamic light scattering 
DNA   ...............................................................................................................Desoxyribonucleic acid 
EDC .......................................................... 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide  
ELS   ................................................................................................ Electrophoretic light scattering 
FDA   ..................................................................... United States Food and Drug Administration 
FT-IR   .......................................................................... Fourier transform infrared spectroscopy 
Gly   ............................................................................................................................................ L-Glycine 
GNPs   .............................................................................................................. Gelatine nanoparticles 
GRAS   ................................................................................................. Generally Recognised as Safe 
His   ......................................................................................................................................... L-Histidine 
HMW   ............................................................................................................. High molecular weight 
HPW   ................................................................................................................ Highly purified water 
HSA   ............................................................................................................... Human serum albumin 
IAD   .................................................................................................... Inflammatory airway disease 
IEP   ............................................................................................................................... Isoelectric point 
IFN-γ   .................................................................................................................................. Interferon γ 
Ig   ................................................................................................................................. Immunoglobulin 
IL   .......................................................................................................................................... Interleukine 
LMW   ............................................................................................................... Low molecular weight 
MALDI MS   .................... Matrix-assisted laser desorption/ionisation mass spectrometry 
MALS   ................................................................................................... Multi-angle light scattering 
MSN   ............................................................................................ Mesoporous silica nanoparticles 
MW   .......................................................................................................................... Molecular weight 
NF-κB   ...................................................................................................................... Nuclear factor κB 
PAMP   ........................................................................... Pathogen-associated molecular pattern 
PBMCs   ................................................................................. Peripheral blood mononuclear cells 
PCL   ........................................................................................................ Poly(epsilon-caprolactone) 
PDI   ...................................................................................................................... Polydispersity index 
PEG   ....................................................................................................................... Polyethylene glycol 
PEI   ............................................................................................................................. Polyethylenimine 
Appendix 
 
 
 
187 
 
PLGA  .................................................................................................... Poly(lactic-co-glycolic) acid 
PTO   ......................................................................................................................... Phosphorothioate 
RAO   .................................................................................................. Recurrent airway obstruction 
rHG  .................................................................................................... recombinant human gelatine 
RNA   ........................................................................................................................... Ribonucleic acid 
RPL13A   ..................................................................................................... Ribosomal protein L13a 
RT-PCR   .............................................................................. Real time polymerase chain reaction 
SDHA   .................................................................. Succinate dehydrogenase complex subunit A 
SEM   ................................................................................................. Scanning Electron Microscopy 
SLNs   ........................................................................................................... Solid lipid nanoparticles 
Tg   ....................................................................................................... Glass transition temperature 
Tg’   .......... Glass transition temperature of the maximally freeze-concentrated solution 
TGF   ..................................................................................................... Transforming growth factor 
Th1   ........................................................................................................................ T helper cell type 1 
Th2   ........................................................................................................................ T helper cell type 2 
TLR   ........................................................................................................................... Toll-like receptor 
TNBS   ...................................................................................... 2,4,6-Trinitrobenzenesulfonic acid 
TNF- α   ...................................................................................................... Tumour necrosis factor α 
TOF   .................................................................................................................................. Time of flight 
Treg   ........................................................................................................................ Regulatory T cells 
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